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ABSTRACT OF THE DISSERTATION 
Enantioselective Synthesis of β-Amino Acid Derivatives Using Amidine-Based and Bifunctional  
Organocatalysts 
for Arts & Sciences Graduate Students 
by 
Matthew Robert Straub 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2021 
Professor Vladimir B. Birman, Principal Investigator 
Two new enantioselective methodologies have been developed that have important 
implications for the asymmetric synthesis of β-amino acids and their derivatives. First, chiral 
amidine-based catalyst (ABC) HBTM-2 catalyzed an asymmetric cyclocondensation between in 
situ activated fluoroacetic acid and N-sulfonyl aldimines to give α-fluoro-β-lactams in highly 
enantioenriched form, achieving modest to excellent diastereoselectivities. These reactive lactams 
can then be quenched with various alcohols and amines to deliver the α-fluoro-β-amino acid 
derivatives in moderate isolated yields. Secondly, bifunctional double hydrogen bond donor-amine 
organocatalysts enable the catalytic alcoholysis of various racemic N-carbalkoxy-3-substituted 
isoxazolidin-5-ones, resulting in their kinetic resolution. The enantioenriched unreacted 
isoxazolidinone and product (easily recyclable via a two-step transesterification-cyclization 
process) can undergo quantitative N-O bond cleavage by hydrogen to give β-amino acids in N-
protected form.  
 The fourth chapter of this dissertation, an extension of previous achievements in our group, 
describes the development of an organocatalyzed rearrangement of S-phenacyl thioesters that is 
mechanistically distinct from our previously published work. Additionally, more examples of 
asymmetric tandem rearrangements of S-aryl thioesters were demonstrated.  
1 
 
Chapter 1: Introduction to β-amino acids 
1.1 Structure, properties, and the practical significance of β-
amino acids 
Compared to the more well-known α-amino acids, β-amino acids are much less abundant 
in the natural world. In fact, polymers of β-amino acids, β-peptides, are virtually nonexistent in 
Nature. Some β-amino acids, such as β-alanine (mostly in the form of the dipeptide carnosine), a 
catabolite of uracil, are quite plentiful in mammals. However, β-amino acids are not incorporated 
into mammalian proteins.1 Despite all this, the β-amino acid moiety itself is quite prevalent in 
Nature and has been found in bioactive natural products such as the anticancer agent taxol 1.01 
(paclitaxel)2, the antifungal cispentacin 1.023, and the known aminopeptidase inhibitors bestatin 
1.034 and amastatin 1.044 (Figure 1.1).  
 
 
Figure 1.1. Pharmacologically important compounds with a β-amino acid moiety.  
 
β-amino acids are similar to α-amino acids in that both have an amino terminus (called the 
N terminus) and a carboxyl terminus (called the C terminus); however, β-amino acids contain an 
2 
 
extra carbon between these two termini (Figure 1.2). The β-amino acid may be further categorized 
based on its substitution pattern. 
 
Figure 1.2. Comparing the structure of α- and β-amino acids. 
 
This extra carbon is a structural feature of β-amino acids that bestows a greater potential 
for molecular design compared to homologous α-amino acids.5 For example, with the additional 
carbon a total of four stereoisomers (two diastereomers each as a pair of enantiomers) is possible 
for each β-amino acid residue in a peptide chain, assuming each stereocenter is monosubstituted. 
Extra structural diversity can be achieved with di- and polysubstitution. This contrasts with α-
amino acids, which can exist as only one of two stereoisomers, the R or S enantiomer. As such, 
the construction of peptides containing β-amino acids is a developing method to meticulously 
adjust physicochemical properties, three-dimensional structure, and conformational preferences.6 
Consequently, there has been much interest in utilizing β-amino acids, and α-peptides 
incorporating them, for therapeutical and pharmacological applications. 
One significant property of β-amino acids that increases their prospects in medicinal 
chemistry is their proteolytic and hydrolytic stability. One potential application for this is enzyme 
inhibition. For example, since proteases and peptidases often play a huge role in inter- and 
intracellular processes, inhibitors of these enzymes would be ideal for probing cellular networks, 
in addition to treating certain diseases.7 This resistance to enzymatic degradation was first reported 
in the 1960s, when naturally occurring polypeptide hormones adrenocorticotropin and angiotensin 
3 
 
II incorporating N-terminus β-amino acids were shown to be resistant to aminopeptidase 
degradation.8 In the late 1990s, Seebach et al. also demonstrated the resistance of β-peptides to 
degradation by proteases such as trypsin, chymotrypsin, and pepsin. Interestingly, these β-peptides 
stayed intact for several days, whereas analogous α-peptides were completely consumed within 
minutes.9   
For another example, EP 24.15 (commonly called CFP, 1.05, Figure 1.3) is an α-peptide 
that serves as an inhibitor of the enzyme endopeptidase EC.10 CFP undergoes hydrolysis by an 
enzyme known as neprilysin. In one study, many substitutions of CFP involving β-amino acids 
were made, almost all of them preventing any proteolytic degradation by neprilysin.11 
 
Figure 1.3. Structure of CFP, an inhibitor of endopeptidase EC. 
Their biological stability, coupled with their structural homology to naturally occurring α-
amino acids, has allowed β-amino acids and β-amino acid-containing proteins to be used as 
peptidomimetics, or protein mimics. This is arguably their most studied pharmacological 
application. For some examples, β-amino acid-containing (aminobenzamidino)succinyl compound 
1.06 (Figure 1.4) was discovered as a peptidomimetic for the Arg-Gly-Asp-Phe sequence of 
fibrinogen, a glycoprotein complex necessary for proper blood clot formation.12 In the mid-1990s 
this orally active fibrinogen receptor antagonist’s ability to inhibit platelet aggregation was studied 
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in vitro and in vivo, where 35% reduction in platelet count was observed after 9 days in canine 
studies.13 In the late 1990s Seebach showed that cyclic β-tetrapeptide 1.07 has the potential to 
serve as an enterobactin-type C3-symmetrical ligand, mimicking compounds that certain species 
of bacteria use to sequester iron from the environment.14 Lastly, this same group showed that 
hexapeptide 1.08 can fold in such a way such that it mimics the amphipathic α-peptide helix 
binding motifs required to inhibit membrane-bound proteins that facilitate lipid transport. When 
tested with CaCo-2 cells, model cells often used to simulate the epithelial lining of mammalian 
small intestines, this hexapeptide was shown to inhibit fat and cholesterol absorption.15 
 
Figure 1.4. Some examples of β-peptides as peptidomimetics. 
Additionally, β-peptide and β-amino acid-containing α-peptide protein hormones have 
been studied as membrane-targeting peptides and receptor ligands. Peptides containing β-amino 
acid moieties have even adopted secondary structures seen in analogous α-peptides, essentially 
mimicking their function. Within these broad categories of biological exploration, β-amino acid-
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containing peptides have displayed antimicrobial activity, anti-angiogenic behavior, and inhibition 
of protein-protein interactions, just to name a few specific uses.16   
In conclusion, given their increased biological stability, increased structural diversity, and 
ease of incorporation using standard solid-phase peptide synthesis, β-amino acids (and peptides 
consisting of) are key candidates for pharmacological and therapeutic exploration, most notably 
and expectedly as peptidomimetics. Since the discovery of the practical significance of β-amino 
acids, the synthetic community has explored asymmetric syntheses of these compounds.    
1.2 Asymmetric, catalytic approaches to β-amino acids and 
their derivatives 
Some of the first methods developed to synthesize enantiomerically enriched β-amino 
acids relied on classical resolution, stoichiometric amounts of chiral auxiliaries, or homologations 
(e.g. Arndt-Eistert) of α-amino acids. However, in recent years, the catalytic asymmetric syntheses 
of these compounds using transition metals, organocatalysts, and biocatalysts have rapidly 
expanded.17 Generally speaking, the most common modern-day, catalytic, asymmetric approaches 
to β-amino acids and their derivatives fall into one of these categories: 1) addition of nucleophiles 
to imines or α,β-unsaturated imides/esters (Eq. 1)18, 2) ring-opening of β-lactams (Eq. 2)19, 3) 
kinetic resolutions (Eq. 3)20, 4) reduction of enamines (Eq. 4)21, and 5) aza-Michael addition to 
enals (Eq. 5)22. Illustrative examples of each category are given in Figure 1.5. 
Though less thoroughly investigated, the Baylis-Hillman reaction (Figure 1.6, Eq. 1)23, 
ring-expansive carbonylation of oxazolines (Eq.2)24, and using sulfoxides as chiral auxiliaries (Eq. 





Figure 1.5. Illustrative catalytic asymmetric approaches to β-amino acids and derivatives. 
 
Figure 1.6. Additional examples of asymmetric approaches to β-amino acids and derivatives. 
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The numerous methodologies to obtain enantioenriched β-amino acids and their derivatives 
indicate the significance of these compounds.26 Nevertheless, our group realized that some 
methods had remained unreported in the literature. These complementary organocatalytic methods 
we had envisioned offered distinct advantages such as obviating the need for transition metals and 
utilizing more easily available/synthesizable chiral catalysts.   
1.3 References  
1. Griffith, O. W. Annu. Rev. Biochem. 1986, 55, 855. 
2. Kudo, F.; Miyanaga, A.; Eguchi, T. Nat. Prod. Rep. 2014, 31, 1056.  
3. E. Juaristi (Ed.). Enantioselective Synthesis of β-Amino Acids; Wiley-VCH: New York, 
1997. 
4. Roers, R.; Verdine, G. L. Tetrahedron Lett. 2001, 42, 3563.  
5. Steer, D. L.; Lew, R. A.; Perlmutter, P.; Smith, A. I.; Aguilar, M.-I. Curr. Med. Chem. 
2002, 9, 811. 
6. (a) Cheng, R. P.; Gellman, S. H.; DeGrado, W. F. Chem. Rev. 2001, 101, 3219. (b) 
Goodman, C. M.; Choi, S.; Shandler, S.; DeGrado, W. F. Nat. Chem. Biol. 2007, 3, 252. 
(c) Koyack, M. J.; Cheng, R. P. Methods Mol. Biol. 2006, 340, 95. (d) Horne, W. S. 
Expert Opin. Drug Discov. 2011, 6, 1247. 
7. Steer, D. L.; Lew, R. A.; Perlmutter, P.; Smith, A. I.; Aguilar, M.-I. Lett. Pept. Sci. 2002, 
8, 241. 
8. (a) Doepfner, W. Progr. Endocrinol., Proc. Int. Congr. Endocrinol., 3rd. 1969, 407.  
8 
 
(b) Riniker, B.; Schwyzer, R. Helv. Chim. Acta. 1964, 2357. 
9. (a) Seebach, D.; Abele, S.; Schreiber, J. V.; Martinoni, B.; Nussbaum, A. K.; Schild, H.; 
Schulz, H.; Hennecke, H.; Woessner, R.; Bitsch, F. Chimia. 1998, 52, 734. (b) 
Hintermann, T.; Seebach, D. Chimia. 1997, 51, 244. 
10. Orlowski, M.; Michand, C.; Molineaux, C. J. Biochemistry, 1988, 27, 597. 
11. Steer, D. L.; Lew, R. A.; Perlmutter, P.; Smith, A. I.; Aguilar, M.-I. Lett. Pept. Sci. 2002, 
8, 241. 
12. Rico, J. G.; Lindmark, R. J.; Rogers, T. E.; Bovy, P. R. J. Org. Chem. 1993, 58, 7948. 
13. Zablocki, J. A.; et al. J. Med. Chem. 1995, 38, 2378. 
14. Gademann, K.; Seebach, D. Helv. Chim. Acta. 1999, 82, 957. 
15. Werder, M.; Hauser, H.; Abele, S.; Seebach, D. Helv. Chim. Acta. 1999, 82, 1774. 
16. (a) Cabrele, C.; Martinek, T. A.; Reiser, O.; Berlicki, L. J. Med. Chem. 2014, 57, 9718.  
(b) Steer, D. L.; Lew, R. A.; Perlmutter, P.; Smith, A. I.; Aguilar, M.-I. Curr. Med. Chem. 
2002, 9, 811. 
17. Weiner, B.; Szymanski, W.; Janssen, D. B.; Minnaard, A. J.; Feringa, B. L. Chem. Soc. 
Rev. 2010, 39, 1656. 
18. (a) Sammis, G. M. Jacobsen, E. N. J. Am. Chem. Soc. 2003, 125, 4442. (b) Hamashima, 
Y.; Somei, H.; Shimura, Y.; Tamura, T.; Sodeoka, M. Org. Lett. 2004, 6, 1861. (c) 
Wenzel, A. G.; Jacobsen, E. N. J. Am. Chem. Soc. 2002, 124, 12964. (d) Hamashima, Y.; 
Sasamoto, N.; Hotta, D.; Somei, H.; Umebayashi, N.; Sodeoka, M. Angew. Chem. Int. 
9 
 
Ed. 2005, 44, 1525. (e) France, S.; Wack, H.; Hafez, A. M.; Taggi, A. E.; Witsil, D. R.; 
Lectka, T. Org. Lett. 2002, 4, 1603.  
19. Hodous, B. L.; Fu, G. C. J. Am. Chem. Soc. 2002, 124, 1578.  
20. (a) Gedey, S.; Liljeblad, A.; Lazar, L.; Fulop, F.; Kanerva, L. T. Tetrahedron Asymmetry 
2001, 12, 105. (b) Forro, E.; Fueloep, F. Org. Lett. 2003, 5, 1209.  
21. (a) Holz, J.; Monsees, A.; Jiao, H.; You, J.; Komarov, I. V.; Fischer, C.; Drauz, K.; 
Borner, A. J. Org. Chem. 2003, 68, 1701. (b) Dubrovina, N. V.; Tararov, V. I.; Monsees, 
A.; Kadyrov, R.; Fiscsher, C.; Borner, A. Tetrahedron Asymmetry 2003, 14, 2739. (c) 
Heller, D.; Holz, J.; Drexler, H.-J.; Lang, J.; Drauz, K.; Krimmer, H.-P.; Boerner, A. J. 
Org. Chem. 2001, 66, 6816. (d) Davies, S. G. Smith, A. D.; Price, P. D. Tetrahedron 
Asymmetry 2005, 16, 2833.  
22. Ibrahem, I.; Rios, R.; Vesely, J.; Zhao, G.-L.; Cordova, A. Synthesis 2008, 1153. 
23. Balan, D.; Adolfsson, H. Tetrahedron Lett. 2003, 44, 2521.  
24. Byrne, C. M.; Church, T. L.; Kramer, J. W.; Coates, G. W. Angew. Chem. Int. Ed. 2008, 
47, 3979.  
25. (a) Davis, F. A.; Szewczyk, J. M.; Reddy, R. E. J. Org. Chem. 1996, 61, 2222. (b) Davis, 
F. A.; Szewczyk, J. M.; Reddy, R. E. Tetrahedron Lett. 1997, 38, 5139.   
26. (a) Kim, S. M.; Yang, J. W. Org. Biomol. Chem. 2013, 11, 4737. (b) Ma, J.-A. Angew. 
Chem. Int. Ed. 2003, 42, 4290. (c) Sleebs, B. E.; Van Nguyen, T. T.; Hughes, A. B. Org. 
Prep. Proced. Int. 2009, 41, 429. (d) Noda, H.; Shibasaki, M. Eur. J. Org. Chem. 2020, 
10 
 
2020, 2350. (e) Liu, M.; Sibi, M. P. Tetrahedron 2002, 58, 7991. (f) Lelais, G.; Seebach, 


















Chapter 2: Enantioselective synthesis of α-
fluoro-β-amino acid derivatives using 
amidine based acyl transfer organocatalysts1 
2.1 Properties of fluorine and its role in medicinal chemistry 
It has been known for quite some time that the introduction of fluorine into organic 
molecules can greatly alter chemical and physical properties, especially those of bioactive 
molecules. In fact, the greatest exploitation of fluorine’s unique properties has been seen in the 
field of medicinal chemistry.2 In 2014, it was estimated that approximately 20% of new 
pharmaceuticals entering the market contained at least one fluorine atom. The reason fluorine plays 
such an important role in drug development is because fluorinated substituents can greatly increase 
the efficacy of a drug. The role of fluorine is usually to enhance lipophilicity, increase metabolic 
stability, and change the pKa of nearby functional groups.3  
Fluorine’s high electronegativity is mostly responsible for the unique properties it confers 
to organofluorine compounds. Because fluorine is the most electronegative element that can be 
incorporated into organic molecules, the C-F bond has a very large dipole compared to other 
carbon-heteroatom bonds. Simple consideration of this large dipole and its interaction with other 
nearby dipoles can allow for a reasonable prediction of favorable conformations of fluorine- 
containing moieties. Another consideration to make when predicting conformations is the low 
lying σ*C-F antibonding orbital, which often likes to stereoelectronically align itself with electron 
rich bonds (e.g C-H bonds).4 The C-F bond is also very strong compared to other carbon-
heteroatom bonds, which may bode well for biological applications. In addition to its effects on 
bond polarization and bond strength, fluorine’s size also makes it the best isosteric replacement 
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for both hydrogen and oxygen, being intermediate in size. Replacing hydrogen with fluorine can 
greatly alter chemical properties of nearby functional groups, oftentimes advantageously.5  
One interesting fact about fluorine is its absence in biology. Since naturally occurring 
organofluorine compounds are near non-existent in nature, biological systems never evolved to 
incorporate fluorine into biopolymers such as proteins nor their constituent amino acids.6 As such, 
the integration of man-made fluorinated amino acids is a distinctive way to modify proteins.7 In 
addition to protein modification, incorporation of fluorinated amino acids has also aided in 
studying local protein environments and dynamics by 19F NMR since the early 1990s.8 
Furthermore, coupled with the unique effects that β-amino acids can have on protein structure and 
properties (vide supra, Chapter 1), fluorinated β-amino acids offer an even greater opportunity for 
protein alteration. Incorporation of fluorine into biomolecules such as amino acids and proteins 
can be very advantageous since the ability to control their conformation is of great interest for 
biomedical applications. 
While many fluorinated β-amino acids contain fluorine on aromatic rings as part of their 
side chain, the monofluorinated, monosubstituted α-fluoro-β-amino acids are relatively less 
explored and have less published procedures pertaining to their synthesis. However, like other 
fluorinated amino acids, α-fluoro-β-amino acids also have a lot of potential biological promise.9 
For example, the incorporation of a single fluorine on the α-carbon of a β-amino acid can have a 
marked effect on the conformation of said moiety. This fluorine incorporation has been known to 
stabilize, for example, secondary structures; however, this can often be unpredictable. As a case 
in point, the fluorinated β-tetrapeptide 2.01a and non-fluorinated analog 2.01b were prepared to 
analyze the effect that fluorine has on a hairpin turn, an important secondary structure that is often 
used as a recognition motif. After performing solution NMR experiments, it was discovered that 
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the fluorinated tetrapeptide adopted a more stable hairpin structure on account of the more stable 
central fluorinated amide bond (Figure 2.1).10     
 
 
Figure 2.1: Effects of fluorine on a hairpin turn in a β-tetrapeptide. All credit for this graphic 
goes to Mathad, et al.10 
Oftentimes it is hard to predict the behaviors/properties that incorporation of a single 
fluorine atom at the α-position will have on a β-amino acid. Nevertheless, a lot of effort has been 




2.2 Asymmetric, catalytic approaches to α-fluoro-β-amino 
acid derivatives 
Though less common than syntheses of other fluorinated amino acids, there still exist many 
methods for making enantiomerically enriched α-fluoro-β-amino acids and their derivatives. It 
should come as no surprise that a lot of the catalytic approaches used to make enantioenriched β-
amino acids have also been applied to make α-fluoro-β-amino acids. Some illustrative examples 
are in Figure 2.2. In 2010, Brenner-Moyer et al. disclosed an enantioselective iminium ion catalysis 
approach (Eq. 1).11 Formation of the iminium cation from the prolinol-derived catalyst and enal, 
followed by Michael addition of the Cbz-protected hydroxylamine generates an intermediate 
enamine. This enamine can react with NFSI (N-fluorobenzenesulfonimide), an electrophilic 
fluorinating agent (“F+” equivalent). The workup delivers the fluorinated aldehyde 2.04 which 
undergoes Pinnick oxidation to the carboxylic acid. Another approach disclosed in 2010 involved 
using a C2-symmetrical guanidine to catalyze the asymmetric addition of fluorinated β-
ketooxazolidinone 2.07 to reactive N-carbamate imine 2.06 (Eq. 2).12 Subsequent selective 
deacylations delivered the final product. Along with these methodologies, another common 
approach to these compounds involves asymmetric reduction of α-fluoro-β-enamino esters. This 
has been achieved in two ways, either using N-sulfinyl urea-catalyzed asymmetric hydrosilylation 
(Eq. 3)13 or via asymmetric hydrogenation using iridium and ZhaoPhos (Eq. 4).14 In addition to 
these asymmetric catalytic approaches, α-fluoro-β-amino acids have also been synthesized via 
kinetic resolution (KR, vide infra, section 3.1). Enantioselective methanolysis of mono-fluorinated 
N-unprotected β-lactam 2.16 was achieved by Burkholderia cepacia lipase (Figure 2.3).15 
Interestingly, the non-fluorinated analogue of this β-lactam did not react, possibly indicating the 




Figure 2.2. Catalytic asymmetric approaches to α-fluoro-β-amino acids.  
 
Figure 2.3. KR of an α-fluoro-β-lactam via enantioselective methanolysis. 
 
While the most illustrative examples were described, more methods exist for the catalytic,  
asymmetric synthesis of these compounds.9  
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2.3 Lewis base-catalyzed asymmetric synthesis of β-lactams 
As aforementioned in subchapter 1.2 (Figure 1.5, Eq. 2), the ring-opening of β-lactams is 
a practical approach to enantioenriched β-amino acid derivatives. In 2002, Fu demonstrated for 
the first time that a chiral organic Lewis base could catalyze an asymmetric Staudinger reaction, 
or an overall formal [2+2] cycloaddition between an imine and ketene, to deliver β-lactams in 
enantioenriched form (Figure 2.4, Eq. 1). Prior to this work, most enantioselective approaches to 
β-lactams via the Staudinger reaction relied on stoichiometric amounts of chiral auxiliaries.16 The 
mechanism is straightforward and starts with the nucleophilic catalyst 2.20 attacking the 
electrophilic ketene 2.18. The resulting zwitterionic enolate will react with imine 2.19. Subsequent 
ring closure turns over the catalyst and generates the β-lactam. One disadvantage of this work, 
however, was the laborious synthesis of the chiral catalyst 2.20. 
Since 2002, others have shown the efficacy of this asymmetric Lewis base-catalyzed 
Staudinger reaction. For example, in 2004 Lectka et. al demonstrated analogous asymmetric 
Staudinger reactions using the much more accessible cinchona alkaloid derivative O-
benzoylquinine 2.26 as Lewis base catalyst (Figure 2.4, Eq. 2). Starting with acid chlorides rather 
than ketenes, non- nucleophilic proton sponge (1,8-bis(dimethylamino)naphthalene) served as a 
proton sink, aiding in the formation of the key intermediate zwitterionic enolate and preventing 
protonation of the catalyst.17 For several years, these two approaches remained the state of the art 
for the asymmetric Lewis base-catalyzed synthesis of β-lactams and capitalized on the chiral Lewis 
bases available at the time. However, around 2004, another important class of Lewis basic catalysts 




Figure 2.4. Lewis-base catalyzed formal [2+2] cycloadditions as an approach to enantioenriched 
β-lactams.  
2.4 Amidine base-catalyzed formal [2+2] cycloadditions 
Since their inception by our group in 2004 (Figure 2.5), amidine-based catalysts (ABCs) 
have been utilized in a myriad of enantioselective organocatalytic processes. These processes 
include, but are not limited to, kinetic resolutions, dynamic kinetic resolutions, desymmetrizations, 
asymmetric Michael additions, rearrangements, and domino reactions.18 Additionally, ABCs have 
displayed their success in enantioselective formal [2+2] and [4+2] cycloadditions, exemplifying 




Figure 2.5. Evolution of ABCs developed by our group. 
The first use of ABCs in a formal [2+2] cycloaddition was demonstrated by Romo et al. A 
homobenzotetramisole (HBTM)-catalyzed intramolecular aldol-lactonization tandem reaction 
converted keto acids 2.32 into bi- and tricyclic β-lactones (Figure 2.6).19 This methodology was 
later used in the total synthesis of (−)-Curcumanolide A and (−)-Curcumalactone.20 
 
Figure 2.6. Homobenzotramisole-catalyzed aldol-lactonization tandem reaction. 
A couple years later, Romo’s group published another impressive tandem transformation 




Figure 2.7. Tandem Michael-aldol-lactonization synthesis of β-lactone fused cyclopentanes. 
Furthermore, in 2014, Smith et. al expanded upon the currently available methods for the 
Lewis-base catalyzed synthesis of β-lactams by using a modified ABC known as HBTM-2.1 (or 
Hyper BTM, 2.31c), where the Me group in HBTM-2 was replaced with a sterically bulkier 
isopropyl group.22 Here, they demonstrated that in situ activated aryl-, alkenyl-, and thioaryl acetic 
acid derivatives could be used in a manner similar to the work of Fu and Lectka (Figure 2.4) to 
make reactive N-sulfonyl β-lactams (Figure 2.8). These reactive lactams were opened with lithium 
methoxide to generate the β-amino acid esters 2.40.23 
 





2.5 Our approach to α-fluoro-β-amino acids via asymmetric 
ABC-catalyzed formal [2+2] cycloaddition 
With all the asymmetric approaches to α-fluoro-β-amino acids outlined in Section 2.2, there 
is one enantioselective catalytic approach that had remained uninvestigated. Given the literature 
precedent outlined in section 2.3, it was envisaged that enantioenriched α-fluoro-β-amino acids 
could be made by quenching α-fluoro-β-lactams 2.42 with nucleophiles (Figure 2.9). While this 
method has been used to prepare enantioenriched non-fluorinated β-amino acid esters (e.g. see 
Figure 1.5, Eq. 2), this reaction had yet to be explored with the analogous fluorinated β-lactams, 
which were expected to be even more reactive.  
 
Figure 2.9. Our proposed strategy to enantioenriched α-fluoro-β-amino acids via [2+2] 
cycloaddition. 
 
This lactam, in turn, could be synthesized via a Lewis base-catalyzed Staudinger [2+2] 
formal cycloaddition between reactive imines and a fluorinated zwitterionic enolate 2.43. This 
enolate could be obtained from in situ activation of fluoroacetic acid, followed by nucleophilic 
attack of a Lewis basic catalyst and subsequent deprotonation. Though having scarce literature 
precedent, especially in the context of asymmetric catalysis, fluoroenolates have found use in 
synthesis. For example, Welch et al. discovered that the lithium enolate of ethyl fluoroacetate can 
be used in diastereoselective aldol reactions with variously substituted aldehydes and ketones.24 
Given how attractive this approach was on paper, it was astonishing to see nearly non-existent 
literature precedent for this strategy. Nevertheless, there did exist some precedent to suggest the 
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viability of this approach. For example, Lectka et al. managed to synthesize the α-fluorinated-β-
lactam using their methodology (Figure 2.4, Eq. 2, R=F, obtained in 97% ee); however, no effort 
was made to further explore the substrate tolerance of this fluoroenolate. It was also unclear if this 
fluoroenolate would be well-behaved using a structurally different class of acyl transfer catalysts, 
namely ABCs. Furthermore, Smith’s group demonstrated for the first time that ABCs can be used 
in formal [2+2] cycloadditions leading to β-lactams (Figure 2.8). However, a fluorine at the α-
carbon (2.38, R=F) remained unexplored. They showed that an electron-stabilizing substituent at 
the α-carbon in 2.38 (R=aryl, alkenyl) was well tolerated. This group most likely further acidifies 
the α-proton, facilitating deprotonation of the acyl ammonium cation and formation of the key 
zwitterionic enolate intermediate. However, other electron withdrawing groups, such as a fluorine 
substituent, can be envisioned to serve the same purpose. Our group wanted to explore this 
possibility; however, it was unknown if the different reactivity between fluoroenolates and the 
enolates employed in Smith’s work would necessitate the optimization of a different set of reaction 
conditions.  
2.6 Optimization of reaction conditions: Activator, base, and 
achiral catalyst  
Fluoroacetic acid had never been used as an acyl donor in Lewis base-catalyzed reactions. 
Therefore, we needed to establish a procedure to activate it in situ and avoid reaction conditions 
that lead to uncatalyzed, racemic background reactions. We started by exploring different 
activators, bases, and achiral acyl transfer catalysts (Table 2.1).  
First, we treated fluoroacetic acid with tosyl chloride23,25 and excess triethylamine. Upon 
addition of N-tosyl benzaldimine 2.46a, without any acyl transfer catalyst, we observed formation 
of β-lactam 2.47a by 1H NMR (entry 1). This racemic background reaction was a pleasant 
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observation, but would not suitable for developing an asymmetric version of this reaction. No 
lactam formation was observed in the presence of DBU or Hünig’s base (N,N-
diisopropylethylamine) in the absence of acyl transfer catalyst (entries 2 and 3). Interestingly, with 
DBU all of the imine was consumed. It was proposed that the α-fluoro β-lactam did form, but was 
rapidly consumed in side reactions as a result of the nucleophilicity of DBU. This imine 
disappearance, however, was not observed with Hünig’s base. Addition of 20 mol % of DHPB26 
2.48a led to rapid lactam formation in the presence of Hünig’s base, but again, not with DBU 
(entries 4 and 5). Thus, Hünig’s base was the optimal choice of base for this study.  
Table 2.1: Optimization of reaction conditions: activator, base, and achiral catalyst. 
 
entry catalyst activator base 2.47a/2.46a 
1 none TsCl NEt3 94:6
a 
2 none TsCl DBU NR 
3 none TsCl i-Pr2NEt NR 
4 2.48a TsCl DBU NR 
5 2.48a TsCl i-Pr2NEt 66:34 
6 2.48a PivCl i-Pr2NEt NR 
7 2.48a TCBC i-Pr2NEt NR 
8 2.48b TsCl i-Pr2NEt 22:78 
9 2.48c TsCl i-Pr2NEt 57:43 
10 2.49 TsCl i-Pr2NEt 72:28 
11 2.50 TsCl i-Pr2NEt NR 
aAfter 24 hours. 
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At this point, extensive analyses of crude reaction mixtures by 19F NMR showed several 
byproducts, suggesting that fluoroacetic acid was being consumed in unproductive pathways. To 
overcome this, excess fluoroacetic acid was used. This immediately translated into higher isolated 
yields of the fluorinated β-lactam after chromatography. Other activating agents such as pivaloyl 
chloride27 and 2,4,6-trichlorobenzoyl chloride28 (TCBC, Yamaguchi reagent) were completely 
ineffective activators (entries 6 and 7). Other achiral catalysts were briefly explored. Electron-poor 
and electron-rich derivatives of DHPB produced lower conversion (entries 8 and 9). DMAP 2.49 
gave slightly higher conversions than DHPB (entry 10). No reaction was observed with the 
triazolium salt 2.50, a precursor to an NHC (N-heterocyclic carbene) catalyst (entry 11).  
2.7 Optimization of reaction conditions: Chiral catalysts and 
exploring nucleophiles  
We next explored chiral DHPB derivatives and analogues to devise an enantioselective 
approach to these compounds (Table 2.2). BTM29 2.30 and HBTM-2.122 2.31c gave excellent 
enantioselectivities, but stalled before all imine was consumed (entries 1 and 2). HBTM30 2.31a 
and HBTM-231 2.31b brought the reaction to completion (entries 3 and 4). Despite high conversion 
being observed by 1H NMR, β-lactam 2.47a was being isolated in relatively low yield (~40%). 
This is most likely due to decomposition during the work up and chromatography. Therefore, we 
converted the lactams into stable esters and amides in situ by introducing an alcohol or amine 
respectively into the reaction mixture. These esters and amides were isolated in moderate overall 
yields and with excellent enantioselectivities (entries 4-7). The ring-opened methyl ester 2.51a-
OMe produced X-ray quality crystals, allowing us to validate its expected relative and absolute 




Furthermore, analysis of the crude reaction mixture by 19F NMR showed that both the 
lactam 2.47a and benzyl ester 2.51a-OBn were produced with 15:1 diastereoselectivity in favor 
of the syn-diastereomer. This proved that no epimerization was taking place during the ring 
opening.33 Comparable yields of product were observed with a larger scale (2.64 mmol, entry 8) 
and at lower catalyst loadings (entries 9 and 10), though reaction times were appropriately 
adjusted.   
Table 2.2: Optimization of the enantioselective variant.a  
 
entry Catalyst (mol %) 2.47a/2.46a % yieldb NuH % ee 
1 2.30 (20) 73:27 50 BnOH 99 
2 ent-2.31c (20) 68:32 38 BnOH -99 
3 ent-2.31a (20) 99:1 45 BnOH -99 
4 2.31b (20) 99:1 60 BnOH >99 
5 2.31b (20) 99:1 61 MeOH 96 
6 2.31b (20) 99:1 53 BnNH2 98 
7 2.31b (20) 99:1 55 Et2NH >99 
8c 2.31b (20) 99:1 58 BnOH >99 
9d 2.31b (10) 99:1 55 BnOH 99 
10d 2.31b (5) 99:1 54 BnOH 98 
a General conditions: FCH2CO2H (0.5 mmol), TsCl (0.75 mmol), i-Pr2NEt (0.75 mmol), CDCl3, 
0 °C, then catalyst, i-Pr2NEt (0.75 mmol), 2.46a (0.25 mmol), 0 °C, 18 h, then NuH (1.2 equiv of 
BnOH or 10 equiv of MeOH, BnNH2, or Et2NH), rt, 4 h. 
b Isolated yields of the pure major 





Figure 2.10: X-ray crystal structure of 2.51a-OMe. 
 
2.8 Substrate scope of new methodology 
With the optimization studies completed, we next explored the substrate scope of the new 
methodology (Table 2.3). Arylsulfonyl groups with a p-methoxy or p-bromo substituent were 
tolerated but produced lower yields compared to tosyl (entries 2 and 3). N-Nosyl benzaldimine 
reacted very quickly to form the corresponding lactam; however, this lactam was also quickly 
consumed via side reactions (entry 4). Variation of the R group showed that while electron-
withdrawing and mildly electron-donating groups were well tolerated (entries 5-11), a p-methoxy 
group rendered the imine unreactive (entry 12). N-tosylfuraldimine was also unreactive and 
underwent mostly side reactions (entry 13). No reaction was observed with N-
tosylcinnamaldimine, a unique case where a formal [2+2] or formal [4+2] cycloaddition could be 
expected to compete (entry 14). An alicyclic substituent with an α-proton reacted but did not 
give the desired product. Instead, deprotonation and subsequent fluoroacetylation delivered the 
N-fluoroacetyl-N-tosylenamine (entry 15). Besides entries 9 and 11, excellent enantioselectivities 





Table 2.3: Substrate scope 
 
entry R Ar2 % yield dr % ee 
1 Ph 4-MeC6H4 60
b 14.9:1 >99 
2 Ph 4-MeOC6H4 50 12.6:1 >99 
3 Ph 4-BrC6H4 38 11.5:1 95 
4 Ph 4-O2NC6H4 <5
d ND ND 
5 4-O2NC6H4 4-MeC6H4 32 13.8:1 >99 
6 4-O2NC6H4 4-MeOC6H4 48 7.5:1 >99 
7 4-BrC6H4 4-MeC6H4 52
b >20:1 98 
8 4-ClC6H4 4-MeC6H4 53
b >20:1 >99 
9a 2-ClC6H4 4-MeC6H4 38 1.1:1 99 
10a 2-MeC6H4 4-MeC6H4 43 18.8:1 99 
11a 1-naphthyl 4-MeC6H4 39 9.1:1 74 
12 4-MeOC6H4 4-MeC6H4 <5
d ND ND 
13 2-furyl 4-MeC6H4 <5
d ND ND 
14 styryl 4-MeC6H4 0 ND ND 
15a cyclohexyl 4-MeC6H4 0
c ND ND 
a Reactions performed at rt. b Yield of the major diastereomer only. c N-Fluoroacetyl-N-
tosylenamine was produced instead in 68% yield. d Complex reaction mixture. 
 
2.9 Exploring other imines 
As evidenced in section 2.8, N-sulfonyl aldimines were well tolerated in this methodology. 
However, even then, some of these imines failed to react (e.g. see Table 2.3, entries 12-14). There 
do exist reliable methods for removing an arylsulfonyl group (e.g. Birch reduction).34 However, 
they are not the most ideal protecting groups, especially considering the relative ease with which 
other nitrogen protecting groups can be removed. As aforementioned, more easily removable 
arylsulfonyl groups such as p-nosyl were tested (Table 2.3, entry 4), but this resulted in lactams 
that were too reactive and consumed in side reactions. Furthermore, classical reagents to remove 
an arylsulfonyl group such as samarium iodide35, sodium naphthalenide36, and hot concentrated 
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acids37 were not expected to bode well for compounds containing a fluorine substituent and 
epimerizable stereocenter. With this in mind, we explored the behavior of other imines such as 
those shown in Figure 2.11.  
 
Figure 2.11. Exploring other imines with optimized reaction conditions. 
t-Butylsulfonyl imine 2.52a was well tolerated, giving moderate conversions to the desired 
lactam by 1H NMR. Unfortunately, major purification issues of the ring-opened product were 
observed when both alcohols and amines were used to quench the lactam. N-Boc benzaldimine 
2.52b suffered the same disadvantage as N-nosyl benzaldimine in that the resulting lactam formed 
very quickly, but was quickly consumed in side reactions. N-acyl benzaldimines 2.52c and 2.52d 
were surprisingly completely unreactive. N-phenylbenzaldimine 2.52e stalled at low 20-25% 
conversions. While the phenyl group is not a standard protecting group for a nitrogen atom, it was 
nonetheless interesting to compare how an N-aryl imine would react.  
2.10 Deprotection of nitrogen 
Being unable to find imines that would lead to products with relatively easier-to-remove 
protecting groups, we were tasked with finding a convenient deprotection protocol. A two-step 
procedure was devised that first involved installation of an electron withdrawing group on the 
nitrogen (Figure 2.12). A Boc group was chosen for convenience. Following a published 
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procedure,38 intermediate 2.54a-OBn was sonicated with magnesium metal in methanol to deliver 
the detosylated 2.55a-OMe product with concomitant transesterification of the benzyl ester. No 
evidence of defluorination or epimerization was observed over these two steps. This is in stark 
contrast to other attempted methods to remove the tosyl group, such as samarium iodide or sodium 
naphthalenide, which gave very complex mixtures and oftentimes removed the fluorine from the 
desired product. 
 
Figure 2.12. Removal of tosyl group from 2.51a-OBn. 
 
2.11 Exploring additional uses of fluoroenolates 
Encouraged by our success with using fluoroacetic acid in the beta-lactam synthesis 
described above, we decided to explore the reactivity of the putative fluoroenolate with other 
electrophiles. As alluded to in Section 2.8, one of the biggest limitations of this new methodology 
is the seemingly exclusive tolerance of N-sulfonyl aldimines. In addition to imines with different 
electron-withdrawing groups on the nitrogen (section 2.9), other electrophiles were also explored 
using the optimized reaction conditions and DHPB as catalyst. These electrophiles and their 
expected products are shown in Figure 2.13. Unfortunately, all of these electrophiles failed to react 
with the fluoroenolate in the expected manner, allowing for 100% recovery of the unreacted 
electrophile.  
Aldehydes, even those with strong electron-withdrawing groups such as p-
nitrobenzaldehyde 2.56, would not react with the fluoroenolates in the expected manner, indicating 
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the importance of an anion-stabilizing group on the electrophile. The resulting formal [2+2] 
cycloaddition to give the analogous α-fluoro-β-lactone 2.56a would be a captivating approach to 
another class of synthetically useful fluorinated four membered rings. Lastly, it was discovered 
that fluoroenolates fail to react with Michael acceptors that contain anion-stabilizing groups. 
Methyl cinnamate 2.57, cinnamonitrile 2.58, and ethyl 2-cyano-3-phenylacrylate 2.59 were all 
unreactive substrates and did not deliver the fluorinated cylcobutanones. However, this is not 
surprising given their relatively low electrophilicity compared to N-sulfonyl imines.  
 
Figure 2.13: Other electrophiles tested using this methodology. 
2.12 Substrate-dependent diastereoselectivities 
The syn-diastereoselectivity observed in this study is consistent with the published work of 
Lectka et al.17, even though they used a different class of acyl transfer catalyst. This stands in stark 
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contrast to the stereochemical outcome observed by Smith et al.23 (see 2.60a-c, Figure 2.14). The 
[2+2] cycloadditions demonstrated by our group and Smith’s group employ essentially the same 
reaction conditions and amidine-based acyl transfer catalysts, but produce different 
diastereoselectivities. In other words, the fluoroenolate seems to force a change in the transition 
state compared to the enolates of aryl-, arylthio-, and alkenylacetic acids. The absolute 
configuration at C3 is the same in both cases, demonstrating the same catalyst-controlled facial 
selectivity with respect to the zwitterionic Z-enolates in the transition state. Hence, the imine must 
approach the zwitterionic enolate from the less hindered face of the catalyst. However, the opposite 
stereochemistry at C4 suggests that this imine’s orientation in the transition state is different (see 
models 2.61 and 2.62, Figure 2.14). Even though it is not definitive, there are possible explanations 
for this transition state behavior. Because the fluoroenolate is not as stabilized as the aryl- or 
alkenyl-enolate (inductive vs resonance argument), it is expected to be a relatively more reactive 
nucleophile. Consequently, the C-C bond forming step is predicted to be more exothermic than in 
the aryl/alkenyl case. According to the Hammond postulate, this will result in an earlier open 
transition state, one which resembles the starting materials more than the products and one in which 
the C-C bond is not close to forming.39 In Smith’s case, the relatively later transition state may 
help govern the preference for the more thermodynamically stable trans-diastereomer; however, 
due to fluorine’s small size, this thermodynamic bias may be overridden by minimum steric 
encumbrance in an open transition state. For example, in transition state 2.62, the small fluorine 
atom can more easily accommodate the sterically bulky -NTs group in a gauche conformation. 
Additionally, fluorine’s other unique properties (see section 2.1), such as its high electronegativity 
and effects on nearby dipoles, may also be contributing in unpredictable manners. Further 
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computational studies will need to be performed to further elucidate this diastereoselective 
predilection (see footnote1).  
 
Figure 2.14. Substrate-dependent diastereoselectivities. 
 
2.13 Conclusions and future directions 
In conclusion, we have developed a new enantioselective approach to esters and amides 
of α-fluoro-β-amino acids. The methodology involves asymmetric synthesis of α-fluoro-β-
lactams via an amidine base-catalyzed [2+2] cycloaddition, followed by quenching of the 
intermediate lactam with an alcohol or amine. This methodology did have some limitations, 
namely in restricted substrate scope. In this regard of failed substrates, either the imine is too 
unreactive, or the resulting fluoro-β-lactam is too unstable and undergoes rapid decomposition. 
The reactivity of fluoroenolates also seems to restrict their use given the broad range of other 
electrophiles that do not react with these enolates. Nevertheless, this methodology greatly 
expanded upon the use of fluoroenolates in asymmetric catalysis. Prior to our work, only one 
known example of a fluoroenolate being used in this manner was known. The 
 
1 Alternative concerted asynchronous transition states are being considered.   
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diastereoselectivity of the [2+2] cycloaddition in favor of the syn-diastereomer is also fascinating 
and requires further study. 
In terms of future directions, it would be intriguing to analyze other haloenolates in the 
exact same context. While fluorine is the most attractive halogen for this application, analogous 
halolactams would arguably be more stable and may even display different substrate-dependent 
diastereoselectivities. Furthermore, it would be interesting to see what other types of nucleophiles 
could be used to quench these reactive intermediate lactams. For example, thiols can be used in 
lieu of alcohols as nucleophiles to make fluorinated thioesters. It would also be compelling to 
explore fluoroenolates with other catalysts such as bifunctional primary amine-thiourea 
organocatalysts (see section 3.3 for an introduction to bifunctional organocatalysis) to try to 
overcome these limitations with the electrophiles listed in Section 2.11. For example, if a double 
hydrogen bond donor serves to activate an aldehyde carbonyl, then the fluoroenolate, which would 
be expected to be in close proximity if employing a bifunctional catalyst, is given a better chance 
to react with said electrophilic moiety. This would introduce a mechanistically distinct approach 
to α-fluorinated-β-lactones that has never been disclosed. 
2.14 Experimental 
All reagents were obtained commercially and used as received unless specified otherwise. 
Catalysts 2.30, 2.31a-c, and 2.48a-c were prepared as previously described.22,26,29,30,31,40,41 All N-
sulfonylaldimines used were prepared according to published procedures.42 Deuterated chloroform 
used as the reaction medium and diisopropylethylamine were freshly distilled from calcium 
hydride. p-toluenesulfonyl chloride was recrystallized from hexanes. Solvents used for 
chromatography were ACS or HPLC grade, as appropriate. Reactions were carried out under inert 
atmosphere and monitored by 1H NMR. Uniplate HLF (2 μm) silica gel plates were used for TLC 
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analyses. Flash column chromatography was performed over Sorbent Technologies silica gel (40-
63 mm). HPLC analyses were performed on a Shimadzu LC system using Chiralcel OD-H, 
Chiralpak AD-H, and Chiralpak AS-H analytical chiral stationary phase columns (4.6x250 mm, 
Chiral Technologies, Inc.) with UV detectors at 254 nm and 204 nm, as appropriate, with a flow 
rate of 1.0 mL/min. 1H and 13C NMR spectra were recorded on Mercury 300 MHz and DD2 500 
MHz Agilent spectrometers. The chemical shifts are reported as  values (ppm) relative to TMS 
using residual CHCl3 peak as the reference (7.26 ppm for 
1H NMR, 77.16 ppm for 13C NMR). The 
chemical shifts for 19F NMR are reported as δ values (ppm) relative to fluoroacetic acid (-230.00 
ppm). Melting points were measured on a Stuart SMP10 melting point apparatus. High-Resolution 
mass spectral analyses were performed at Washington University MS Center on a Bruker MaXis 
QTOF mass spectrometer using Electrospray Ionization (ESI). Infrared spectra were recorded on 
a Bruker Alpha Platinum-ATR. Optical rotations were determined on a Rudolph Autopol III 
polarimeter. 
2.14.1 Preparation of anhydrous fluoroacetic acid 2.45 
A published procedure43 was followed with minor modifications. A solution of ethyl fluoroacetate 
(13.6 mL, 141 mmol) in 180 mL of 95% EtOH was treated with 20 mL of aqueous NaOH (6.72 g, 
168 mmol) and stirred at rt for 1 day. The solvent was rotary evaporated to dryness. The sodium 
fluoroacetate thus obtained was redissolved in 120 mL of 3 M aqueous HCl, the solution was 
saturated with NaCl and then extracted four times with Et2O (4×25 mL). The organic extract was 
dried with MgSO4, filtered, and the filtrate was rotary evaporated to produce fluoroacetic acid as 
a clear oil. This crude product, which was still slightly wet, was redissolved in anhydrous Et2O, 
dried with copious amounts of MgSO4 overnight, filtered, and rotary evaporated to dryness to 
produce crystalline fluoroacetic acid, which was stored in a desiccator over large amounts of 
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phosphorus pentoxide until ready to use. Note: the dryness of fluoroacetic acid is critical to ensure 
reproducibility of reactions described below. Also note that fluoroacetic acid and its derivatives 
are highly toxic! 
2.14.2 Enantioselective synthesis and ring opening of 3-fluoro-β-lactams 
 
Optimized procedure: An oven-dried round bottom flask was charged with fluoroacetic acid (39 
mg, 0.50 mmol) and 2.5 mL of CDCl3, placed under an inert atmosphere, and cooled to 0 °C. The 
mixture was treated with TsCl (143 mg, 0.75 mmol) followed by i-Pr2NEt (124 μL, 97 mg, 0.75 
mmol) and stirred at 0 °C for 30 min. Then, (S)-HBTM-2 2.31b (14 mg, 0.05 mmol), N-
sulfonylimine 2.46 (0.25 mmol), and additional i-Pr2NEt (124 μL, 97 mg, 0.75 mmol) were added 
sequentially. The mixture was left to stir at the temperature indicated below, and the reaction 
progress was monitored by 1H NMR. Upon reaching complete conversion (>9:1 ratio of β-lactam 
2.47 to N-sulfonylimine 2.46), the reaction mixture was brought to room temperature and either 
worked up directly or treated with an alcohol or amine in the amount indicated. Stirring was 
continued until 1H NMR analysis indicated complete consumption of β-lactam 2.47. The reaction 
was quenched with 1M aqueous HCl and the aqueous phase was extracted twice with CH2Cl2. The 
organic extract was dried with Na2SO4 and concentrated by rotary evaporation. The crude products 
were purified by column chromatography or recrystallization. The major diastereomer was 
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isolated, at least in part, in pure form using these methods. The diastereomeric ratios reported in 
Table 2.3 in Section 2.8 were determined by 1H and 19F NMR analysis of crude reaction mixtures. 
β-lactam 2.47a 
After addition of N-tosylimine 2.46a, the reaction was stirred at 0 °C for 9 hours and then quenched 
and worked up as described above. Isolated as a colorless, crystalline solid (43 mg, 40% combined 
yield, 39 mg isolated as pure major diastereomer shown) after chromatography (5→20% 
EtOAc/hexanes). Other ring opened products listed below were prepared analogously. Reaction 
times and temperatures to make the β-lactam and the nucleophile used are listed below. 
(3S,4R)-3-fluoro-4-phenyl-1-tosylazetidin-2-one (2.47a) 
Colorless, crystalline solid. 1H NMR (500 MHz, CDCl3) δ 7.62 (d, J = 8 Hz, 2H), 
7.37-7.33 (m, 1H), 7.30-7.22 (m, 4H), 7.13 (d, J = 8 Hz, 2H), 5.68 (dd, J = 54 Hz, 6 
Hz, 1H), 5.35 (dd, J = 6 Hz, 5 Hz, 1H), 2.43 (s, 3H); 13C{1H} NMR (125 MHz, CDCl3): δ 160.00 
(d, J = 23 Hz), 145.91, 135.39, 130.28, 130.04, 129.63, 128.70, 128.56, 127.80, 91.08 (d, J = 232 
Hz), 63.84 (d, J = 23 Hz), 21.87; 19F NMR (282 MHz, CDCl3): Major diastereomer: -198.65 (dd, 
J= 54 Hz, 5 Hz), Minor diastereomer: -189.98 (dd, J = 53 Hz, 13 Hz); IR (cm-1): 1784, 1363, 
1163, 1140, 545; MS: HR-ESI calculated for [C16H14FNO3S+Na]
+ : 342.0570, found 342.0554; 
mp: 148- 149 °C; [α] 𝐷
23 = -70.5° (c=.400, CH2Cl2).  
Ester 2.51a-OBn 
Small-scale preparation: The reaction was conducted as described above at 0 °C for 24 hours. 
Treated with 1.2 equiv of BnOH. Product isolated as a white solid (64 mg; 60% yield, single 
diastereomer) after chromatography (5→50% EtOAc/hexanes). Large-scale preparation: The 
reaction was carried out analogously to the small-scale procedure using the following quantities: 
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FCH2CO2H (412 mg, 5.28 mmol), CDCl3 (26 mL), TsCl (1.51 g, 7.92 mmol), i-Pr2NEt (1.38 mL, 
1.02 g, 7.92 mmol), (S)-HBTM-2 2.31b (1.66 mL of 0.318 M stock solution in CDCl3, 0.53 mmol), 
PhCH=NTs 2.46a (684 mg, 2.64 mmol), i-Pr2NEt (1.38 mL, 1.02 g, 7.92 mmol), PhCH2OH (329 
μL, 3.17 mmol). After workup and chromatography, 654 mg of the product was isolated as a single 
diastereomer (58% yield). 
benzyl (2S,3R)-2-fluoro-3-((4-methylphenyl)sulfonamido)-3-phenylpropanoate (2.51a-OBn) 
White solid. 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 8 Hz, 2H), 7.41 – 7.35 
(m, 3H), 7.35-7.31 (m, 2H), 7.23-7.14 (m, 3H), 7.14-7.06 (m, 4H), 5.96 (d, J = 
10 Hz, 1H), 5.21 (d, J = 12 Hz, 1 H), 5.12- 4.98 (m, 2H), 5.05 (d, J = 12 Hz, 
1H), 2.32 (s, 3H); 13C{1H} NMR (125 MHz, CDCl3): δ 166.95 (d, J = 25 Hz), 143.37, 137.42, 
135.56, 134.62, 129.42, 128.75, 128.73, 128.62, 128.26, 127.12, 127.09, 127.08, 90.91 (d, J = 
193 Hz), 67.93, 58.60 (d, J = 20 Hz), 21.49; 19F NMR (282 MHz, CDCl3): Major diastereomer: -
199.82 (dd, J = 50 Hz, 27 Hz), Minor diastereomer: -202.15 (dd, J = 52 Hz, 28 Hz); IR (cm-1): 
3327, 1758, 1322, 1151, 1085, 1059, 697, 665, 549; MS: HR-ESI calculated for 
[C23H22FNO4S+Na]+: 450.1146, found: 450.1149; mp: 131-134 °C; HPLC: (25 % 
isopropanol/hexanes, AS-H): Minor enantiomer: 21.3 min; Major enantiomer: 32.0 min; >99% 
ee; [α] 𝐷
23 = -11.2° (c=1.13, CH2Cl2). 
methyl (2S,3R)-2-fluoro-3-((4-methylphenyl)sulfonamido)-3-phenylpropanoate (2.51a-
OMe) 
The reaction was conducted at 0 °C for 10 hours. Treated with 10 equiv of 
MeOH. Isolated as a white solid (58 mg, 61% combined yield of 
diastereomers) after chromatography (5→30% EtOAc/hexanes). Major 
37 
 
diastereomer: 1H NMR (500 MHz, CDCl3), δ 7.55 (d, J = 8 Hz, 2H), 7.24-7.19 (m, 3H), 7.15-
7.10 (m, 4H), 5.53 (d, J = 10 Hz, 1H), 5.03 (dd, J = 47 Hz, 3 Hz, 1H), 4.97 (ddd, J = 26 Hz, 10 
Hz, 3 Hz, 1H), 3.68 (s, 3H), 2.34 (s, 3H); 13C{1H} NMR (125 MHz, CDCl3): 167.44 (d, J = 24 
Hz), 143.56, 137.49, 135.90, 129.54, 128.79, 128.46, 127.17, 127.00, 90.95 (d, J = 193 Hz), 
58.46 (d, J = 20 Hz), 52.91, 21.58; IR (cm-1): 3230, 1747, 1234, 1158, 670; MS: HR-ESI 
calculated for [C17H18FNO4S+H]
+: 352.1013, found 352.1002; mp: 147-149 °C; HPLC: (10% 
isopropanol/hexanes, AD-H): Major enantiomer: 31.0 min; Minor enantiomer: 42.1 min; 96% ee; 
[α] 𝐷
24 = -28.3° (c=.400, CH2Cl2). 
(2S,3R)-N-benzyl-2-fluoro-3-((4-methylphenyl)sulfonamido)-3-phenylpropanamide (2.51a-
NHBn) 
The reaction was conducted at 0 °C for 10 hours. Treated with 10 equiv. of 
BnNH2. Isolated as a white powder (62 mg, 53% yield, single diastereomer) 
after recrystallization (50% CH2Cl2/hexanes) from the crude reaction 
mixture. 1H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 9 Hz, 2H), 7.25- 7.20 (m, 4H), 7.19-7.14 (m, 
2H), 7.14-7.08 (m, 4H), 6.95-6.90 (m, 2H), 6.38 (d, J = 10 Hz, 1H), 6.29 (br s, 1H), 5.09-4.97 
(m, 2H), 4.36 (dd, J= 15 Hz, 7 Hz, 1H), 4.19 (dd, J = 15 Hz, 6 Hz, 1H), 2.34 (s, 3H); 13C{1H} 
NMR (125 MHz, CDCl3): 167.61 (d, J = 19 Hz), 143.40, 137.89, 136.75, 135.20, 129.57, 128.83, 
128.49, 128.25, 127.84, 127.71, 127.53, 127.11, 90.76 (d, J = 196 Hz), 57.45 (d, J = 24 Hz), 
42.97, 21.59; IR (cm-1): 3348, 3325, 1659, 1156, 702; MS: HR-ESI calculated for 
[C23H23FN2O3S+Na]
+ : 449.1306, found 449.1313; mp: 213-215 °C; HPLC: (20% 
isopropanol/hexanes, AD-H): Minor enantiomer: 17.5 min; Major enantiomer: 24.5 min; 98% ee;   
[α] 𝐷





The reaction was conducted at 0 °C for 10 hours. Treated with 10 equiv of 
HNEt2. Isolated as a white solid (57 mg, 55% yield, single diastereomer) after 
chromatography (5→50% EtOAc/hexanes) and subsequent recrystallization 
(50% CH2Cl2/hexanes). 
1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 8 Hz, 2H), 7.22-7.12 (m, 5H), 
7.10 (d, J = 8 Hz, 2H), 6.38 (br s, 1H), 5.14 (dd, J = 48 Hz, 6 Hz, 1H), 4.90-4.82 (m, 1H), 3.25-
3.14 (m, 2H), 3.03-2.88 (m, 2H), 2.33 (s, 3H), 0.96 (t, J = 7 Hz, 3H), 0.93 (t, J = 7 Hz, 3H); 
13C{1H} NMR (125 MHz, CDCl3): 165.68 (d, J = 20 Hz), 143.21, 137.47, 135.48, 129.40, 
128.32, 128.24, 128.06, 127.19, 89.51 (d, J = 193 Hz), 58.80 (d, J = 23 Hz), 41.5, 41.32, 21.52, 
14.41, 12.4; IR (cm-1): 3239, 1642, 1451, 1326, 1155, 1089, 700, 547; MS: HR-ESI calculated 
for [C20H25FN2O3S+H]
+: 393.1643, found: 393.1632; mp: 146-147 °C; HPLC: (20% 
isopropanol/hexanes, AD-H): Minor enantiomer: 17.0 min; Major enantiomer: 25.7 min; >99% 
ee; [α] 𝐷
24 = -30.0° (c=.800, CH2Cl2). 
benzyl (2S,3R)-2-fluoro-3-((4-methoxyphenyl)sulfonamido)-3-phenylpropanoate (2.51b-
OBn) 
The reaction was conducted at rt for 5 hours. Treated with 1.2 
equiv of BnOH. Isolated as a white solid (44 mg, 50% combined 
yield of diastereomers) after chromatography (5→30% 
EtOAc/hexanes). Major diastereomer: 1H NMR (500 MHz, 
CDCl3) δ 7.57 (d, J = 9 Hz, 2H), 7.40-7.29 (m, 5H), 7.23-7.15 (m, 3H), 7.12- 7.07 (m, 2H), 6.75 
(d, J = 9 Hz, 2H), 5.60 (d, J = 10 Hz, 1H), 5.20 (d, J = 12 Hz, 1H), 5.05 (dd, J = 47 Hz, 3 Hz, 
1H), 5.06 (d, J = 12 Hz, 1H), 5.03-4.94 (m, 1 H), 3.78 (s, 3H); 13C{1H} NMR(125 MHz, CDCl3): 
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166.97 (d, J = 24 Hz), 162.93, 135.63, 134.62, 132.03, 129.30, 128.84, 128.81, 128.80, 128.75, 
128.44, 127.11, 114.07, 90.88 (d, J = 193 Hz), 68.03, 58.51 (d, J = 20 Hz), 55.70; IR (cm-1): 
3316, 1757, 1144, 1086, 1060, 929, 699, 552; MS: HR-ESI calculated for [C23H22FNO5S+Na]+: 
466.1095, found: 466.1084; mp: 141-142 °C; HPLC: (25% isopropanol/hexanes, AS-H): Minor 
enantiomer: 30.0 min; Major enantiomer: 55.5 min; >99% ee; [α] 𝐷
22 = -13.5° (c=.267, CH2Cl2). 
benzyl (2S,3R)-3-((4-bromophenyl)sulfonamido)-2-fluoro-3-phenylpropanoate (2.51c-OBn) 
The reaction was conducted at 0 °C for 4 hours. Treated with 1.2 
equiv of BnOH. Isolated as a white solid (47 mg, 38% combined 
yield of diastereomers) after chromatography (5→20% 
EtOAc/hexanes). Major diastereomer: 1H NMR (500 MHz, CDCl3) 
δ 7.45 (d, J = 9 Hz, 2H), 7.41-7.36 (m, 5H), 7.34-7.31 (m, 2H), 7.25-7.21 (m, 1H), 7.20-7.15 (m, 
2H), 7.06 (d, J = 8 Hz, 2H), 5.72 (br s, 1H), 5.21 (d, J = 12 Hz, 1H), 5.09 (d, J = 12 Hz, 1H), 5.06 
(dd, J = 47 Hz, 3 Hz, 1H), 5.02 (ddd, J = 25 Hz, 10 Hz, 3 Hz, 1H); 13C{1H} NMR (125 MHz, 
CDCl3): 166.88 (d, J = 25 Hz), 139.47, 135.17, 134.54, 132.11, 128.93, 128.87, 128.81, 128.66, 
128.64, 127.66, 127.16, 127.15, 90.81 (d, J = 194 Hz), 68.16, 58.75 (d, J = 20 Hz); IR (cm-1): 
3241, 2930, 1750, 1244, 1156, 707, 524; MS: HR-ESI calculated for [C22H19BrFNO4S+Na]
+: 
514.0094, found: 514.0100; mp: 124- 126 °C; HPLC: (7% isopropanol/hexanes, OD-H): Minor 
enantiomer: 27.5 min; Major enantiomer: 41.3 min; 95% ee; [α] 𝐷








The reaction was conducted at 0 °C for 3 hours. Treated with 1.2 
equiv of BnOH. Isolated as a white solid (36 mg, 32 % combined 
yield of diastereomers) after chromatography (5→20% 
EtOAc/hexanes). Major diastereomer: 1H NMR (300 MHz, CDCl3) δ 7.98 (d, J = 9 Hz, 2H), 7.56 
(d, J = 8 Hz, 2H), 7.41-7.33 (m, 3H), 7.30- 7.23 (m, 4H), 7.15 (d, J = 9 Hz, 2H), 5.70 (d, J = 9 
Hz, 1H), 5.16 (d, J = 12 Hz, 1H), 5.13-4.95 (m, 2H), 5.00 (d, J = 12 Hz, 1H), 2.34 (s, 3H); 
13C{1H} NMR (125 MHz, CDCl3): 166.48 (d, J = 24 Hz), 147.83, 144.23, 142.53, 137.16, 
134.24, 129.75, 129.12, 128.96, 128.86, 128.24, 127.13, 123.75, 89.93 (d, J = 195 Hz), 68.33, 
57.81 (d, J = 21 Hz), 21.59; IR (cm-1): 3223, 1756, 1513, 1347, 1225, 1165, 1068, 694, 553; MS: 
HR-ESI calculated for [C23H21FN2O6S+Na]
+ : 495.0997, found: 495.1001; mp: 154-157 °C; 
HPLC: (20% isopropanol/hexanes, AD-H): Major enantiomer: 39.5 min; Minor enantiomer: 59.8 
min; >99% ee; [α] 𝐷
24 = -12.6° (c=.333, CH3CN). 
benzyl (2S,3R)-2-fluoro-3-((4-methoxyphenyl)sulfonamido)-3-(4-nitrophenyl)propanoate 
(2.51e-OBn) 
The reaction was conducted at 0 °C for 2 hours. Treated with 1.2 
equiv of BnOH. Isolated as a light tan solid (54 mg, 48% 
combined yield of diastereomers) after chromatography (5→50% 
EtOAc/hexanes). Major diastereomer 1H NMR (500 MHz, CDCl3) 
δ 7.99 (d, J = 9 Hz, 2H), 7.60 (d, J = 9 Hz, 2H), 7.37- 7.32 (m, 3H), 7.31-7.26 (m, 4H), 6.80 (d, J 
= 9 Hz, 2H), 5.76 (br s, 1 H), 5.18 (d, J = 12 Hz, 1H), 5.10-4.99 (m, 2H), 5.03 (d, J = 12 Hz, 1H), 
3.79 (s, 3H); 13C{1H} NMR (125 MHz, CDCl3): 166.50 (d, J = 24 Hz), 163.35, 147.90, 142.66, 
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134.23, 131.58, 129.31, 129.15, 128.97, 128.88, 128.27, 123.79, 114.31, 89.89 (d, J = 196 Hz), 
68.35, 57.75 (d, J = 21 Hz), 55.80; IR (cm-1): 3249, 1748, 1156; MS: HR-ESI calculated for 
[C23H21FN2O7S+Na]
+ : 511.0946, found: 511.0944; mp: 174-176 °C; HPLC: (30% 
isopropanol/hexanes, AD-H): Major enantiomer: 27.3 min; Minor enantiomer: 38.8 min; >99% 
ee; [α] 𝐷
24  = -11.5° (c= 0.200, CH2Cl2). 
benzyl (2S,3R)-3-(4-bromophenyl)-2-fluoro-3-((4-methylphenyl)sulfonamido)propanoate 
(2.51f-OBn) 
The reaction was conducted at 0 °C for 20 hours. Treated with 1.2 
equiv of BnOH. Isolated as a white solid (57 mg, 52% yield, single 
diastereomer) after chromatography (5→20 % EtOAc/hexanes). 1H 
NMR (500 MHz, CDCl3) δ 7.53 (d, J = 8 Hz, 2H), 7.40-7.36 (m, 3H), 7.31-7.25 (m, 4H), 7.13 (d, 
J = 9 Hz, 2H), 6.95 (d, J = 9 Hz, 2H), 5.66 (br s, 1H), 5.18 (d, J = 12 Hz, 1H), 5.07-4.90 (m, 2H), 
5.05 (d, J = 12 Hz, 1H), 2.37 (s, 3H); 13C{1H} NMR (125 MHz, CDCl3): 166.76 (d, J = 24 Hz), 
143.87, 137.31, 134.47, 134.44, 131.80, 129.62, 128.96, 128.90, 128.85, 128.84, 127.15, 122.63, 
90.38 (d, J = 194 Hz), 68.14, 57.96 (d, J = 20 Hz), 21.61; IR (cm-1): 3301, 1735, 1337, 1158, 
816, 666, 549; MS: HR-ESI calculated for [C23H21BrFNO4S+Na]
+ : 528.0251, found: 528.0252; 
mp: 147-148 °C; HPLC: (7% isopropanol/hexanes, OD-H): Major enantiomer: 33.2 min; Minor 
enantiomer: 52.2 min; 98% ee; [α] 𝐷








The reaction was conducted at 0 °C for 20 hours. Treated with 1.2 
equiv of BnOH. Isolated as a white solid (55 mg, 53% yield, single 
diastereomer) after chromatography (5→20% EtOAc/hexanes). 1H 
NMR (500 MHz, CDCl3) δ 7.53 (d, J = 9 Hz, 2H), 7.42-7.36 (m, 3H), 7.33-7.27 (m, 2H), 7.16-
7.10 (m, 4H), 7.02 (d, J = 9 Hz, 2H), 5.69 (d, J = 10 Hz, 1H), 5.18 (d, J = 12 Hz, 1H), 5.09-4.93 
(m, 2H), 5.04 (d, J = 12 Hz, 1H), 2.36 (s, 3H); 13C{1H} NMR (125 MHz, CDCl3): 166.78 (d, J = 
24 Hz), 143.83, 137.33, 134.49, 134.45, 133.99, 129.60, 128.95, 128.84, 128.59, 128.58, 127.15, 
90.46 (d, J = 194 Hz), 68.12, 57.89 (d, J = 20 Hz), 21.59; IR (cm-1): 3303, 2970, 1735, 1338, 
1158, 1088, 1062, 815, 666, 549; MS: HR-ESI calculated for [C23H21ClFO4S+Na]
+: 484.0756, 
found: 484.0755; mp: 137-140 °C; HPLC: (12 % isopropanol/hexanes, AD-H): Major 
enantiomer: 36.2 min; Minor enantiomer: 48.2 min; >99% ee; [α] 𝐷
23 = -16.4° (c=.733, CH2Cl2). 
benzyl (2S,3R)-3-(2-chlorophenyl)-2-fluoro-3-((4-methylphenyl)sulfonamido)propanoate 
(2.51h-OBn) 
The reaction was conducted at rt for 2 hours. Treated with 1.2 equiv of 
BnOH. Isolated as a white solid (35 mg total, 38 % combined yield of 
diastereomers) after chromatography (5→20% EtOAc/hexanes). Syn 
diastereomer: 1H NMR (300 MHz, CDCl3) δ 7.57 (d, J = 8 Hz, 2H), 7.39-7.32 (m, 5H), 7.30-7.26 
(m, 1H), 7.19-7.13 (m, 2H), 7.11-7.06 (m, 3H), 5.77 (d, J = 10 Hz, 1H), 5.54 (ddd, J = 27 Hz, 10 
Hz, 2 Hz, 1H), 5.24 (d, J = 12 Hz, 1 H), 5.10 (dd, J = 47 Hz, 2 Hz, 1H), 4.96 (d, J = 12 Hz, 1H), 
2.29 (s, 3H); 13C{1H} NMR (125 MHz, CDCl3): 166.51 (d, J = 25 Hz), 143.69, 137.08, 134.71, 
133.42, 132.31, 129.78, 129.57, 128.81, 128.76, 128.46, 127.18, 127.15, 89.50 (d, J = 192 Hz), 
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67.97, 55.54 (d, J = 19 Hz), 21.56; IR (cm-1): 3268, 1767, 1336, 1077, 556; MS: HR-ESI 
calculated for [C23H21ClFNO4S+Na]
+ : 484.0756, found: 484.0753; mp: 124-127 °C; HPLC: 
(10% isopropanol/hexanes, AD-H): Minor enantiomer: 36.9 min; Major enantiomer: 55.2 min; 
99% ee; [α] 𝐷
23 = -0.30° (c=.333, CH2Cl2). 
benzyl (2S,3R)-2-fluoro-3-((4-methylphenyl)sulfonamido)-3-(o-tolyl)propanoate (2.51i-
OBn) 
The reaction was conducted at rt for 10 hours. Treated with 1.2 equiv of 
BnOH. Isolated as a white solid (26 mg, 43% combined yield of 
diastereomers) after chromatography (5→30% EtOAc/hexanes). Major 
diastereomer: 1H NMR (500 MHz, CDCl3) δ 7.47 (d, J = 9 Hz, 2H), 7.42-7.30 (m, 5 H), 7.11-
7.03 (m, 4H), 6.98-6.93 (m, 2H), 5.51 (d, J = 10 Hz, 1H), 5.29 (ddd, J = 25 Hz, 10 Hz, 3 Hz, 
1H), 5.20 (d, J = 13 Hz, 1H), 5.07 (d, J = 13 Hz, 1H), 4.95 (dd, J = 47 Hz, 3 Hz, 1H), 2.30 (s, 
3H), 2.28 (s, 3H); 13C{1H} NMR (125 MHz, CDCl3): 166.97 (d, J = 25 Hz), 143.46, 137.38, 
135.07, 134.71, 133.84, 130.76, 129.41, 128.81, 128.80, 128.65, 128.25, 127.03, 126.86, 126.42, 
90.26 (d, J = 193 Hz), 67.99, 54.64 (d, J = 20 Hz), 21.56, 19.34; IR (cm-1): 3275, 1748, 1271, 
1161, 546; MS: HR-ESI calculated for [C24H24FNO4S+Na]
+: 464.1302, found: 464.1288; mp: 
120-122 °C; HPLC: (25% isopropanol/hexanes, AS-H): Minor enantiomer: 18.5 min; Major 
enantiomer: 33.0 min; 99% ee; [α] 𝐷
22 = +0.50° (c=.200, CH2Cl2). 
benzyl (2S,3R)-2-fluoro-3-((4-methylphenyl)sulfonamido)-3-(naphthalen-1-yl)propanoate 
(2.51j-OBn) 
The reaction was conducted at rt for 9 hours. Treated with 1.2 equiv of 
BnOH. Isolated as a white solid (37 mg, 39 % combined yield of 
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diastereomers) after chromatography (5→20% EtOAc/hexanes). Major diastereomer: 1H NMR 
(500 MHz, CDCl3) δ 7.94 (d, J = 8 Hz, 1H), 7.84 (d, J = 9 Hz, 1H), 7.74-7.70 (m, 1H), 7.56-7.48 
(m, 2H), 7.44 (d, J = S‐7 8 Hz, 2H), 7.41-7.35 (m, 5H), 7.26-7.23 (m, 2H), 6.94 (d, J = 8 Hz, 
2H), 5.92 (ddd, J = 25 Hz, 10 Hz, 3 Hz, 1H), 5.63 (d, J = 9 Hz, 1H), 5.26 (d, J = 12 Hz, 1H), 5.17 
(dd, J = 47 Hz, 3 Hz, 1H), 5.08 (d, J = 12 Hz, 1H), 2.24 (s, 3H); 13C{1H} NMR (125 MHz, 
CDCl3): 167.06 (d, J = 25 Hz), 143.44, 137.26, 134.74, 133.88, 131.10, 129.99, 129.34, 129.02, 
128.86, 128.70, 127.17, 127.10, 126.05, 125.14, 125.05, 121.74, 90.27 (d, J = 193 Hz), 68.15, 
54.68 (d, J = 19 Hz), 21.49; IR (cm-1): 3264, 2920, 1772, 1759, 1330, 1158, 1089, 801, 700, 546; 
MS: HR-ESI calculated for [C27H24FNO4S+Na]
+ : 500.1302, found: 500.1309; mp: 148-150 °C; 
HPLC: (12% isopropanol/hexanes, AD-H): Minor enantiomer: 32.2 min; Major enantiomer: 45.5 
min; 74% ee; [α] 𝐷
23 = +8.00° (c=.400, CH2Cl2). 
N-(cyclohexylidenemethyl)-2-fluoro-N-tosylacetamide (2.63) 
The reaction was conducted at rt for 20 hours, at which time all N-tosylimine was 
consumed. The reaction was worked up as described above. Isolated as a white 
solid (60 mg, 68% yield) after chromatography (5→20% EtOAc/hexanes). 1H 
NMR (500 MHz, CDCl3) δ 7.90 (d, J = 9 Hz, 2H), 7.31 (d, J = 9 Hz, 2H), 5.73 (s, 1H), 4.80 (d, J 
= 48 Hz, 2H), 2.42 (s, 3H), 2.21 (t, J = 6 Hz, 2H), 2.01 (t, J = 6 Hz, 2H), 1.66-1.59 (m, 2H), 1.59-
1.53 (m, 2H), 1.52-1.45 (m, 2H); 13C{1H} NMR (125 MHz, CDCl3): 166.59 (d, J = 21 Hz), 
153.01, 145.45, 135.34, 129.59, 128.93, 111.50, 78.92 (d, J = 182 Hz), 33.30, 28.40, 27.61, 
26.77, 26.05, 21.75; IR (cm-1): 2926, 2857, 1728, 1350, 1169, 1152, 1077, 565; MS: HR-ESI 
calculated for [C16H20FNO3S+Na]




2.14.3 Protecting group exchange 
 
Intermediate 2.54a-OBn: To a solution of 2.51a-OBn (104 mg, 0.24 mmol) in 1.25 mL of freshly 
distilled CH2Cl2 stirred under inert atmosphere at 0 C̊ was added dropwise a solution of Boc2O (64 
mg, 0.29 mmol, 1.2 equiv) and DMAP (2 mg, ca. 5 mol %) in 1.25 mL of CH2Cl2. The mixture 
was slowly warmed to rt and monitored by TLC for completion (10% EtOAc/hexanes). After 
complete consumption of the starting material, the reaction was quenched with saturated aqueous 
NaHCO3. The organic phase was separated, dried with MgSO4, and rotary evaporated. After 
column chromatography (5→10% EtOAc/hexanes), 2.54a-OBn was obtained as a clear, colorless 
oil which crystallized on standing (123 mg, 96%). 
benzyl (2S,3R)-3-((N-(tert-butoxycarbonyl)-4-methylphenyl)sulfonamido)-2-fluoro-3-
phenylpropanoate (2.54a-OBn) 
1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 9 Hz, 2H), 7.59-7.55 (m, 2H), 
7.35-7.27 (m, 8H), 7.12-7.08 (m, 2H), 6.17-6.02 (m, 2H), 5.11 (d, J = 12 Hz, 
1H), 5.04 (d, J = 12 Hz, 1H), 2.44 (s, 3H), 1.29 (s, 9H); 13C{1H} NMR (125 
MHz, CDCl3): 167.63 (d, J = 22 Hz), 150.61, 144.27, 137.38, 134.64, 134.59, 129.46, 129.21, 
128.94, 128.67, 128.63, 128.56, 128.39, 128.37, 87.51 (d, J = 186 Hz), 85.35, 67.64, 61.21 (d, J 
= 21 Hz), 27.94, 21.73; IR (cm-1): 2981, 2929, 1751, 1726, 1353, 1148, 697, 671, 577, 545; MS: 
HR-ESI calculated for [C28H30FNO6S+Na]
+: 550.1670, found: 550.1646; mp: 135-137 °C; [α] 𝐷
22 
= +2.5° (c=1.133, CH2Cl2).  
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Carbamate 2.55a-OMe: To a solution of 2.54a-OBn (54 mg, 0.102 mmol) dissolved in 1.6 mL of 
anhydrous MeOH and 0.54 mL of anhydrous THF was added powdered magnesium (50 mg, 2.05 
mmol, 20 equiv). This solution was sonicated for one hour, at which time TLC (10% 
EtOAc/hexanes) confirmed complete consumption of the starting material. The mixture was 
diluted with CH2Cl2 (10 mL) and poured into 10 mL of 0.5 M aqueous HCl. The organic phase 
was separated, washed with 1 M aqueous NaHCO3 and brine, dried with MgSO4 and rotary 
evaporated to yield a slightly crude crystalline solid. Successive recrystallizations from 15% 
EtOAc/hexanes gave 24 mg (80% yield) of pure 2.55a-OMe. 
methyl (2S,3R)-3-((tert-butoxycarbonyl)amino)-2-fluoro-3-phenylpropanoate (2.55a-OMe) 
1H NMR (500 MHz, CDCl3) δ 7.41- 7.29 (m, 5H), 5.44-5.25 (m, 2H), 5.15 
(dd, 2JH-F= 48 Hz, 
3JH-H cannot be measured, 1H), 3.82 (s, 3H), 1.43 (s, 9H); 
13C{1H} NMR (125 MHz, CDCl3): 168.15 (d, J = 25 Hz), 155.03, 137.65, 
128.95, 128.33, 126.86, 90.58 (d, J = 190 Hz), 80.45, 55.51 (d, J = 19 Hz), 52.85, 28.37; IR   
(cm-1): 1748, 1695, 1510, 1239, 707; MS: HR-ESI calculated for [C15H20FNO4+H]
+ : 298.1449, 
found: 298.1442; mp: 121-124 °C; [α] 𝐷











2.15 X-ray crystal structure of 2.51a-OMe 
Table 2.4.  Crystal data and structure refinement for 2.51a-OMe. 
Identification code  v10818t5/lt/x8/MS_03_25 
Empirical formula  C17 H18 F N O4 S 
Formula weight  351.38 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 11.4126(14) Å a= 90°. 
 B = 5.3638(6) Å b= 109.453(8)°. 
 C = 14.3993(19) Å g = 90°. 
Volume 831.14(18) Å3 
Z 2 
Density (calculated) 1.404 Mg/m3 
Absorption coefficient 0.226 mm-1 
F(000) 368 
Crystal size 0.575 x 0.212 x 0.041 mm3 
Theta range for data collection 1.500 to 27.541°. 
Index ranges -14≤h≤14, -6≤k≤6, -18≤l≤18 
Reflections collected 25583 
Independent reflections 25583 [R(int) = 0.037] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9143 and 0.7949 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 25583 / 2 / 223 
Goodness-of-fit on F2 1.023 
Final R indices [I>2sigma(I)] R1 = 0.0496, wR2 = 0.1010 
R indices (all data) R1 = 0.0677, wR2 = 0.1104 
Absolute structure parameter -0.02(4) 





Table 2.5.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters (Å2 x 
103) for 2.51a-OMe.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
S(1) 847(1) 3621(3) 2282(1) 18(1) 
F(1) 3544(3) 8909(6) 4134(2) 22(1) 
O(1) 4353(4) 7358(7) 2689(3) 28(1) 
O(2) 4894(3) 3673(7) 3454(2) 21(1) 
O(3) 989(3) 1268(6) 2788(3) 21(1) 
O(4) -358(3) 4724(7) 1867(3) 26(1) 
N(1) 1712(4) 5626(8) 3053(3) 17(1) 
C(1) 3831(5) 6369(9) 4137(4) 16(1) 
C(2) 4375(5) 5927(10) 3333(4) 17(1) 
C(3) 5487(5) 2932(10) 2747(4) 23(1) 
C(4) 2641(5) 4868(9) 3977(3) 14(1) 
C(5) 2185(5) 5009(10) 4848(4) 15(1) 
C(6) 1458(4) 6979(9) 4972(4) 18(1) 
C(7) 1044(5) 7013(10) 5774(4) 22(1) 
C(8) 1352(5) 5124(11) 6461(4) 22(1) 
C(9) 2079(5) 3155(10) 6341(4) 22(1) 
C(10) 2490(5) 3097(9) 5539(4) 18(1) 
C(11) 1495(5) 3290(11) 1347(4) 19(1) 
C(12) 2316(5) 1370(10) 1386(4) 22(1) 
C(13) 2848(5) 1155(11) 657(4) 28(1) 
C(14) 2586(6) 2865(11) -108(4) 29(2) 
C(15) 1758(6) 4792(12) -134(4) 33(2) 
C(16) 1208(5) 5020(11) 583(4) 23(1) 









Table 2.6. Bond lengths [Å] and angles [°] for 2.51a-OMe. 
_______________________________________________  
S(1)-O(4)  1.432(4) 
S(1)-O(3)  1.439(4) 
S(1)-N(1)  1.623(4) 
S(1)-C(11)  1.747(5) 
F(1)-C(1)  1.401(5) 
O(1)-C(2)  1.198(6) 
O(2)-C(2)  1.332(6) 
O(2)-C(3)  1.452(6) 
N(1)-C(4)  1.457(6) 
N(1)-H(1N)  0.85(3) 
C(1)-C(2)  1.505(7) 
C(1)-C(4)  1.528(7) 
C(1)-H(1)  1.0000 
C(3)-H(3A)  0.9800 
C(3)-H(3B)  0.9800 
C(3)-H(3C)  0.9800 
C(4)-C(5)  1.512(7) 
C(4)-H(4)  1.0000 
C(5)-C(10)  1.390(7) 
C(5)-C(6)  1.391(7) 
C(6)-C(7)  1.385(7) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.377(8) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.389(7) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.384(7) 
C(9)-H(9)  0.9500 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.381(7) 
C(11)-C(16)  1.393(7) 
C(12)-C(13)  1.382(8) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.388(8) 
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C(13)-H(13)  0.9500 
C(14)-C(15)  1.392(9) 
C(14)-C(17)  1.503(9) 
C(15)-C(16)  1.380(8) 
C(15)-H(15)  0.9500 
C(16)-H(16)  0.9500 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 































































































Table 2.7. Anisotropic displacement parameters (Å2 x 103) for 2.51a-OMe.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
S(1) 15(1)  17(1) 19(1)  0(1) 2(1)  -2(1) 
F(1) 22(2)  11(2) 32(2)  -3(2) 7(1)  0(1) 
O(1) 33(2)  23(2) 29(2)  10(2) 13(2)  7(2) 
O(2) 23(2)  15(2) 26(2)  2(2) 12(2)  5(2) 
O(3) 25(2)  15(2) 21(2)  1(2) 7(2)  -6(2) 
O(4) 14(2)  28(2) 29(2)  -4(2) 1(2)  0(2) 
N(1) 19(2)  10(2) 18(2)  -2(2) 0(2)  2(2) 
C(1) 18(3)  8(3) 20(3)  1(2) 4(2)  4(2) 
C(2) 11(3)  14(3) 23(3)  -1(2) 1(2)  -1(2) 
C(3) 23(3)  21(4) 29(3)  -1(2) 12(3)  -2(2) 
C(4) 15(3)  11(3) 16(3)  0(2) 3(2)  0(2) 
C(5) 11(3)  14(3) 18(3)  -2(2) 2(2)  0(2) 
C(6) 16(3)  13(3) 23(3)  0(2) 4(3)  -2(2) 
C(7) 16(3)  19(3) 30(3)  -3(3) 7(3)  3(2) 
C(8) 19(3)  27(3) 21(3)  -5(3) 9(3)  -2(3) 
C(9) 24(3)  21(4) 19(3)  4(3) 6(2)  4(2) 
C(10) 18(3)  11(3) 21(3)  -2(2) 2(2)  3(2) 
C(11) 19(3)  20(3) 14(3)  -5(3) 1(2)  -5(2) 
C(12) 25(3)  19(3) 19(3)  4(3) 3(3)  -1(3) 
C(13) 27(3)  31(4) 25(3)  -5(3) 8(3)  2(3) 
C(14) 28(3)  41(4) 18(3)  -5(3) 6(3)  -10(3) 
C(15) 34(4)  40(4) 20(3)  8(3) 1(3)  -5(3) 
C(16) 24(3)  23(3) 19(3)  4(3) 1(3)  0(3) 







Table 2.8. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 10 3) 
for 2.51a-OMe. 
________________________________________________________________________________  
 x  y  z  U(eq) 
  
H(1N) 1460(50) 7130(70) 3000(40) 21 
H(1) 4456 5914 4788 19 
H(3A) 5036 3660 2103 35 
H(3B) 5477 1110 2693 35 
H(3C) 6348 3524 2969 35 
H(4) 2845 3082 3903 17 
H(6) 1244 8301 4507 22 
H(7) 542 8357 5851 26 
H(8) 1070 5168 7012 26 
H(9) 2295 1844 6811 26 
H(10) 2984 1741 5460 21 
H(12) 2514 202 1912 26 
H(13) 3402 -183 680 33 
H(15) 1567 5972 -655 40 
H(16) 642 6339 555 28 
H(17A) 4031 2106 -609 74 
H(17B) 3095 4158 -1258 74 


























































Table 2.10.  Hydrogen bonds for 2.51a-OMe [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1N)...O(3)#1 0.85(3) 2.28(3) 3.127(5) 173(5) 
 C(1)-H(1)...F(1)#2 1.00 2.53 3.456(6) 153.3 
 C(3)-H(3B)...O(1)#3 0.98 2.39 3.247(7) 146.5 
 C(4)-H(4)...F(1)#3 1.00 2.36 3.343(6) 166.5 
 C(12)-H(12)...O(1)#3 0.95 2.53 3.264(7) 133.7 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Chapter 3: Kinetic resolution of 
isoxazolidinones1 
 Isoxazolidinones are nitrogen- and oxygen-containing heterocycles that have garnered 
considerable attention in the synthetic community. One of the more common application of these 
compounds is to serve as precursors to β-amino acids via hydrogenolytic cleavage of the N-O bond 
(see Figure 1.5, Eq. 5 for an example). Given their importance, many asymmetric approaches to 
these compounds exist.2-8  
 
Figure 3.1: N-carbalkoxy-isoxazolidin-5-ones as precursors to β-amino acids. 
Of all isoxazolidinones, N-carbalkoxy-isoxazolidin-5-ones remain an attractive subset, 
namely due to the simplicity of deprotecting the nitrogen atom (Figure 3.1). Some asymmetric 
catalytic approaches to these valuable precursors are illustrated in Figure 3.2; however, more 
methods exist.3-6 It is interesting to see the broad range of different modes of catalysis (outlined in 
red) that have been used to access these compounds in enantioenriched form.   
In 2015 Brière et al. published a one pot-multicomponent racemic synthesis of 3-
substituted-N-carbalkoxy-isoxazolidin-5-ones.9 This method involved mixing an aldehyde, an N-
hydroxycarbamate, and Meldrum’s acid 3.12 using DABCO as a basic catalyst. Unfortunately, 





Figure 3.2. Asymmetric catalytic approaches to N-Boc-isoxazolidinones. 
At first glance this result may be discouraging. However, the simplicity and broad substrate 
scope (with regard to the aldehyde) of this racemic synthesis offers an opportunity to obtain these 
compounds in enantioenriched form via resolution into their two enantiomers. Given the vast 
literature precedent for enantioselective alcoholysis of cyclic acyl donors (see Section 3.2), kinetic 





Figure 3.3: a) Brière’s racemic, one pot-multicomponent synthesis, b) Attempts at rendering this 
multicomponent reaction enantioselective.9 
3.1 Introduction to kinetic resolution 
Kinetic resolution (KR) is one of many available methods in asymmetric catalysis and was 
discussed very briefly in section 2.2 as one approach to enantioenriched α-fluoro-β-amino acids. 
Further discussion on this topic has been delayed to this subchapter.  In short, KR is one of the 
oldest means of making enantioenriched compounds from a racemic starting material and relies 
on both enantiomers reacting with different rates in a chemical process utilizing a chiral catalyst 
or reagent.10 Consequently, the enantiomeric excess (ee) of the unreacted starting material 
continually rises as more product is formed. This process can be summarized with the graph and 
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equations outlined in Figure 3.4, where kR (the reaction rate of the (R) enantiomer) is larger than 
kS (the reaction rate of the (S) enantiomer).     
 
Figure 3.4: A graphical representation of KR and the equations used to calculate its efficacy. 
The maximum height of the curve “S-R” represents the conversion that maximizes the 
enantioenrichment of both starting material and product. Graphic borrowed from Kagan.10   
 
 The most important variable in determining the efficiency of a kinetic resolution is the 
selectivity factor10, which is the ratio of the reaction rates of the two enantiomers. Thus, when s=7, 
one enantiomer is reacting seven times faster than the other. As can be seen from the graph, a 
selectivity factor of 7 is not useful, especially considering that high levels of conversion are 
necessary to obtain the starting material with practically useful levels of enantioenrichement. 
Ideally, the selectivity factor should be as large as possible. As a general rule of thumb, a selectivity 
factor of 20 or greater is deemed sufficient for practical applications.11 Assuming perfect 
selectivity then one enantiomer will react completely and leave the unreacted enantiomer with 
~100% ee at 50% conversion. One disadvantage of KR is this maximum theoretical yield of 50%, 
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especially when only one enantiomer is wanted/needed. Conversely, KR is useful when both 
enantiomers are required. 
3.2 Kinetic resolution, dynamic kinetic resolution, and  
desymmetrization of cyclic acyl donors via organocatalytic  
enantioselective alcoholysis 
 Many cyclic compounds structurally related to isoxazolidin-5-ones have been utilized as 
acyl donors in organocatalytic enantioselective alcoholysis, resulting in their KR, dynamic kinetic 
resolution (DKR), or desymmetrization. All of these processes are mechanistically similar since 
they rely on the enantiofacial discrimination of the cyclic acyl donor. In 2001, Deng et al. reported 
an asymmetric approach to α-amino acids via a cinchona alkaloid-catalyzed kinetic resolution of 
carbamate-protected α-amino acid carboxyanhydrides 3.19 (Figure 3.5a).12 Prochiral and meso 
cyclic anhydrides are still very commonly used as precursors in desymmetrizations, a process 
where chirality is introduced by removing a symmetry element within a molecule.13 One 
illustrative example of a desymmetrization involves the cinchona alkaloid-catalyzed alcoholysis 
of prochiral cyclic anhydride 3.23 (Figure 3.5b).14 In 2011 our group disclosed the first non-
enzymatic KR of β-lactams. ABC-catalyzed alcoholysis delivers the β-amino acid derivatives in 
highly enantioenriched form (Figure 3.5c)15 In 2005 Berkessel et. al published a DKR of 
azlactones via enantioselective alcoholysis using a bifunctional thiourea-amine organocatalyst 
(Figure 3.5d).16 Only a single enantiomer of product is isolated because the azlactone can 
epimerize under the reaction conditions. This equilibration of the two enantiomers of a racemate 
is the key difference between DKR and KR. In 2010 our group published an analogous DKR via 
a covalent mode of catalysis using ABC-catalyzed alcoholysis (Figure 3.5d).17 In 2005 Mukherjee 




Figure 3.5. Examples of enantioselective alcoholysis of cyclic acyl donors. a) KR of α-amino acid 
carboxyanhydrides, b) desymmetrization of prochiral cyclic anhydrides, c) KR of N-acyl-β-
lactams, d) DKR of azlactones via non-covalent and covalent modes of catalysis, e) KR of 
oxazinones.   
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one carbon homologues of azlactones (Figure 3.5e).18 A bifunctional thiourea-amine 
organocatalyst was employed to achieve this resolution. 
 3.3 Introduction to bifunctional organocatalysis 
The term bifunctional organocatalyst was used throughout section 3.2 and warrants further 
discussion. A bifunctional catalyst is a catalyst which complementarily activates two components 
of a chemical reaction due to having two moieties with separate functionalities. For almost all 
bifunctional catalysts, these two functional groups work synergistically to activate both the 
nucleophile (HOMO activation) and electrophile (LUMO activation). In fact, electrophile 
activation by hydrogen bonding is very common in biological enzymatic pathways, especially 
hydrolysis of amide bonds.19 This mode of activation seen in Nature has certainly inspired modern-
day chemists, especially considering that at least one hydrogen bond donor is present in virtually 
all notable bifunctional organocatalysts.20 Of all these bifunctional organocatalysts, double 
hydrogen bond donor-amine organocatalysts, especially those containing 
thiourea/urea/squaramide and tertiary amine functional groups, have arguably received the most 
attention. The general structure of these catalysts is illustrated in Figure 3.6. The chiral scaffold 
usually consists of a naturally occurring Cinchona alkaloid or an enantiomerically pure 1,2-
cyclohexanediamine, though other chiral scaffolds exist, such as Ricci’s chiral thiourea with a 2-
indanol scaffold.21 
In 2003, Takemoto discovered that bifunctional thiourea-amine organocatalyst 3.17 
(Figure 3.7) can catalyze the asymmetric Michael addition of various 1,3-dicarbonyls to 
nitroolefins.22 This work served as a major foothold in asymmetric bifunctional organocatalysis.  




Figure 3.6. General structure of the most common bifunctional double hydrogen bond donor-
amine organocatalysts. Catalyst is shown H-bonding to a generic carbonyl group. 
catalysts or strict reaction conditions. This methodology offered a metal-free and mild approach 
to these synthetically useful Michael adducts. The transition state Takemoto proposed involved 
the nitroolefin forming hydrogen bonds to the thiourea moiety, activating the electrophile. The 
dimethylamino moiety, more than basic enough to deprotonate the 1,3-dicarbonyl, forms a 
hydrogen bond to the enolic form of the 1,3-dicarbonyl. This places the nucleophile near the 
nitroolefin, facilitating the Michael addition. 
 
Figure 3.7. Asymmetric Michael addition of 1,3-dicarbonyls to nitroolefins. 
 
Despite these synthetic advances at the time, the underlying mechanistic details were still 
not fully understood. In 2006, Pápai et al. conducted extensive DFT calculations to better elucidate 
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the dual activation mode of these bifunctional thioureas.23 These calculations suggested that the 
actual transition state and the nature of the hydrogen bonding was most likely much more complex 
than initially proposed by Takemoto. However, dual activation of both substrates is undoubtedly 
the predominant role of the bifunctional catalyst.   
Starting in the mid-2000s, the use of thiourea-tertiary amine organocatalysts in asymmetric 
synthesis expanded rapidly. Novel catalyst designs and new applications by Wang,24 Soós,25 and 
Jun-An26 became commonplace (Figure 3.8). 
 
Figure 3.8. Novel thiourea-tertiary amine organocatalyst designs.   
3.4 Initial screening of reaction conditions 
With the idea of kinetic resolution, it can be easy to envision how resolution of racemic N-
carbalkoxy-isoxazolin-5-ones can be achieved by enantioselective alcoholysis (Figure 3.9).  
 
Figure 3.9: Proposed KR of N-carbalkoxy-isoxazolidin-5-ones. 
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 Though this KR has never been pursued, these compounds have been known to be 
relatively reactive acyl donors, reacting with alcohols under mild conditions (Figure 3.10).4 
However, catalytic acceleration of this process has never been described in the literature for this 
specific class of acyl donors.  
 
Figure 3.10: Ring opening of an N-Boc-isoxazolidinone with MeOH and NEt3. 
Encouraged by extensive, albeit indirect, literature precedent our group started to explore 
the asymmetric catalytic ring opening of N-Boc-3-phenylisoxazolidin-5-one 3.43a, our model 
substrate (Table 3.1).  
First, we wanted to confirm whether methanolysis would occur with the test substrate in 
the absence of base. As expected, no racemic background reaction occurred, but rapid and 
quantitative ring opening was observed with addition of stoichiometric NEt3 (entries 1 and 2). 
Next, we tested covalent modes of acyl transfer catalysis. Unfortunately, widely used acyl transfer 
catalysts (R)-BTM27 3.26 and (R)-H-PIP28 3.45 (see Figure 3.11) delivered hardly any asymmetric 
induction (entries 3 and 4). As anticipated by their relative Lewis basicities, H-PIP performed 
much faster than BTM. We next sought out using non-covalent modes of catalysis. Given the 
performance displayed by bifunctional thiourea-amine organocatalyst 3.29 in the dynamic kinetic 




Table 3.1: Initial screening of reaction conditions.a 
 
entry Catalyst (mol %) ROH (equiv) Time (h) % conversion s 
1 none MeOH (10) 24 0b N/A 
2 NEt3 (100) MeOH (10) 0.5 100
b N/A 
3 3.26 (20) MeOH (1) 192 45b 1.1 
4 3.45 (20) MeOH (1) 2.5 63b 1.5 
5 3.17 (10) MeOH (1) 5 53 5.2 
6c 3.17 (10) MeOH (1) 8 55 5.9 
7c 3.17 (10) BnOH (1) 16 46 16.3 
8 3.17 (10) Ph2CHOH (1) 120 25 7.7 
9 3.17 (10) i-PrOH (1) 24 <5 N/A 
a General conditions: 0.1 mmol of (±)-3.43a, 0.1 or 1.0 mmol of ROH, 0.01 mmol of catalyst, 
500 μL of CDCl3, rt. 
b Determined by 1H NMR. c Carried out at °C. 
 
With this idea we were trying to achieve similar dual modes of activation of the alcohol 
and isoxazolidinone, which is structurally analogous to the azlactone. The first result was very 
promising, giving a five-fold increase in selectivity compared to BTM (entry 5). A very slight 
increase in s was observed at 0 °C (entry 6). When testing more sterically bulky alcohols, we 
discovered that benzyl alcohol further increased the selectivity factor three-fold (entry 7). 
Secondary alcohols like benzhydrol were very slow and gave lower selectivity factor (entry 8). 
Finally, isopropyl alcohol was virtually unreactive (entry 9). The difference in reactivity of 
benzhydrol and isopropyl alcohol is interesting and has been speculated to be the result of an 





Figure 3.11: Catalysts used in this study. 
3.5 Optimization of solvent and alcohol using Takemoto’s  
catalyst 
After the discovery that Takemoto’s catalyst gave increased selectivity, we explored a wide 
variety of solvents (Table 3.2). Most solvents examined gave selectivity factors that were 
comparable or inferior to chloroform. Of these, the most nonpolar solvents (entries 3-5) were 
inferior to chloroform and more polar solvents, apart from acetonitrile, gave similar performance 
to chloroform (entries 6-8). Most interestingly a serendipitous discovery was made with t-amyl 
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alcohol which delivered the best selectivity factor up to this point (entry 9). This result was 
surprising considering that the hydrogen bond-donor properties of the solvent can be expected to 
disrupt hydrogen bonding between the catalyst and the alcohol and/or isoxazolidinone. After re-
examining other alcohols, we discovered that allyl alcohol gave yet a better selectivity factor (entry 
10). Methanol performed much worse, but still better than with chloroform as solvent (compare 
Table 3.2, entry 11 to Table 3.1, entry 6). Even better yet, benzhydrol reproducibly delivered a 
selectivity factor of 199 (entry 12) and demonstrates the drastic effect that solvent can have 
(compare to Table 3.1, entry 8). Isopropyl alcohol failed to react under these conditions (entry 13).  
Table 3.2: Solvent study. 
 
entry solvent ROH Time (h) % conversion s 
1 CHCl3 BnOH 16 46 16.3 
2 CH2Cl2 BnOH 16 43 16.1 
3 PhMe BnOH 7 54 13.0 
4 Cyclohexane BnOH 16 73 6.0 
5 THF BnOH 72 25 21.0 
6 EtOAc BnOH 22 37 18.9 
7 Me2CO BnOH 23 24 19.3 
8 MeCN BnOH 23 37 7.4 
9 EtCMe2OH BnOH 22 34 25 
10 EtCMe2OH allylOH 22 36 45 
11 EtCMe2OH MeOH 22 31 14.6 
12 EtCMe2OH Ph2CHOH 22 39 199 
13 EtCMe2OH i-PrOH 22 0 ND 






3.6 Bifunctional catalyst survey 
Next we explored a diverse range of bifunctional organocatalysts (Table 3.3).  
Table 3.3: Bifunctional catalyst survey.a   
 
 
entry catalyst ROH % conversion s 
1 3.46 Ph2CHOH 0 N/A 
2b 3.47 Ph2CHOH 35 1.4 
3 3.48 Ph2CHOH 0 N/A 
4 3.49 Ph2CHOH 41 33 
5b 3.50 Ph2CHOH 42 94 
6b 3.51 Ph2CHOH 38 123 
7 3.52 Ph2CHOH 42 419 
8 3.52 MeOH 47 23 
9 3.52 BnOH 47 23 
10 3.52 allylOH 43 37 
a General conditions: 0.10 mmol of (±)-3.43a, 0.10 mmol of ROH, 0.01 mmol of catalyst, 500 μL 
of t-amyl alcohol. b The absolute stereochemistry of the product is opposite of that shown.  
 
C2-symmetrical bis-thiourea 3.46
29 gave zero conversion, confirming that a basic moiety 
must be present in the catalyst (entry 1). Bis-benzimidazole catalyst 3.4730 gave decent 
conversion, but very little enantioselectivity (entry 2). Tosylamide 3.4831 was completely 
ineffective (entry 3). This can be a result of the sulfonamide moiety not being a strong enough 
hydrogen bond donor, or alternatively, that a double hydrogen bond donor in the catalyst is 
necessary. Squaramide analogue of Takemoto’s catalyst 3.4932 gave lower selectivity than 
Takemoto’s catalyst itself; however, this was most likely due to solubility issues in t-amyl 
alcohol (entry 4). Quinine-derived amino-thiourea 3.5025 and amino-squaramide 3.5133 gave 
comparable selectivity factors (entries 5 and 6). Interestingly, the pseudoenantiomeric quinidine-
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derived amino-squaramide 3.5233 gave the superior selectivity factor (entry 7). This difference in 
performance between these two pseudoenantiomers is surprising; however, there is extensive 
literature precedent for discrepancies in enantioselectivity (and often reactivity) for asymmetric 
reactions catalyzed by a pair of pseudoenantiomeric cinchona alkaloid-derived catalysts.34 Other 
alcohols were inferior to benzhydrol with this new catalyst (entries 8-10). 
3.7 Substrate scope of new methodology 
Having completed the optimization studies, we next explored the substrate scope of this 
new methodology (Table 3.4). In some cases, the isoxazolidinone starting materials were insoluble 
in pure t-amyl alcohol, necessitating the use of chloroform/t-amyl alcohol mixtures, and in some 
cases, pure chloroform. The addition of chloroform did not effect the selectivity factor with 
substrate 3.43a (compare entries 1 and 2). Substrates with variously substituted aromatic and 
heteroaromatic groups delivered excellent selectivity factors (entries 1-10). A styryl and primary 
alkyl group delivered diminished, but still practically useful levels of selectivity (entries 11-12). 
A secondary alkyl group decreased the reactivity (entry 13); however, less sterically demanding 
alcohols gave increased conversion without loss of selectivity (entries 14-15). Unfortunately, the 
tert-butyl substrate gave zero conversion with benzhydrol and barely detectable levels of 
conversion with allyl alcohol (entries 16-17). We also explored the effects of switching from a 
Boc group to a Cbz group. Surprisingly, this substrate was completely unreactive with benzhydrol 
(entry 18). Thankfully, just as in the isopropyl substituent case, less sterically hindered alcohols 
gave increased conversion and practically useful selectivities (entries 19-21). The reaction scale 
was also increased 10-fold and delivered comparable selectivity factors to the 0.1 mmol scale 
(compare entries 6 and 22). Finally, we demonstrated that Takemoto’s catalyst 3.17 gave 
practically useful selectivity factors with a 2-naphthyl and isobutyl group (entries 23-24). Even 
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though the selectivity factors are lower than that obtained with catalyst 3.52, the commercial 
availability of Takemoto’s catalyst makes it an attractive alternative.  
Table 3.4: Substrate scope.a 
 
entry R1 R2 ROH % conversion s 
1 Ph t-Bu Ph2CHOH 45 361 
2b Ph t-Bu Ph2CHOH 45 487 
3b 4-ClC6H4 t-Bu Ph2CHOH 37 344 
4b 4-MeOC6H4 t-Bu Ph2CHOH 41 301 
5c 4-NO2Ph t-Bu Ph2CHOH 31 127 
6 2-ClC6H4 t-Bu Ph2CHOH 44 107 
7 3-MeOC6H4 t-Bu Ph2CHOH 45 430 
8d 1-naphthyl t-Bu Ph2CHOH 29 171 
9d 2-naphthyl t-Bu Ph2CHOH 42 334 
10 2-thienyl t-Bu Ph2CHOH 48 352 
11 styryl t-Bu Ph2CHOH 50 80 
12 isobutyl t-Bu Ph2CHOH 40 67 
13 isopropyl t-Bu Ph2CHOH 24 151 
14 isopropyl t-Bu BnOH 35 144 
15 isopropyl t-Bu allylOH 37 92 
16 tert-butyl t-Bu Ph2CHOH N/A N/A 
17 tert-butyl t-Bu allylOH <5% N/A 
18c Ph Bn Ph2CHOH N/A N/A 
19c Ph Bn MeOH 54 27 
20c Ph Bn BnOH 50 40 
21c Ph Bn allylOH 49 50 
22e 2-ClC6H4 t-Bu Ph2CHOH 44 80 
23d,f  2-naphthyl t-Bu Ph2CHOH 41 118 
24f isobutyl t-Bu Ph2CHOH 27 21 
a General conditions: 0.10 mmol of substrate, 0.10 mmol of alcohol, 0.01 mmol of 3.52, 500 μL 
tert-amyl alcohol. b A 4:1 tert-amyl alcohol/CHCl3 mixture was used as the solvent. 
c CHCl3 was 
used as the solvent. d A 3:2 tert-amyl alcohol/CHCl3 mixture was used as the solvent. 
e 
Performed on a 1.0 mmol of substrate scale. f Catalyst 3.17 was used. 
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All of the resulting ester products underwent transesterification to the methyl ester, a 
necessary task to analyze these compounds by HPLC (see Appendix A.2). These esters were 
stable upon long term exposure at 0 °C, even after several months. 
3.8 Reversible ring closure of t-Bu derivative 3.44m-Me 
After obtaining the result with t-butyl substrate 3.43m, we wanted to deduce a logical 
explanation as to why the KR fails in this one case. It was observed that branching at the α-position 
of the alkyl substituent (i.e. the isopropyl group) greatly diminished the reactivity with benzhydrol. 
While two substituents at this position would be expected to further decrease the reactivity, it was 
still not clear why <5% conversion was observed in one case and 37% was observed in the other 
(compare Table 3.4, entry 17 to entry 15). While quantitative methanolysis of 3.43m occurs under 
mild conditions, it was quickly discovered that the methyl ester will spontaneously convert back 
into the ring-closed isoxazolidinone starting material (Figure 3.12). By observing this ring closure 
by 1H NMR in CDCl3, after 64 hours, 64% of the product had converted back into starting material. 
Heating this mixture led to quantitative ring closure after a couple of hours. 
 
Figure 3.12: Reversible ring-closure of t-butyl substrate 3.43m.  
According to Baldwin’s rules, this 5-exo-trig cyclization is kinetically favorable.35 
However, it should be noted that this was the only substrate that exhibited this behavior. Several 
other freshly prepared methyl and benzhydryl esters were left in pure chloroform for three days at 
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rt, and not a single one converted back to the isoxazolidinone. Clearly, this idiosyncratic behavior 
requires an alternative explanation. Instead, a strong Thorpe-Ingold effect was proposed (see 
Appendix A.1).36 It is known that substituents, especially a bulky t-butyl group, limit the flexibility 
of long chains, resulting in restricted rotation relative to the unsubstituted chain. Due to this limited 
flexibility, there is a much lower entropic penalty for cyclization (ΔS‡ is less negative). 
Consequently, ΔG‡ is more negative and the ring forms faster. Under thermodynamic control, as 
is the case with the long reaction times and heating employed, it is not surprising to detect 
quantitative ring closure in this specific case.  
3.9 Additional transformations 
Our group demonstrated that the starting materials and products obtained with this KR can 
partake in useful synthetic transformations. The entire purpose of this project was to demonstrate 
how these enantioenriched isoxazolidinones can serve as precursors to β-amino acids. Thus, 
enantioenriched (R)-3.43a underwent quantitative hydrogenolysis to yield Boc-protected β-
phenylalanine (Figure 3.13).3a 
 
Figure 3.13: Quantitative N-O bond cleavage to yield an enantioenriched β-amino acid. 
Additionally, we showed that the benzhydryl esters, after being transesterified to the 
methyl esters, undergo cyclization to the isoxazolidinone with complete retention of 
enantioenrichement (Figure 3.14).5 This is a desirable transformation for a couple of reasons. First, 
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in cases where the isoxazolidinone is not at satisfactory levels of enantioenrichment after the KR, 
the reacted starting material can be recycled and put forward through another resolution. 
Furthermore, in cases where conversion is less than optimal (e.g. Table 3.4, entry 8) for a KR, the 
unreacted starting material may not be as enantioenriched as the reacted product. Thus, in these 
few cases, the enantioenriched isoxazolidinone can be obtained from the reacted enantiomer at the 
expense of yield.   
 
Figure 3.14: Recycling of reacted enantiomer.  
3.10 Conclusions and future directions  
This work provides a complementary approach to enantioenriched isoxazolidinones, 
important precursors to β-amino acids. One practical advantage of this work is that the resolution 
can be used to further enhance levels of enantiomeric enrichment, even if the isoxazolidinones 
were obtained from alternative asymmetric methodologies. Though the levels of conversion were 
less than optimal in certain cases, we demonstrated the efficacy of a two-step transesterification-
cyclization procedure that delivered the isoxazolidinone with complete retention of ee and assured 
that the reacted enantiomer does not go to waste. Furthermore, we demonstrated for the first time 
that N-carbalkoxy-isoxazolidinones are well-tolerated acyl donors amenable to asymmetric acyl 
transfer catalysis. In addition to these 3-substituted isoxazolidinones, it would be compelling to 
explore additional substitution patterns such as 4-substituted and 3,4-disubstituted analogues.  
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While a vast literature precedent indicates the usefulness of acyl donors in asymmetric 
catalysis, especially in kinetic resolution, this work suggests that there may be other classes of 
compounds that are worth exploring in kinetic resolutions (Figure 3.15). For example, O-acylated 
derivatives of N-hydroxysuccinimides 3.54 are expected to be reactive acyl donors. They may 
even serve as precursors to enantioenriched α-amino acid derivatives (e.g. R1 = NHBoc). 
Isoxazolidine-3,5-diones 3.55 and 1,2-oxazinane-3,6-diones 3.56 may also be viable substrates for 
enantioselective alcoholysis. All these different classes of compounds can be explored with a wide 
variety of catalysts, investigating both covalent and non-covalent modes (e.g monofunctional 
Lewis basic catalysts, bifunctional catalysts, chiral phosphoric acid catalysts, etc.).  
 
Figure 3.15. Other acyl donors that may be amenable to KR via enantioselective alcoholysis. 
3.11 Experimental 
All reagents were obtained commercially and used as received unless specified otherwise. 
Catalysts 3.26, and 3.45-3.52 were prepared as described in the literature.25,27,28,29,30,31,32,33 
Chloroform used as reaction medium was freshly distilled from calcium hydride. Triethylamine 
was freshly distilled from potassium hydroxide pellets. Reactions that required heating were 
carried out in an electrically heated mineral oil bath. Solvents used for chromatography were ACS 
or HPLC grade. Sorbent Technologies XHL silica gel plates (glass-backed, 250 μm) were used for 
TLC analyses. Flash column chromatography was performed over Sorbent Technologies silica gel 
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(40–63 μm). HPLC analyses were performed on a Shimadzu LC system using Chiralcel OD-H, 
Chiralpak AS-H and Chiralpak AD-H analytical chiral stationary phase columns (4.6 × 250 mm, 
Chiral Technologies, Inc.) with UV detectors at 254 nm and 204 nm with a flow rate of 1.0 
mL/min. 1H and 13C NMR spectra were recorded on Mercury 300 MHz and DD2 500 MHz Agilent 
spectrometers. The chemical shifts are reported as δ values (ppm) relative to TMS using a residual 
CHCl3 peak (7.26 ppm for 
1H NMR, 77.16 ppm for 13C NMR) or (CH3)2CO (206.26 ppm for 
13C 
NMR) peak as the reference. Melting points were measured on a Stuart SMP10 melting point 
apparatus. High resolution mass spectral analyses were performed at Washington University MS 
Center on a Bruker MaXis QTOF mass spectrometer using electrospray ionization (ESI). Infrared 
spectra were recorded on a Bruker Alpha Platinum-ATR. Optical rotations were determined on a 
Rudolph Autopol III polarimeter. 
3.11.1 Synthesis of new isoxazolidinones 
Most isoxazolidinone substrates used in this study were known compounds synthesized according 
to the published procedure.9 Isoxazolidinones 3.43e-3.43h, which have not been previously 
reported, were synthesized in one step following the same general procedure. Compounds 3.43i 
and 3.43m, which could not be prepared in this manner, were synthesized via the two-step 
modification shown below. 
 
Intermediate 3.57i: A solution of 2-thiophenecarboxaldehyde 3.10i (234 μL, 2.5 mmol, 1.0 equiv) 
and Meldrum’s acid (360 mg, 2.5 mmol, 1.0 equiv) in 1 mL of pyridine stirring at rt was treated 
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with one drop of piperidine. After stirring for 1 h, the mixture was quenched by slow addition of 
3M aq. HCl until a solid started to form and thicken the reaction mixture. This solid was filtered, 
washed with copious amounts of water and left to air dry. The product was isolated as a pale orange 
powder (360 mg, 60% yield). The spectroscopic data matched those reported in the literature.37 
Isoxazolidinone 3.43i: A solution of 3.57i (238 mg, 1.00 mmol, 1 equiv), N-Boc-hydroxylamine 
(133 mg, 1.00 mmol, 1 equiv) and DABCO (11 mg, 0.10 mmol, 0.1 equiv) in 4 mL of EtOAc was 
heated at 50 °C for 6 h, at which time TLC (30% EtOAc/hexanes) indicated near complete 
consumption of the starting material. The reaction mixture was diluted with 10 mL of EtOAc and 
10 mL of 10% aq. Na2CO3. The aqueous layer was further extracted with CH2Cl2 (×2). The organic 
layer was dried with Na2SO4 and concentrated in vacuo. The product was isolated as a clear, 
colorless oil (183 mg, 68% yield) after chromatography (5→30% EtOAc/hexane). 
Intermediate 3.57m: A solution of pivaldehyde 3.10m (1.0 mL, 9.2 mmol, 1.0 equiv) and 
Meldrum’s acid (1.33 g, 9.2 mmol, 1.0 equiv) in 7.3 mL of pyridine stirring at rt was treated with 
two drops of piperidine. After stirring at rt overnight, the mixture was diluted with 30 mL of water 
followed by 10 mL of 3M HCl. The aqueous layer was extracted with CH2Cl2 (×3). The combined 
organic phase was dried with Na2SO4 and concentrated in vacuo. The crude mixture was subjected 
to column chromatography (5→20% EtOAc/hexanes) to yield the product as a white powder (580 
mg, 30% yield). The spectroscopic data are in accordance with the literature.38 
Isoxazolidinone 3.43m: A solution of 3.57m (340 mg, 1.60 mmol, 1 equiv), N-Boc-
hydroxylamine (320 mg, 2.40 mmol, 1.5 equiv) and DABCO (18 mg, 0.16 mmol, 0.1 equiv) in 
6.4 mL of EtOAc was heated at 50 °C for 18 h, at which time TLC (20% EtOAc/hexanes) indicated 
near complete consumption of the starting material. The reaction mixture was diluted with 10 mL 
of EtOAc and 10 mL of 10% aq. Na2CO3. The aqueous layer was further extracted with CH2Cl2 
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(×2). The organic layer was dried with Na2SO4 and concentrated in vacuo. The product was 
isolated as a clear, colorless oil (272 mg, 70% yield) after chromatography (5→20% 
EtOAc/hexane). 
tert-butyl 3-(2-chlorophenyl)-5-oxoisoxazolidine-2-carboxylate (3.43f). 
Isolated as a clear, colorless oil which solidified into a colorless, crystalline 
solid at 0 °C (50% yield) after chromatography (5→20% EtOAc/hexanes). 1H 
NMR (500 MHz, CDCl3) δ 7.57-7.53 (m, 1H), 7.42-7.38 (m, 1H), 7.35-7.27 (m, 
2H), 5.93 (dd, J = 9.5 Hz, 3.5 Hz, 1H), 3.42 (dd, J = 18 Hz, 9.5 Hz, 1H), 2.75 (dd, J = 18 Hz, 3.5 
Hz, 1H), 1.49 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.9, 155.3, 136.6, 131.8, 130.1, 
129.8, 127.7, 126.9, 84.7, 60.7, 36.7, 28.1; IR (cm-1): 2982, 1789, 1721, 1347, 1146, 759; HRMS 
(ESI-TOF) m/z: [M+H]+ calcd for C14H16ClNO4, 298.0841; found, 298.0845. mp: 53-56 °C. 
HPLC: (5 % isopropanol/hexanes, AD-H): Minor enantiomer: 7.1 min; Major enantiomer: 23.4 
min (77% ee, Table 3.8, entry 6). [α]𝐷
25 = +48° (c=0.533, CHCl3).  
tert-butyl 3-(3-methoxyphenyl)-5-oxoisoxazolidine-2-carboxylate (3.43e). 
Isolated as a light yellow oil (65% yield) after chromatography (5→20% 
EtOAc/hexane). 1H NMR (500 MHz, CDCl3) δ 7.32-7.27 (m, 1H), 6.94-
6.85 (m, 3H), 5.51 (dd, J = 9.5 Hz, 4 Hz, 1H), 3.81 (s, 3H), 3.32 (dd, J = 
18 Hz, 9.5 Hz, 1H), 2.84 (dd, J = 18 Hz, 4 Hz, 1H), 1.46 (s, 9H). 13C{1H} NMR (125 MHz, 
CDCl3): δ 171.8, 160.2, 155.3, 140.6, 130.3, 117.9, 113.9, 111.5, 84.3, 63.0, 55.4, 37.6, 28.1; IR 
(cm-1): 2974, 2938, 1803, 1720, 1143; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C15H19NO5, 
316.1155; found, 316.1172. HPLC: (5 % isopropanol/hexanes, AD-H): Major enantiomer: 13.6 
min; Minor enantiomer: 22.1 min; (81% ee, Table 3.8, entry 8). [α] 𝐷
25= +30° (c=0.533, CHCl3). 
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tert-butyl 3-(naphthalen-1-yl)-5-oxoisoxazolidine-2-carboxylate (3.43g). 
Isolated as a clear, colorless oil which solidified into a white powder at 0 °C 
(30% yield) after chromatography (5→20% EtOAc/hexane). 1H NMR (500 
MHz, CDCl3) δ 7.94-7.90 (m, 1H), 7.88-7.83 (m, 2H), 7.69-7.65 (m, 1H), 
7.60-7.47 (m, 3H), 6.37 (dd, J = 9.5 Hz, 3 Hz, 1H), 3.52 (dd, J = 17.5 Hz, 9.5 Hz, 1H), 2.88 (dd, 
J = 17.5 Hz, 3 Hz, 1H), 1.51 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 172.5, 155.8, 134.1, 
133.8, 129.6, 129.4, 129.2, 126.9, 126.1, 125.6, 123.1, 122.3, 84.6, 60.4, 37.0, 28.1; IR (cm-1): 
2983, 1805, 1720, 1337, 1125; HRMS (ESI-TOF) m/z: [M+H]+ calcd for C18H19NO4, 314.1387; 
found, 314.1391. mp: 111-113 °C. [α] 𝐷
25= +30° (c=1.067, CHCl3). (40% ee, Table 3.8, entry 9, 
measured by HPLC as the corresponding methyl ester). 
tert-butyl 3-(naphthalen-2-yl)-5-oxoisoxazolidine-2-carboxylate (3.43h). 
Isolated as a white powder (42% yield) after chromatography (5→20% 
EtOAc/hexane). 1H NMR (500 MHz, CDCl3) δ 7.90-7.82 (m, 4H), 7.54-
7.48 (m, 2H), 7.45-7.41 (m, 1H), 5.71 (dd, J = 9 Hz, 4.5 Hz, 1H), 3.40 (dd, 
J = 18 Hz, 9 Hz, 1H), 2.94 (dd, J = 18 Hz, 4.5 Hz, 1H), 1.46 (s, 9H). 13C{1H} NMR (125 MHz, 
CDCl3): δ 171.8, 155.5, 136.1, 133.3, 133.2, 129.4, 128.2, 127.8, 126.8, 126.6, 125.0, 123.3, 
84.4, 63.2, 37.5, 28.1; IR (cm-1): 2971, 1791, 1732, 1148; HRMS (ESI-TOF) m/z: [M+Na]+ calcd 
for C18H19NO4Na, 336.1206; found, 336.1217. mp: 133-134 °C. [α] 𝐷
25 = +21° (c=0.733, CHCl3) 






tert-butyl 5-oxo-3-(thiophen-2-yl)isoxazolidine-2-carboxylate (3.43i). 
Isolated as a clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.30 (dd, J = 5.3 
Hz, 1.5 Hz, 1H), 7.08-7.06 (m, 1H), 6.99 (dd, J = 5.3 Hz, 3.8 Hz, 1H), 5.80 (dd, 
J = 9 Hz, 3.5 Hz, 1H), 3.32 (dd, J = 18 Hz, 9 Hz, 1H), 2.95 (dd, J = 18 Hz, 3.5 
Hz, 1H), 1.48 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.6, 154.9, 141.4, 127.2, 125.9, 
125.3, 84.6, 59.3, 37.5, 28.0; IR (cm-1): 2980, 1804, 1718, 1142, 705; HRMS (ESI-TOF) m/z: 
[M+H]+ calcd for C12H15NO4S, 270.0795; found, 270.0796.  [α] 𝐷
25 = +28° (c=0.200, CHCl3) for 
(R)- enantiomer (92% ee, Table 3.8, entry 11, measured by HPLC as the corresponding methyl 
ester). 
tert-butyl 3-(tert-butyl)-5-oxoisoxazolidine-2-carboxylate (3.43m). 
Isolated as a clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 4.29 (dd, J = 10 
Hz, 1.5 Hz, 1H), 2.88 (dd, J = 18 Hz, 10 Hz, 1H), 2.59 (dd, J = 18 Hz, 1.5 Hz, 
1H), 1.52 (s, 9H), 0.95 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 174.1, 
156.8, 84.0, 68.2, 34.8, 29.9, 28.2, 25.4; IR (cm-1): 2968, 2874, 1801, 1742, 1716, 1369, 848; 
HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C12H21NO4Na, 266.1363; found, 266.1379. 
Note: Melting points were determined using racemic samples. HPLC analysis of ester products 
required prior conversion to the corresponding methyl esters (see Section 3.12.1) or 
isoxazolidinones (see Section 3.12.2), as indicated. 
3.11.2 Kinetic resolution experiments: Initial survey of reaction conditions 
 
Typical procedure: Unless indicated otherwise, each reaction mixture was prepared by mixing 
aliquots of the following solutions in an NMR tube: (a) 0.500 M solution of (±)-3.43a in CDCl3 
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(200 μL, 0.100 mmol, 1 equiv), (b) 1.00 M solution of the alcohol indicated in CDCl3 (100 μL, 
0.100 mmol, 1 equiv), (c) 0.100 M solution of Takemoto’s catalyst 3.17 (100 μL, 0.0100 mmol, 
0.1 equiv). The mixture was brought up to 500 μL total volume with CDCl3 (final concentration 
of the substrate is 0.2 M), the tube capped, sealed off with Parafilm, and kept in an ice bath for the 
specified amount of time, except to monitor the reaction progress by 1H NMR. Deviations from 
this protocol (nature of catalyst and catalyst loading, amount of alcohol, reaction temperature) are 
noted in Table 3.1. The reaction mixture was then diluted with 10 mL of CH2Cl2 and quenched 
with 5 mL of saturated aqueous ammonium chloride. The aqueous layer was extracted twice with 
CH2Cl2. The combined organic layers were dried with Na2SO4 and concentrated by rotary 
evaporation. The crude mixture was pre-adsorbed on silica gel and eluted with 5-30% EtOAc in 
toluene to separate the ester product from the unreacted isoxazolidinone. The methyl ester (S)-
3.44a-Me and the unreacted starting material (R)-3.43a were analyzed directly by chiral stationary 
phase HPLC to determine their enantiomeric excess. Other esters were converted into the methyl 
ester (see Section 3.12.1) prior to HPLC analysis. When necessary, the unreacted starting material 
was also converted into the methyl ester to facilitate its analysis. Calculations of conversion 
(CHPLC) and selectivity factor (s) were performed using Kagan’s equations
10:  
% CHPLC = [eeSM/(eeSM+eePR)]×100% 
Selectivity factor s = ln[(1—C)(1—eeSM)]/ln[(1— C)(1+eeSM)]). 
In case of racemic or poorly enantioselective reactions (entries 1-4), conversions were estimated 





Table 3.5. Initial survey of reaction conditions. (corresponds to Table 3.1, section 3.4) 
entry Catalyst (mol %) ROH (equiv) Time (h) Temp, °C  %eeSM %eePR %CHPLC S 
1 none MeOH (10) 24 23 N/A N/A 0a N/A 
2 NEt3 (100) MeOH (10) 0.5 23 N/A N/A 100a N/A 
3 3.26 (20) MeOH (1) 192 23 5.44 2.01 45a 1.1 
4 3.45 (20) MeOH (1) 2.5 23 24.0 9.5 62a 1.5 
5 3.17 (10) MeOH (1) 5 23 56.4 50.7 52.7 5.2 
6 3.17 (10) MeOH (1) 8 0 64.2 51.6 55.4 5.9 
7 3.17 (10) BnOH (1) 16 0 58.9 80.0 42.4 16 
8 3.17 (10) Ph2CHOH (1) 120 23 23.4 72.0 24.6 7.7 
9 3.17 (10) i-PrOH (1) 24 23 0 0 N/A N/A 
a The conversion shown was estimated by 1H NMR. 
3.11.3 Kinetic resolution experiments: Exploring solvents and alcohols with 
Takemoto’s catalyst 
General procedure. The reactions were performed analogously to the procedure described above 
(entries 6-9 in Table 3.5), except that other solvents were used instead of CDCl3. 
Table 3.6. Survey of solvents and alcohols using Takemoto’s catalyst 3.17. (corresponds to 
Table 3.2, section 3.5) 
entry solvent ROH Time (h) %eeSM %eePR %CHPLC s 
1 CH2Cl2 BnOH 16 59.4 79.7 42.7 16 
2 PhMe BnOH 7 79.1 69.3 53.3 13 
3 Cyclohexane BnOH 16 92.8 34.3 73.0 6.0 
4 THF BnOH 72 28.7 88.2 24.6 21 
5 EtOAc BnOH 22 49.4 84.2 37.0 19 
6 Me2CO BnOH 23 26.6 87.4 23.3 19 
7 MeCN BnOH 23 39.5 66.5 37.3 7.3 
8 t-amyl alcohol BnOH 22 45.0 88.2 33.8 25 
9 t-amyl alcohol MeOH 22 36.6 82.2 30.8 15 
10 t-amyl alcohol AllylOH 22 51.7 92.9 35.8 45 
11a t-amyl alcohol Ph2CHOH 22 60.4 98.2 38.1 208 
12a t-amyl alcohol Ph2CHOH 22 65.4 97.9 40.0 190 
aExperiments were performed in duplicate. The values reported for conversion and selectivity 





3.11.4 Kinetic resolution experiments: Bifunctional catalyst survey 
General procedure. The reactions were performed analogously to the procedure described above 
(entries 11 and 12 in Table 3.6), except that other catalysts were used instead of 3.17. The reactions 
were run for 22 h in t-amyl alcohol in all cases. The absolute stereochemistry of the unreacted 
isoxazolidinones 3.43 was determined at this point to be (R) by comparing signs of optical rotation 
of (R)-3.43a (obtained from Table 3.7, entry 7) to that of the literature value3a: [α]𝐷
25 = +41° (c=1.0, 
CDCl3) compared to the literature value of [α] 𝐷
25= -13° (c=1.0, CDCl3) reported for (S)-X.  
Table 3.7: Bifunctional catalyst survey. (corresponds to Table 3.3, section 3.6) 
entry catalyst alcohol %eeSM % 
recovery 
%eePR % yield %CHPLC s 
1 3.46 Ph2CHOH N/A N/A N/A N/A 0
a N/A 
2b 3.47 Ph2CHOH -7.3 50 -13.6 29 34.9 1.4
-1 
3 3.48 Ph2CHOH N/A N/A N/A N/A 0
a N/A 
4 3.49 Ph2CHOH 61.5 46 89.2 31 40.8 33 
5b 3.50 Ph2CHOH -68.9 46 -95.7 36 41.9 94
-1 
6b 3.51 Ph2CHOH -59.0 50 -97.1 33 37.8 123
-1 
7c 3.52 Ph2CHOH 73.5 46 99.8 38 42.6 441 
8c 3.52 Ph2CHOH 69.4 46 99.0 33 41.2 397 
9 3.52 MeOH 72.3 42 82.5 37 46.7 23 
10 3.52 BnOH 72.3 42 82.6 41 46.7 23 
11 3.52 AllylOH 67.4 42 89.7 38 42.9 37 
a No conversion was observed by 1H NMR. b The absolute stereochemistry obtained in these 
cases was the opposite of other entries. c Experiments were performed in duplicate. The values 
reported for conversion and selectivity factor are averaged over two runs. 
3.11.5 Kinetic resolution experiments: Substrate scope 
General procedure. The reactions were performed analogously to the procedure described above 
(entries 7-11 in Table 3.7), except that other substrates were used besides (±)-3.43a. The reactions 




Table 3.8: Substrate scope. (corresponds to Table 3.4, section 3.7) 
entry # 
(3.43) 





1 a Ph t-Bu Ph2CHOH 81.6 42 98.6 38 45.3 361 
2 a Ph t-Bu Ph2CHOH 79.5 46 99.4 38 44.6 487 
3 b 4-ClC6H4 t-Bu Ph2CHOH 57.6 53 99.0 31 36.8 344 
4 c 4-MeOC6H4 t-Bu Ph2CHOH 68.9 45 98.6 35 41.1 301 
5 d 4-NO2Ph t-Bu Ph2CHOH 44.3 42 97.6 27 31.2 127 
6 f 2-ClC6H4 t-Bu Ph2CHOH 76.5 43 95.8 38 44.4 107 
7 e 3-MeOC6H4 t-Bu Ph2CHOH 80.9 41 98.8 38 45.0 430 
8 g 1-naphthyl t-Bu Ph2CHOH 39.9 55 98.3 28 28.9 171 
9 h 2-naphthyl t-Bu Ph2CHOH 72.6 45 98.7 36 42.4 334 
10 i 2-thienyl t-Bu Ph2CHOH 91.7 44 98.2 40 48.3 352 
11 j styryl t-Bu Ph2CHOH 91.3 38 92.3 40 49.7 80 
12 k Isobutyl t-Bu Ph2CHOH 62.3 50 94.5 37 39.8 67 
13 l Isopropyl t-Bu Ph2CHOH 31.7 56 98.2 20 24.4 151 
14 l Isopropyl t-Bu BnOH 52.9 52 97.7 29 35.1 144 
15 l Isopropyl t-Bu AllylOH 57.5 52 96.2 34 37.4 92 
16 m t-butyl t-Bu Ph2CHOH N/A N/A N/A N/A 0 N/A 
17 m t-butyl t-Bu AllylOH N/A N/A N/A N/A 0 N/A 
18 n Ph Bn Ph2CHOH N/A N/A N/A N/A 0 N/A 
19 n Ph Bn MeOH 93.3 33 78.1 42 54.4 27 
20 n Ph Bn BnOH 88.1 30 86.5 39 50.4 40 
21 n Ph Bn AllylOH 86.7 30 89.4 39 49.3 50 
22 e 2-ClC6H4 t-Bu Ph2CHOH 74.4 43 94.6 32 44.0 80 
23 h 2-naphthyl t-Bu Ph2CHOH 67.8 52 96.6 40 41.2 118 
24 k isobutyl t-Bu Ph2CHOH 31.9 50 88.0 26 26.6 21.4 
a 4:1 t-amyl alcohol/CHCl3 was used as solvent. 
b CHCl3 was used as solvent. 
c 3:2 t-amyl 
alcohol/ CHCl3 was used as solvent. 
d No conversion was detected by 1H NMR. e Performed on 
1.0 mmol of substrate. f Catalyst 3.17 was used instead of 3.52. 
 
3.12 Interconversion of kinetic resolution products 
3.12.1 Methanolysis of isoxazolidinones or esters 
 
Typical procedure. A solution of an isoxazolidinone (3.43) or a benzhydryl, benzyl or allyl ester 
(3.44) in MeOH (0.5M) was stirred with 3 equiv of potassium carbonate at rt for 1 h or until TLC 
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indicated complete consumption of the starting material. The reaction mixture was quenched with 
10 mL of saturated aqueous ammonium chloride and the methyl ester was extracted with CH2Cl2 
(×3). The organic extract was dried with Na2SO4 and concentrated by rotary evaporation. The 
product methyl esters 3.44-Me were purified by chromatography (10→30% EtOAc/toluene) and 
isolated in essentially quantitative yields. 
3.12.2 Recyclization of methyl ester 3.44f-Me into isoxazolidinone 3.43f 
 
A published procedure was followed.5 A solution of methyl ester (S)-3.44f-Me obtained as 
described above (33 mg, 0.10 mmol) and dibutyltin oxide (3 mg, 0.01 mmol, 0.1 equiv) in 2 mL 
of dry toluene (0.05 M) was gently refluxed for 4 h, at which time TLC (30% ethyl 
acetate/hexanes) revealed complete consumption of the starting material. The toluene was 
removed by rotary evaporation and the crude mixture pre-adsorbed onto silica gel. Elution with 
EtOAc/toluene (5→20%) gave (S)-3.43f in 57% yield (17 mg). 
3.12.3. Recyclization of methyl ester 3.44m-Me into 3.43m 
 
Methyl ester (±)-3.44-Me obtained as described above from (±)-3.43m (28 mg, 0.10 mmol) was 
dissolved in 500 μL of CDCl3 and its conversion to 3.43m was monitored by 
1H NMR. After 64 h 
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at rt, the conversion was estimated at 64%. The solution was heated at 50 °C for 2.5 h at which 
time NMR showed complete conversion to isoxazolidinone. 
3.13 Hydrogenolysis of 3.43a into β-phenylalanine  
 
A slightly modified literature procedure was followed.3a To a solution of isoxazolidinone (R)-3.43a 
(54 mg, 0.21 mmol) in 2 mL of EtOAc was added 5.3 mg of 10% Pd/C. The resulting mixture was 
placed in a steel bomb and stirred under 40 atm of hydrogen for 20 h, at which time TLC (30% 
EtOAc/ hexanes) indicated complete consumption of starting material. The crude mixture was 
filtered through a plug of Celite and concentrated by rotary evaporation to yield pure (R)-3.53a as 
a clear, colorless oil which quickly solidified into a white powder under vacuum (54 mg, 
quantitative yield). The spectroscopic and optical rotation data are in accordance with the 
literature.39 1H NMR (300 MHz, CDCl3) δ 7.37-7.27 (m, 5H), 5.08 (br, 1H), 2.86 (br, 2H), 1.40 
(br s, 9H). HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C14H19NO4, 288.1206; found 288.1203. 
[α]𝐷






3.14 Characterization of ester products  
methyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-phenylpropanoate (3.44a-Me).  
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.41-7.37 (m, 2H), 
7.35-7.27 (m, 3H), 6.55 (br s, 1H), 5.51 (dd, J = 9.5 Hz, 6 Hz, 1H), 3.68 (s, 
3H), 3.20 (dd, J = 15.3 Hz, 9.5 Hz, 1H), 2.89 (dd, J = 15.3 Hz, 6 Hz, 1H), 1.43 (s, 9H). 13C{1H} 
NMR (125 MHz, CDCl3): δ 171.7, 156.6, 138.9, 128.6, 128.1, 127.4, 82.5, 59.4, 52.1, 37.1, 28.4; 
IR (cm-1): 3209 (br), 2978, 1737, 1684, 1161, 1103, 699; HRMS (ESI-TOF) m/z: [M+H]+ calcd 
for C15H22NO5, 296.1492; found, 296.1494. HPLC: (7 % isopropanol/hexanes, AS-H): Major 
enantiomer: 7.0 min; Minor enantiomer: 9.9 min; 82% ee (Table 3.6, entry 9). [α] 𝐷
25 = −15° 
(c=0.350, CHCl3).  
benzyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-phenylpropanoate (3.44a-Bn) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.41-7.27 (m, 10H), 
6.10 (s, 1H), 5.53 (dd, J = 9.5 Hz, 6 Hz, 1H), 5.12 (s, 2H), 3.23 (dd, J = 15 
Hz, 9.5 Hz, 1H), 2.96 (dd, J = 15 Hz, 6 Hz, 1H), 1.43 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): 
δ 171.0, 156.5, 138.6, 135.8, 128.72, 128.65, 128.4, 128.3, 128.2, 127.5, 82.6, 66.8, 59.5, 37.4, 
28.4; IR (cm-1): 3200 (br), 2976, 1735, 1685, 1159, 1103, 696; HRMS (ESI-TOF) m/z: [M+Na]+ 
calcd for C21H25NO5Na, 394.1625; found, 394.1630. [α] 𝐷
25 = −14° (c=0.550, CHCl3); 88% ee 
(Table 3.6, entry 8, measured by HPLC as the corresponding methyl ester).  
allyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-phenylpropanoate (3.44a-Allyl). 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.42-7.38 (m, 2H), 
7.36-7.27 (m, 3H), 6.02 (s, 1H), 5.93-5.84 (m, 1H), 5.52 (dd, J = 9.5 Hz, 
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6 Hz, 1H), 5.32-5.21 (m, 2H), 4.61-4.58 (m, 2H), 3.22 (dd, J = 15 Hz, 9.5 Hz, 1H), 2.93 (dd, J = 
15 Hz, 6 Hz, 1H), 1.44 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 170.9, 156.5, 138.7, 132.0, 
128.7, 128.2, 127.5, 118.6, 82.6, 65.7, 59.4, 37.3, 28.4; IR (cm-1): 3203 (br), 2978, 2932, 1736, 
1686, 1161, 1103, 699; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C17H23NO5Na, 344.1468; 
found, 344.1456. [α] 𝐷
25 = −17° (c=0.550, CHCl3); 93% ee (Table 3.6, entry 10, measured by 
HPLC as the corresponding methyl ester).  
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-phenylpropanoate (3.44a-Bzh). 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.42-7.39 (m, 2H), 
7.35-7.25 (m, 13H), 6.87 (s, 1H), 6.46 (s, 1H), 5.56 (dd, J = 9 Hz, 7 
Hz, 1H), 3.29 (dd, J = 15 Hz, 9 Hz, 1H), 3.09 (dd, J = 15 Hz, 7 Hz, 1H), 1.40 (s, 9H). 13C{1H} 
NMR (125 MHz, CDCl3): δ 170.2, 156.5, 139.99, 139.97, 138.6, 128.64, 128.61, 128.12, 128.08, 
128.0, 127.6, 127.2, 127.1, 82.5, 77.6, 59.5, 37.8, 28.3; IR (cm-1): 2922, 2852, 1737, 1692, 1284, 
1102, 697; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C27H29NO5Na, 470.1938; found, 
470.1929. [α] 𝐷
25 = −11° (c=0.700, CHCl3); 98% ee (Table 3.6, entry 11, measured by HPLC as 
the corresponding methyl ester). 
methyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(4-chlorophenyl)propanoate (3.44b-
Me) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 8.5 Hz, 
2H), 7.29 (d, J = 8.5 Hz, 2H), 6.88 (br s, 1H), 5.46 (dd, J = 9 Hz, 6.5 Hz, 
1H), 3.67 (s, 3H), 3.15 (dd, J = 16 Hz, 9 Hz, 1H), 2.87 (dd, J = 16 Hz, 6.5 
Hz, 1H), 1.42 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.4, 156.5, 
137.4, 134.0, 128.9, 128.8, 82.8, 58.7, 52.2, 37.1, 28.3; IR (cm-1): 3205 (br), 2978, 2930, 1738, 
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1686, 1163, 1109, 1091; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C15H20NO5ClNa, 352.0922; 
found, 352.0923. HPLC: (7 % isopropanol/hexanes, AS-H): Major enantiomer: 6.4 min; Minor 
enantiomer: 9.9 min; 99% ee. [α] 𝐷
25 = −19° (c=0.400, CHCl3). 
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(4-chlorophenyl)propanoate 
(3.44b-Bzh) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.35-7.25 (m, 12H), 
7.25-7.21 (m, 2H), 6.85 (s, 1H), 6.51 (br s, 1H), 5.49 (dd, J = 8 Hz, 7 
Hz, 1H), 3.23 (dd, J = 15 Hz, 8 Hz, 1H), 3.06 (dd, J = 15 Hz, 7 Hz, 
1H), 1.39 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 169.9, 156.4, 
139.84, 139.81, 137.0, 134.0, 129.1, 128.8, 128.7, 128.6, 128.2, 128.1, 127.2, 127.1, 82.8, 77.7, 
58.8, 37.8, 28.3; IR (cm-1): 3197 (br s), 2925, 2362, 1736, 1686, 1160, 1108; HRMS (ESI-TOF) 
m/z: [M+Na]+ calcd for C27H28ClNO5Na, 504.1548; found, 504.1523. [α] 𝐷
25  = −13° (c=0.993, 
CHCl3); 99% ee (Table 3.8, entry 3, measured by HPLC as the corresponding methyl ester). 
methyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(4-methoxyphenyl)propanoate 
(3.44c-Me) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 9 Hz, 2H), 
6.85 (d, J = 9 Hz, 2H), 6.25 (br s, 1H), 5.46 (dd, J = 9 Hz, 6.5 Hz, 1H), 
3.79 (s, 3H), 3.67 (s, 3H), 3.16 (dd, J = 15.3 Hz, 9 Hz, 1H), 2.87 (dd, J = 
15.3 Hz, 6.5 Hz, 1H), 1.44 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 
171.7, 159.4, 156.6, 130.7, 128.8, 114.0, 82.5, 58.9, 55.4, 52.1, 37.2, 28.4; IR (cm-1): 3205 (br s), 
2929, 1737, 1684, 1513, 1247, 1162, 1103, 780; HRMS (ESI-TOF) m/z: [M+H]+ calcd for 
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C16H24NO6, 326.1598; found, 326.1595. [α] 𝐷
25 = −24° (c=0.450, CHCl3); 99% ee (measured by 
HPLC as the corresponding isoxazolidinone). 
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(4-methoxyphenyl)propanoate 
(3.44c-Bzh) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.34-7.21 (m, 11H), 
6.86-6.81 (m, 3H), 6.52 (br s, 1H), 5.50 (dd, J = 8.5 Hz, 7.5 Hz, 1H), 
3.79 (s, 3H), 3.24 (dd, J = 16 Hz, 8.5 Hz, 1H), 3.07 (dd, J = 16 Hz, 7.5 
Hz, 1H), 1.39 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 170.2, 
159.4, 156.6, 140.0, 139.98, 130.5, 128.9, 128.61, 128.56, 128.1, 128.0, 127.2, 127.1, 113.9, 
82.5, 77.5, 58.9, 55.3, 37.9, 28.3; IR (cm-1): 2977, 2933, 1735, 1686, 1248, 1158, 1108, 735, 
697; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C28H31NO6Na, 500.2044; found, 500.2059.  
[α] 𝐷




Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.19 (d, J = 9 Hz, 2H), 
7.58 (d, J = 9 Hz, 2H), 6.99 (br s, 1H), 5.57 (dd, J = 9 Hz, 7 Hz, 1H), 3.69 
(s, 3H), 3.18 (dd, J = 16 Hz, 9 Hz, 1H), 2.92 (dd, J = 16 Hz, 7 Hz, 1H), 
1.42 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.1, 156.4, 147.7, 
146.2, 128.4, 123.9, 83.2, 58.7, 52.3, 37.0, 28.3; IR (cm-1): 3211 (br), 2928, 1740, 1691, 1523, 
1347, 1166, 1110; HRMS (ESI-TOF) m/z: [M+H]+ calcd for C15H21N2O7, 341.1343; found, 
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341.1342. HPLC: (7 % isopropanol/hexanes, AD-H): Major enantiomer: 21.7 min; Minor 
enantiomer: 27.7 min; 96% ee. [α] 𝐷
25 = −12° (c=0.550, CHCl3). 
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(4-nitrophenyl)propanoate 
(3.44d-Bzh) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.12 (d, J = 9 Hz, 
2H), 7.54 (d, J = 9 Hz, 2H), 7.35-7.22 (m, 10H), 6.85 (s, 1H), 6.52 (br 
s, 1H), 5.58 (dd, J = 8.5 Hz, 7.5 Hz, 1H), 3.25 (dd, J = 15.5 Hz, 8.5 Hz, 
1H), 3.08 (dd, J = 15.5 Hz, 7.5 Hz, 1H), 1.38 (s, 9H). 13C{1H} NMR 
(125 MHz, CDCl3): δ 169.6, 156.3, 147.7, 145.8, 139.7, 139.6, 128.72, 128.66, 128.5, 128.3, 
128.2, 127.2, 127.1, 123.8, 83.3, 77.9, 58.8, 37.6, 28.3; IR (cm-1): 3194 (br), 2926, 1737, 1688, 
1522, 1346, 1163, 1110; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C27H28N2O7Na, 515.1789; 
found, 515.1790.  [α] 𝐷
25 = −8° (c=0.600, CHCl3); 96% ee (Table 3.8, entry 5, measured by 
HPLC as the corresponding methyl ester). 
methyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(3-methoxyphenyl)propanoate 
(3.44e-Me). 
Clear, colorless oil which slowly solidified into a white powder. 1H NMR 
(500 MHz, CDCl3) δ 7.24-7.21 (m, 1H), 6.97-6.93 (m, 2H), 6.83-6.79 (m, 
1H), 5.48 (dd, J = 9 Hz, 6 Hz, 1H), 3.78 (s, 3H), 3.67 (s, 3H), 3.18 (dd, J 
= 16 Hz, 9 Hz, 1H), 2.86 (dd, J = 16 Hz, 6 Hz, 1H), 1.42 (s, 9H). 13C{1H} NMR (125 MHz, 
CDCl3): δ 171.7, 159.7, 156.5, 140.5, 129.6, 119.7, 113.5, 113.1, 82.4, 59.2, 55.3, 52.1, 37.1, 
28.4; IR (cm-1): 3215 (br), 2976, 1737, 1685, 1255, 1160, 1104; HRMS (ESI-TOF) m/z: 
[M+Na]+ calcd for C16H23NO6Na, 348.1418; found, 348.1413. mp: 66- 67 °C. HPLC: (7 % 
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isopropanol/hexanes, AS-H): Major enantiomer: 10.0 min; Minor enantiomer: 13.5 min; 99% ee.        
[α] 𝐷
25 = −11° (c=0.600, CHCl3).  
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(3-methoxyphenyl)propanoate 
(3.44e-Bzh) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.35-7.21 (m, 
11H), 7.01-6.95 (m, 2H), 6.87 (s, 1H), 6.85-6.82 (m, 1H), 5.54 (dd, J 
= 8.5 Hz, 7 Hz, 1H), 3.77 (s, 3H), 3.28 (dd, J = 16 Hz, 8.5 Hz, 1H), 
3.08 (dd, J = 16 Hz, 7 Hz, 1H), 1.39 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 170.1, 159.7, 
156.5, 140.1, 140.0, 129.6, 128.60, 128.57, 128.03, 127.97, 127.2, 127.1, 119.9, 113.7, 113.1, 
82.4, 77.5, 59.3, 55.3, 37.7, 28.3; IR (cm-1): 3209 (br), 2975, 2931, 1736, 1685, 1156, 1104, 696; 
HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C28H31NO6Na, 500.2044; found, 500.2043. [α] 𝐷
25 = 




Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.69-7.65 (m, 1H), 
7.36-7.33 (m, 1H), 7.28-7.20 (m, 2H), 6.69 (br s, 1H), 5.93 (dd, J = 11 Hz, 
5 Hz, 1H), 3.72 (s, 3H), 3.08 (dd, J = 15 Hz, 11 Hz, 1H), 2.85 (dd, J = 15 
Hz, 5 Hz, 1H), 1.40 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.5, 156.4, 137.9, 132.5, 
129.6, 129.1, 128.3, 127.4, 82.6, 56.5, 52.2, 36.4, 28.3; IR (cm-1): 3199 (br), 2928, 1742, 1688, 
1168, 1112; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C15H20ClNO5Na, 352.0922; found, 
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352.0936. HPLC: (7 % isopropanol/hexanes, AD-H): Minor enantiomer: 13.4 min; Major 
enantiomer: 17.0 min; 96% ee. [α] 𝐷
25 = +6° (c=0.533, CHCl3). 
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(2-chlorophenyl)propanoate 
(3.44f-Bzh) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.70-7.67 (m, 1H), 
7.36-7.17 (m, 13H), 6.88 (s, 1H), 6.03 (dd, J = 9.5 Hz, 6 Hz, 1H), 3.18 
(dd, J = 15.5 Hz, 9.5 Hz, 1H), 3.05 (dd, J = 15.5 Hz, 6 Hz, 1H), 1.33 (s, 
9H). 13C{1H} NMR (125 MHz, CDCl3): δ 169.8, 156.2, 140.01, 139.99, 137.6, 132.7, 129.6, 
129.0, 128.6, 128.5, 128.0, 127.3, 127.12, 127.09, 82.5, 77.5, 56.3, 36.9, 28.2; IR (cm-1): 3193 
(br), 2978, 2930, 1739, 1686, 1159, 1109, 744, 697; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for 
C27H28ClNO5Na, 504.1548; found, 504.1534. [α] 𝐷
25 = +2° (c=1.067, CHCl3); 96% ee (Table 3.8, 
entry 6, measured by HPLC as the corresponding methyl ester). 
methyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(naphthalen-1-yl)propanoate 
(3.44g-Me) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.21-8.17 (m, 1H), 
7.87-7.84 (m, 1H), 7.81-7.77 (m, 1H), 7.71-7.67 (m, 1H), 7.56-7.52 (m, 
1H), 7.51-7.42 (m, 2H), 6.70 (br s, 1H), 6.38 (dd, J = 9.5 Hz, 5.5 Hz, 1H), 
3.69 (s, 3H), 3.33 (dd, J = 15.5 Hz, 9.5 Hz, 1H), 3.01 (dd, J = 15.5 Hz, 5.5 Hz, 1H), 1.36 (s, 9H). 
13C{1H} NMR (125 MHz, CDCl3): δ 171.8, 156.0, 134.9, 133.9, 130.9, 129.0, 128.7, 126.5, 
125.8, 125.4, 124.7, 123.1, 82.4, 54.9, 52.2, 36.6, 28.3; IR (cm-1): 3201 (br), 2976, 2928, 1737, 
1685, 1165, 1107, 778; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C19H23NO5Na, 368.1468; 
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found, 368.1446. HPLC: (7 % isopropanol/hexanes, OD-H): Minor enantiomer: 8.1 min; Major 
enantiomer: 10.0 min; 98% ee. [α] 𝐷
25 = +7° (c=0.467, CHCl3).  
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(naphthalen-1-yl)propanoate 
(3.44g-Bzh) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.24-8.20 (m, 1H), 
7.89-7.86 (m, 1H), 7.82-7.78 (m, 1H), 7.75-7.72 (m, 1H), 7.56-7.48 
(m, 2H), 7.45-7.41 (m, 1H), 7.33-7.15 (m, 10H), 7.03 (br s, 1H), 6.85 
(s, 1H), 6.47 (dd, J = 8.5 Hz, 7 Hz, 1H), 3.38 (dd, J = 16 Hz, 8.5 Hz, 1H), 3.29 (dd, J = 16 Hz, 7 
Hz, 1H), 1.30 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 170.0, 155.8, 140.0, 139.9, 134.5, 
134.0, 131.1, 129.0, 128.7, 128.6, 128.5, 128.0, 127.9, 127.1, 127.0, 126.5, 125.7, 125.4, 125.0, 
123.2, 82.4, 77.5, 54.5, 37.2, 28.2; IR (cm-1): 2975, 2928, 1736, 1684, 1158, 1104, 696; HRMS 
(ESI-TOF) m/z: [M+Na]+ calcd for C31H31NO5Na, 520.2094; found, 520.2075. [α] 𝐷
25 = −5° 




Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.86-7.78 (m, 4H), 7.55-
7.51 (m, 1H), 7.50-7.44 (m, 2H), 7.19 (br s, 1H), 5.68 (dd, J = 9 Hz, 6 Hz, 
1H), 3.68 (s, 3H), 3.29 (dd, J = 16 Hz, 9 Hz, 1H), 3.01 (dd, J = 16 Hz, 6 
Hz, 1H), 1.39 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.7, 156.6, 
136.4, 133.3, 133.1, 128.3, 128.2, 127.7, 126.4, 126.24, 126.17, 125.6, 82.5, 59.4, 52.1, 37.1, 
28.; IR (cm-1): 3206 (br), 3058, 2977, 1736, 1683, 1162, 1103; HRMS (ESI-TOF) m/z: [M+Na]+ 
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calcd for C19H23NO5Na, 368.1468; found, 368.1444. HPLC: (7 % isopropanol/hexanes, AS-H): 
Major enantiomer: 8.1 min; Minor enantiomer: 13.4 min; 99% ee. [α] 𝐷




Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.84-7.76 (m, 4H), 
7.56-7.53 (m, 1H), 7.51-7.46 (m, 2H), 7.30-7.18 (m, 10H), 6.85 (s, 
1H), 6.78 (br s, 1H), 5.72 (dd, J = 8 Hz, 7.5 Hz, 1H), 3.36 (dd, J = 15.5 
Hz, 8 Hz, 1H), 3.22 (dd, J = 15.5 Hz, 7.5 Hz, 1H), 1.36 (s, 9H). 
13C{1H} NMR (125 MHz, CDCl3): δ 170.2, 156.5, 139.91, 139.88, 136.0, 133.3, 133.2, 128.6, 
128.5, 128.4, 128.3, 128.1, 128.0, 127.7, 127.2, 127.0, 126.6, 126.24, 126.22, 125.7, 82.6, 77.6, 
59.5, 37.8, 28.3; IR (cm-1): 2975, 1735, 1685, 1159, 1103; HRMS (ESI-TOF) m/z: [M+Na]+ 
calcd for C31H31NO5Na, 520.2094; found, 520.2103. [α] 𝐷
25 = −9° (c=1.200, CHCl3); 99% ee 
(Table 3.8, entry 9, measured by HPLC as the corresponding methyl ester). 
methyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(thiophen-2-yl)propanoate (3.44i-
Me) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.23 (dd, J = 5 Hz, 1 
Hz, 1H), 7.05-7.02 (m, 1H), 6.95 (dd, J = 5 Hz, 4 Hz, 1H), 6.13 (br s, 1H), 
5.76 (dd, J = 9 Hz, 6.5 Hz, 1H), 3.69 (s, 3H), 3.19 (dd, J = 15 Hz, 9 Hz, 
1H), 2.96 (dd, J = 15 Hz, 6.5 Hz, 1H), 1.48 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.1, 
156.7, 140.5, 126.6, 125.9, 125.3, 83.1, 55.5, 52.2, 38.3, 28.4; IR (cm-1): 3236 (br), 2928, 1738, 
1693, 1163, 1102; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C13H19NO5SNa, 324.0876; found, 
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324.0885. HPLC: (7 % isopropanol/hexanes, AS-H): Major enantiomer: 8.4 min; Minor 
enantiomer: 11.9 min; 98% ee. [α] 𝐷
25 = −15° (c=0.400, CHCl3).  
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-3-(thiophen-2-yl)propanoate 
(3.44i-Bzh) 
Clear, colorless oil which slowly solidified into a white powder. 1H 
NMR (500 MHz, CDCl3) δ 7.35-7.25 (m, 10H), 7.22 (dd, J = 5 Hz, 1 
Hz, 1H), 7.04-7.02 (m, 1H), 6.93 (dd, J = 5 Hz, 4 Hz, 1H), 6.87 (s, 
1H), 6.70 (br s, 1H), 5.82 (dd, J = 8 Hz, 7 Hz, 1H), 3.28 (dd, J = 16 Hz, 8 Hz, 1H), 3.13 (dd, J = 
16 Hz, 7 Hz, 1H), 1.44 (s, 9H). 13C{1H} NMR (125 MHz, CDCl3): δ 169.6, 156.7, 140.1, 139.9, 
128.61, 128.57, 128.1, 128.0, 127.2, 127.1, 126.6, 126.0,125.3, 83.0, 77.6, 55.4, 38.9, 28.3; IR 
(cm-1): 3186 (br), 2914, 1744, 1690, 1366, 1101, 699; HRMS (ESI-TOF) m/z: [M+H]+ calcd for 
C25H28NO5S, 454.1683; found, 454.1675. mp: 103-105 °C. [α] 𝐷
25 = −14° (c=1.067, CHCl3); 98% 
ee (Table 3.8, entry 10, measured by HPLC as the corresponding methyl ester).  
methyl (S,E)-3-((tert-butoxycarbonyl)(hydroxy)amino)-5-phenylpent-4-enoate (3.44j-Me) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.40-7.36 (m, 2H), 
7.35-7.29 (m, 2H), 7.28-7.23 (m, 1H), 6.61 (d, J = 16 Hz, 1H), 6.49 (br s, 
1H), 6.29 (dd, J = 16 Hz, 7 Hz, 1H), 5.10-5.03 (m, 1H), 3.72 (s, 3H), 2.96 
(dd, J = 15 Hz, 8.5 Hz, 1H), 2.75 (dd, J = 15 Hz, 6.5 Hz, 1H), 1.50 (s, 9H). 13C{1H} NMR (125 
MHz, CDCl3): δ 171.7, 157.0, 136.4, 132.9, 128.7, 128.1, 126.7, 125.5, 82.6, 58.5, 52.1, 37.2, 
28.4; IR (cm-1): 3224 (br), 2977, 1737, 1685, 1161, 1103, 966, 750, 694; HRMS (ESI-TOF) m/z: 
[M+Na]+ calcd for C17H23NO5Na, 344.1468; found, 344.1480. HPLC: (7 % isopropanol/hexanes, 
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OD-H): Minor enantiomer: 8.0 min; Major enantiomer: 17.2 min; 92% ee. [α] 𝐷




 Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.37-7.23 (m, 
15H), 6.90 (s, 1H), 6.58-6.53 (m, 1H), 6.38 (br s, 1H), 6.31-6.26 (m, 
1H), 5.13-5.07 (m, 1H), 3.07-3.01 (m, 1H), 2.93-2.87 (m, 1H), 1.46 (s, 
9H). 13C{1H} NMR (125 MHz, CDCl3): δ 170.1, 157.1, 140.01, 139.97, 136.4, 133.1, 128.7, 
128.62, 128.59, 128.1, 128.01, 128.00, 127.3, 127.1, 126.7, 125.2, 82.6, 77.6, 58.7, 37.9, 28.4; 
IR (cm-1): 2977, 1735, 1686, 1157, 1103, 694; HRMS (ESITOF) m/z: [M+Na]+ calcd for 
C29H31NO5Na, 496.2094; found, 496.2091. [α] 𝐷
25 = +2° (c=0.933, CHCl3); 92% ee (Table 3.8, 
entry 11, measured by HPLC as the corresponding methyl ester).  
methyl (R)-3-((tert-butoxycarbonyl)(hydroxy)amino)-5-methylhexanoate (3.44k-Me) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 6.45 (br s, 1H), 4.52- 
4.45 (m, 1H), 3.67 (s, 3H), 2.69 (dd, J = 15 Hz, 8.5 Hz, 1H), 2.43 (dd, J = 
15 Hz, 5.5 Hz, 1H), 1.77-1.71 (m, 1H), 1.65-1.58 (m, 1H), 1.48 (s, 9H), 
1.19-1.12 (m, 1H), 0.94-0.90 (m, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 172.3, 156.3, 81.9, 
53.9, 51.9, 41.1, 37.4, 28.4, 24.8, 23.3, 21.8; IR (cm-1): 3207 (br), 2955, 2929, 1740, 1683, 
1365, 1168, 1120, 1097; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C13H25NO5Na, 298.1625; 
found, 298.1639. HPLC: (5 % isopropanol/hexanes, AD-H): Minor enantiomer: 7.5 min; Major 
enantiomer: 9.9 min; 95% ee. [α] 𝐷




benzhydryl (R)-3-((tert-butoxycarbonyl)(hydroxy)amino)-5-methylhexanoate (3.44k-Bzh) 
 Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.37-7.24 (m, 
10H), 6.88 (s, 1H), 4.57-4.49 (m, 1H), 2.79 (dd, J = 15 Hz, 8 Hz, 1H), 
2.61 (dd, J = 15 Hz, 7 Hz, 1H), 1.78-1.71 (m, 1H), 1.63-1.56 (m, 1H), 
1.42 (s, 9H), 1.16-1.10 (m, 1H), 0.88 (d, J = 7 Hz, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 
170.8, 156.4, 140.2, 128.7, 128.6, 128.1, 127.23, 127.18, 82.0, 77.4, 53.9, 40.8, 38.1, 28.3, 24.7, 
23.3, 21.8; IR (cm-1): 3199 (br), 2956, 1738 1684, 1165, 1118; HRMS (ESI-TOF) m/z: [M+Na]+ 
calcd for C25H33NO5Na, 450.2251; found, 450.2269. [α] 𝐷
25 = +1° (c=1.000, CHCl3); 95% ee 
(Table 3.8, entry 12, measured by HPLC as the corresponding methyl ester). 
methyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-4-methylpentanoate (3.44l-Me) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 6.27 (br s, 1H), 4.13- 
4.07 (m, 1H), 3.67 (s, 3H), 2.73 (dd, J = 15 Hz, 10 Hz, 1H), 2.55 (dd, J = 
15 Hz, 4 Hz, 1H), 1.98-1.89 (m, 1H), 1.48 (s, 9H), 0.95 (dd, J = 6.5 Hz, 
2Hz, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 172.8, 156.5, 81.6, 61.4, 51.9, 34.8, 31.1, 28.4, 
19.8, 19.5; IR (cm-1): 3209 (br), 2964, 1742, 1683, 1169, 1129; HRMS (ESI-TOF) m/z: [M+Na]+ 
calcd for C12H23NO5Na, 284.1468; found 284.1480. HPLC: (5 % isopropanol/hexanes, AD-H): 
Minor enantiomer: 9.5 min; Major enantiomer: 12.9 min; 98% ee. [α] 𝐷
25 = −1° (c=0.600, 
CHCl3).  
benzhydryl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-4-methylpentanoate (3.44l-Bzh) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.34-7.27 (m, 10H), 
6.87 (s, 1H), 6.06 (br s, 1H), 4.19-4.12 (m, 1H), 2.84 (dd, J = 15 Hz, 10 
Hz, 1H), 2.67 (dd, J = 15 Hz, 5 Hz, 1H), 2.00-1.90 (m, 1H), 1.41 (s, 
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9H), 0.94 (d, J = 7 Hz, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.4, 156.3, 140.12, 140.05, 
128.67, 128.65, 128.1, 127.3, 127.2, 81.8, 77.5, 61.3, 35.5, 31.3, 28.4, 19.8, 19.5; IR (cm-1): 3207 
(br), 2968, 1737, 1681, 1162, 1117, 743, 697; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for 
C24H31NO5Na, 436.2094; found, 436.2090. [α] 𝐷
25 = −1° (c=0.467, CHCl3); 98% ee (Table 3.8, 
entry 13, measured by HPLC as the corresponding methyl ester).  
benzyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-4-methylpentanoate (3.44l-Bn) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.38-7.30 (m, 5H), 5.10 
(s, 2H), 4.17-4.11 (m, 1H), 2.79 (dd, J = 15 Hz, 10 Hz, 1H), 2.60 (dd, J = 
15 Hz, 5 Hz, 1H), 1.99-1.90 (m, 1H), 1.46 (s, 9H), 0.95 (dd, J = 6.5 Hz, 2 
Hz, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 172.1, 156.6, 135.8, 128.6, 128.29, 128.25, 81.6, 
66.6, 61.3, 35.1, 31.1, 28.4, 19.8, 19.4; IR (cm-1): 3206 (br), 2966, 1737, 1681, 1164, 1118; 
HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C18H27NO5Na, 360.1781; found 360.1782. [α] 𝐷
25 = 
−4° (c=0.667, CHCl3); 98% ee (Table 3.8, entry 14, measured by HPLC as the corresponding 
methyl ester). 
allyl (S)-3-((tert-butoxycarbonyl)(hydroxy)amino)-4-methylpentanoate (3.44l-Allyl) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 6.16 (br s, 1H), 5.95-
5.85 (m, 1H), 5.34-5.29 (m, 1H), 5.25-5.22 (m, 1H), 4.59-4.55 (m, 2H), 
4.15-4.08 (m, 1H), 2.75 (dd, J = 15 Hz, 10 Hz, 1H), 2.58 (dd, J = 15 Hz, 4 
Hz, 1H), 1.99-1.91 (m, 1H), 1.48 (s, 9H), 0.95 (dd, J = 7 Hz, 3 Hz, 6H). 13C{1H} NMR (125 
MHz, CDCl3): δ 171.9, 156.6, 132.1, 118.4, 81.5, 65.4, 61.3, 35.1, 31.0, 28.4, 19.8, 19.4; IR  
(cm-1): 3197 (br), 2966, 1738, 1682, 1166, 1120; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for 
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C14H25NO5Na, 310.1625; found 310.1616. [α] 𝐷
25 = −2° (c=0.667, CHCl3); 96% ee (Table 3.8, 
entry 15, measured by HPLC as the corresponding methyl ester). 
methyl 3-((tert-butoxycarbonyl)(hydroxy)amino)-4,4-dimethylpentanoate (3.44m-Me) 
1H NMR (500 MHz, CDCl3) δ 6.82 (br s, 1H), 4.18 (br dd, 1H), 3.65 (s, 
3H), 2.88 (br dd, 1H), 2.45 (br dd, 1H), 1.48 (s, 9H), 0.97 (s, 9H). 13C{1H} 
NMR (125 MHz, (CD3)2CO): δ 172.9, 157.2, 80.8, 63.6, 51.8, 36.0, 31.8, 
28.7, 27.6; IR (cm-1): 3188 (br), 2957, 1741, 1680, 1163, 1108; HRMS (ESI-TOF) m/z: [M+Na]+ 
calcd for C13H25NO5Na, 298.1625; found 298.1635. 
methyl (S)-3-(((benzyloxy)carbonyl)(hydroxy)amino)-3-phenylpropanoate (3.44n-Me) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.38-7.27 (m, 10H), 
6.52 (br s, 1H), 5.60 (dd, J = 10 Hz, 5.5 Hz, 1H), 5.19 (d, J = 12 Hz, 1H), 
5.14 (d, J = 12 Hz, 1H), 3.65 (s, 3H), 3.21 (dd, J = 15.5 Hz, 10 Hz, 1H), 2.89 (dd, J = 15.5 Hz, 
5.5 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 171.7, 157.1, 138.4, 135.9, 128.7, 128.6, 
128.4, 128.19, 128.17, 127.4, 68.3, 59.3, 52.2, 36.8; IR (cm-1): 3276 (br), 2952, 1695, 1271, 
1098, 696; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C18H19NO5Na, 352.1155; found, 
352.1157. HPLC: (10 % isopropanol/hexanes, AD-H): Major enantiomer: 16.8 min; Minor 
enantiomer: 24.1 min; 78% ee (Table 3.8, entry 19). [α] 𝐷
25  = −24° (c=0.800, CHCl3). 
benzyl (S)-3-(((benzyloxy)carbonyl)(hydroxy)amino)-3-phenylpropanoate (3.44n-Bn) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.38-7.26 (m, 15H), 
6.74 (br s, 1H), 5.63 (dd, J = 10 Hz, 6 Hz, 1H), 5.18-5.14 (m, 1H), 5.11-
5.06 (m, 3H), 3.25 (dd, J = 16 Hz, 10 Hz, 1H), 2.96 (dd, J = 16 Hz, 6 Hz, 1H). 13C{1H} NMR 
(125 MHz, CDCl3): δ 171.0, 157.1, 138.3, 135.8, 135.6, 128.63, 128.56, 128.4, 128.3, 128.13, 
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128.09, 127.5, 68.2, 66.8, 59.2, 37.1; IR (cm-1): 3261 (br), 2950, 1731, 1695, 694; HRMS (ESI-
TOF) m/z: [M+Na]+ calcd for C24H23NO5Na, 428.1458; found, 428.1468. [α] 𝐷
25 = −26° 
(c=0.800, CHCl3); 87% ee (Table 3.8, entry 20, measured by HPLC as the corresponding methyl 
ester). 
allyl (S)-3-(((benzyloxy)carbonyl)(hydroxy)amino)-3-phenylpropanoate (3.44n-Allyl) 
Clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.39-7.27 (m, 10H), 
6.73 (br s, 1H), 5.89-5.80 (m, 1H), 5.62 (dd, J = 10 Hz, 6 Hz, 1H), 5.29-
5.24 (m, 1H), 5.22-5.15 (m, 2H), 5.15-5.10 (m, 1H), 4.57-4.55 (m, 2H), 3.23 (dd, J = 15 Hz, 10 
Hz, 1H), 2.92 (dd, J = 15 Hz, 6 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 170.8, 157.1, 
138.4, 135.9, 131.8, 128.61, 128.55, 128.3, 128.11, 128.09, 127.5, 118.6, 68.2, 65.6, 59.2, 37.0; 
IR (cm-1): 3267 (br), 2947, 1732, 1696, 1271, 1098, 696; HRMS (ESI-TOF) m/z: [M+Na]+ calcd 
for C20H21NO5Na, 378.1312; found, 378.1308. [α] 𝐷
25 = −26° (c=0.667, CHCl3); 89% ee (Table 
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Chapter 4: Organocatalyzed rearrangements 
of thioesters1 
4.1 General introduction to asymmetric acyl transfer 
catalysis 
Asymmetric acyl transfer catalysis is an indispensable tool in enantioselective synthesis. 
As was evidenced in Chapters 2 and 3, new discoveries are still being made in this area of research, 
but a lot of areas are yet to be explored. Acyl transfer catalysis operates via three general reaction 
pathways outlined in Figure 4.1. Pathway 3a, starting with an activated carboxylic acid derivative 
4.10, was outlined in Chapter 2.  
In pathway 1, a generic acyl donor 4.01 reacts with a Lewis basic acyl transfer catalyst 
(Cat) to generate reactive ion pair 4.02. A nucleophile H-Nu then displaces the catalyst and 
generates the final product. A classic example of this reaction pathway would be an esterification 
of an alcohol catalyzed by 4-(dimethylamino)pyridine (DMAP).2 In pathway 2, an α,β-unsaturated 
acyl donor 4.04 reacts with the catalyst to form reactive ion pair 4.05 which can react with a 
Michael donor (Pathway 2a). Alternatively, the unsaturated acyl ammonium cation may react with 
a diene in a [4+2] cycloaddition fashion to deliver Diels-Alder adduct 4.08 (Pathway 2b).  
Regardless of which pathway operates, another nucleophile is introduced to turn over the catalyst. 
In pathway 3, an acyl donor with an acidic α proton reacts with a catalyst and undergoes 
deprotonation to form zwitterion 4.13. This zwitterionic species can also be made from the 
corresponding ketene 4.12. This zwitterion can react with a pi-electrophile, delivering a product 
resulting from a formal [2+2] cycloaddition (Pathway 3a). Alternatively, the zwitterion can react 
with an electophile in an SN2 fashion. The displaced nucleofuge can then replace the catalyst, 




Figure 4.1. Three mechanistically distinct pathways involving catalytic acyl transfer. 
 
Several structurally distinct groups of Lewis basic catalysts have been used as acyl transfer 
catalysts (Figure 4.2). 4-aminopyridines such as DMAP and 4-pyrrolidinopyridine (PPY), 





Figure 4.2. Some examples from the most common classes of achiral acyl transfer catalysts. 
While all the catalysts listed in Figure 4.2 are achiral, significant progress has been made 
since the 1990s to synthesize chiral variants of these catalysts and render their catalyzed processes 
enantioselective.3 Some of the most illustrative chiral catalysts in this regard are given in Figure 
4.3.4   
Prior to these works, lipase and esterase families of enzymes, in addition to naturally 
occurring alkaloids, were most used for enantioselective acyl transfer. In 2004 our group designed 
and introduced an alternative class of chiral acyl transfer catalysts that we called amidine-based 
catalysts (ABCs) (see Figure 2.5, section 2.4 where they were first introduced). With this new class 
of catalysts, our goal was to i) make these catalysts from cheap and commercially available starting 
materials, ii) synthesize them with a minimal number of steps, and iii) allow for easy incorporation 
of a chiral center adjacent to the Lewis basic nitrogen without destroying its catalytic activity.5 
Continually inspired by the broad synthetic uses of ABCs by our group and others, we became 
interested in yet another unexplored application: their ability to activate thioesters via nucleophilic 





Figure 4.3. Chiral acyl transfer catalysts developed by other groups.  
4.2 Introduction to thioesters as acyl donors 
 The most conventional acyl donors (Figure 4.4) such as acid chlorides, mixed and 
symmetrical acid anhydrides, and highly activated esters are all easily activated by Lewis base 
catalysts. However, less reactive acyl donors such as thioesters had remained underexplored in this 
context of acyl transfer catalysis until recently.  
Despite their relatively low reactivity thioesters offer some distinct advantageous as acyl 
donors. As shown in Figure 4.4, acyl donors generate stoichiometric amounts of byproduct, the 





Figure 4.4: Conventional acyl donors and thioesters. The acyl group is highlighted in red and 
the leaving group (nucleofuge) is highlighted in blue.  
additive to quench the byproduct over the course of the reaction. Thioesters are unique in that the 
displaced nucleofuge, the thiolate anion, is an inherently soft and highly nucleophilic species. If 
the structure of the acyl donor allows it, the resulting thiolate anion can essentially be repurposed 
in the next step of the catalytic cycle as a nucleophile, allowing the sulfur-containing leaving 
group to be incorporated into the final product. This obviates the need for additional 
stoichiometric reagents and allows the acyl donor to rearrange into a new product, possibly 
without generating additional byproducts. Furthermore, this rearrangement mode allows for an 
unconventional approach to C1 ammonium zwitterionic enolates, key intermediates in many 
pathways involving catalytic acyl transfer (Figure 4.5). This can exclude the need for up to two 
procedural steps, activation of a carboxylic acid and an externally introduced nucleophile (NuH), 
translating to greater operational simplicity.  
Figure 4.5: Thioesters: An alternative approach to C1 ammonium zwitterionic enolates. 
117 
 
 Interestingly, prior to our involvement, few examples of an acyl donor amenable to this 
rearrangement mode were reported in the literature. An example by the Lupton group in 2009 
demonstrated that enol ester 4.37 reacted with NHC catalyst 4.38. The displaced enolate reacted 
via a Michael addition to generate zwitterionic ammonium enolate 4.40. Tautomerization and 
lactonization led to the final product 4.42. (Figure 4.6).6 
 
Figure 4.6: Organocatalyzed rearrangement of an enol ester. 
Another example of an asymmetric organocatalyzed rearrangement was disclosed in 2014 
by Matsubara.7 γ-hydroxy-α,β-unsaturated thioesters 4.43 were subjected to rearrangement into β-
mercaptolactones 4.45 using Takemoto’s catalyst 4.44 (see Chapter 3.3); however, further studies 




Figure 4.7. Organocatalyzed rearrangement of ω-hydroxy-α,β-unsaturated thioesters. 
4.3 Our previous work on rearrangements of thioesters 
Despite the scarcity of literature precedent our group aimed to verify the use of thioesters 
as acyl donors operating in a rearrangement mode.  
4.3.1 Asymmetric synthesis of thiochromenes 
 With this newly conceived idea in hand, our group set out to explore the catalytic 
rearrangement of α,β-unsaturated thioester 4.46a (Figure 4.8, R = H, R1 = Ph, X=CH).  
 




The key to this test substrate is the pi-electrophilic aldehyde moiety that is tethered in the 
molecule. In addition to activating the thioacyl moiety, this serves as a trap for the zwitterionic 
ammonium enolate intermediate. A member of our group, Dr. Nick Ahlemeyer, discovered that 
not only does this reaction work in the envisioned rearrangement mode, but that the process can 
be rendered enantioselective with chiral acyl transfer catalyst (R)-HBTM-28 4.47.9  
4.3.2 Asymmetric synthesis of thiochromanes 
 After revealing this proof of concept, our group quickly began exploring an analogous 
[4+2] cycloaddition10 utilizing enone-containing S-aryl thioesters 4.53 (Figure 4.9). The 
mechanism is conceptually analogous to the thiochromene synthesis, with the main difference 
being an intramolecular Michael addition replacing the intramolecular aldehyde addition.  
 
Figure 4.9: Organocatalyzed enantioselective rearrangement of S-aryl thioesters into tricyclic 
ene-lactones using H-PIP. 
While this reaction did work with catalyst DHPB11 4.56a, the reaction was very sluggish, 
reaching about 35% conversion after 5 days. This was in stark contrast to DHPB’s activity with 
ortho-formylthioester 4.46a, where clean conversion to the thiochromene was observed after 15 
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hours. Unfortunately, the reaction did not occur even after one week with chiral derivative 
HBTM-2, which worked optimally in the enantioselective thiochromene synthesis. 
 It was hypothesized that more Lewis basic catalysts would overcome the issue of lower 
reactivity of this structure of thioesters. As a result, a computational study was performed to 
calculate the isodesmic acyl transfer enthalpy between N-acetyl DHPB cation 4.56a-Ac and 
various other achiral amidine-based catalysts (Figure 4.10, see reference 10 for more specific 
details). With the acylation enthalpy of DHPB being set to zero, a negative acylation enthalpy 
implies that the catalyst is more Lewis basic than DHPB. 
The results of this study suggested that all catalysts for which the calculation was 
conducted would display higher Lewis basicity than DHPB. This correlated well with reality, with 
DHIP12 4.59a, for example, giving 430 times increase in reaction rate compared to DHPB (relative 
rate) for the tandem reaction outlined in Figure 4.9. Consequently, the chiral derivative of DHIP, 
H-PIP12 4.54, was chosen for the substrate scope (Figure 4.9). It should also be noted that during 
studies by our group, Xu et al. disclosed the same transformation enabled by a chiral NHC 
catalyst.13   
The results of this study were vital. The data suggested that more Lewis basic acyl transfer 
catalysts were necessary for reacting with these less reactive acyl donors and that the standard “go-
to” acyl transfer catalysts like DMAP are insufficient in this context. While intuition will naturally 
lead to this conclusion, simple computational results correlated well with experimental reality. In 
fact, all catalysts listed in Figure 4.10 catalyzed the tandem transformation faster than DHPB. Of 
all catalysts listed in Figure 4.10, the modification of one core structure remained uninvestigated: 
the DHIP structure. Considering that DHIP gave one of the largest accelerations of the tandem 




Figure 4.10. Relative acylation enthalpies and relative rates of various achiral ABCs.  
lead to even larger relative rates. Furthermore, these highly nucleophilic catalysts were expected 





4.4 Synthesis and exploration of 5-aryl-DHIP derivatives 
Computational results from the isodesmic acyl transfer equation revealed that DHIP with 
electron-donating substituents, particularly aryl groups, at the 5-position display even more 
negative acylation enthalpies (see 4.59b and 4.59c in Figure 4.13). Simple resonance 
considerations would place greater negative charge on the reacting nitrogen (Figure 4.11). While 
7-substitution would also increase electron density on the nitrogen, the 5-substituted derivatives 
are arguably easier to prepare. Additionally, our calculations predicted little difference in how 5- 
and 7-substitution would affect the reactivity of the catalyst. Placing an electron donating group 
such as methoxy or dialkylamino on the DHIP core is also expected to increase its Lewis basicity; 
however, these compounds were predicted to be unstable during catalyst preparation.    
 
Figure 4.11. 5- and 7-substituted DHIP derivatives. 
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An optimized synthetic sequence to catalysts 4.59b and 4.59c was devised (Figure 4.12a). 
Heating 2,6-dibromopyridine with ethanolamine gives monosubstituted aminoalcohol 4.62 cleanly 
and in high yield. Then, a Suzuki coupling installs the aromatic ring, tailoring the electron donating 
properties through the choice of boronic acid. This order of reactions turned out to be the most 
effective. If the Suzuki reaction is conducted on 2,6-dibromopyridine, then a hard-to-separate 
mixture of unreacted starting material, 2-arylated, and 2,6-diarylated compounds is obtained. 
Conversion of the hydroxyl group in 4.64 into the chloride and subsequent cyclization delivers the 
hydrochloride salts 4.65 which can be stored long term. To obtain the active catalysts, the salt is 
treated with aq. NaOH and the free bases 4.59b and 4.59c are extracted into dichloromethane. 
Chiral PIP analogues (5-substituted H-PIPs) can be synthesized in the exact same manner, with 
(R)-2-phenylglycinol 4.66 replacing ethanolamine in the first step (Figure 4.12b).  
These two achiral catalysts, 4.59b and 4.59c, were tested in the rearrangement of thioester 
4.53a (Figure 4.13). As a result of these two derivatives catalyzing the reaction very rapidly, there 
was too much error associated with the calculation of the relative rate. However, the time at which 
the reaction reached 50% completion (t1/2) was reliably and reproducibly calculated (see Appendix 
A.1 for specifics). 
Clearly, the Ph derivative 4.59b outperforms DHIP itself. As expected, the p-MeOPh 
derivative 4.59c is yet more reactive than 4.59b, as indicated by the slightly lower value of t1/2. 
The efficacy of the designed synthetic route allows for a quick and facile approach to many 
arylated DHIP derivatives whose electronics (reactivity) may be tailored for a specific application.  
These two achiral catalysts, in addition to one chiral analogue 4.69, are the most Lewis basic ABCs 
reported to date and were quickly explored in other rearrangements of even less reactive thioesters 




Figure 4.12. Synthesis of achiral 5-aryl-DHIP and chiral 5-aryl-PIP derivatives.  
 
Figure 4.13. Testing 5-aryl DHIP derivatives.  
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4.5 Organocatalyzed rearrangement of S-(2-oxoalkyl)-
thioenoates 
4.5.1 Mechanistically different rearrangement 
With more electron rich ABCs on hand, our group set out to explore the rearrangement of 
an even less reactive class of acyl donor, an S-alkyl thioester. It was envisaged that S-alkyl 
thioesters may rearrange in a manner similar to the two previous S-aryl thioester cases that our 
group reported (cf. Figures 4.8 and 4.9). The test substrate, S-phenacyl thiocinnamate 4.73a, was 
easily prepared via alkylation of crude thiocinnamic acid 4.71 (Figure 4.16a).  
 
Figure 4.14: a) Synthesis of S-phenacyl thiocinnamate, b) The expected catalyzed 
rearrangement pathway, c) The experimentally observed rearrangement pathway. 
Analogously to the S-aryl thioester cases, 4.73a was expected to react to form zwitterionic 
enolate 4.74. Cyclization onto the aryl ketone followed by displacement of the catalyst will give 
beta-lactone fused tetrahydrothiophene 4.76. This may or may not lose carbon dioxide to give 4.77 
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(Figure 4.14b). However, when this test substrate was mixed with 20 mol% of DHIP 4.59a, the 
formation of neither 4.76 nor 4.79 were observed by 1H NMR. While surprising at first, a clean 
singlet at around 14 ppm in the 1H NMR spectra, characteristic of a chelated proton, confirmed 
that an unexpected, yet easily identifiable product formed (Figure 4.14c). Instead of cyclizing onto 
the aryl ketone carbonyl, zwitterionic enolate 4.74 undergoes a proton transfer. The resulting 
enolate reacts with the acyl ammonium moiety to deliver a 1,3-diketone which exists exclusively 
as its enol tautomer 4.79a. Although unexpected at first glance, this Dieckmann-like cyclization is 
well reported in the literature.14  
4.5.2 Optimization of solvent and achiral catalyst 
 After the initial discovery that DHIP catalyzes this rearrangement, we sought to optimize 
this new process by first exploring achiral catalysts (Figure 4.15) and solvent (Table 4.1).  
 
Figure 4.15: Achiral catalysts used in this study. 
 We fist confirmed that stoichiometric triethylamine does not promote the reaction in the 
absence of a Lewis basic catalyst (compare Table 4.1, entry 1 vs entry 2). Catalysts 4.59b1a and 
4.57c10 displayed comparable reactivity to DHIP (entries 3 and 4). DHPB 4.56a, though active 
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enough to react with S-aryl thioesters 4.46a and 4.53a (see Figures 4.8 and 4.9), failed to react 
with an S-alkyl thioester (entry 5). N-heterocyclic carbene precursor 4.80 did catalyze the 
rearrangement, but required extended heating (entry 6). DMAP 4.18 was completely ineffective, 
even with heating (entry 7). With DHIP clearly being the optimal catalyst, a brief solvent survey 
was conducted. Both toluene and THF gave lower isolated yields of the product (entries 8 and 9). 
While the reaction is slower with triethylamine absent or with a lower catalyst loading, comparable 
yields are eventually obtained in both cases with prolonged reaction time (entries 10 and 11). 
Finally, heating the reaction increases the reaction rate but does not deliver a higher yield (entry 
12).  
Table 4.1: Optimization of achiral catalyst and solvent.a 
 
entry Catalyst (mol %) solvent Time (h) Yield (%) 
1 4.59a (20) CDCl3 12.5 75 
2 none CDCl3 48 0 
3 4.59b (20) CDCl3 12 75 
4 4.57c (20) CDCl3 12.5 75 
5 4.56a (20) CDCl3 47 0 
6b 4.80 (20) CDCl3 120 46 
7b 4.18 (20) CDCl3 48 0 
8 4.59a (20) PhMe 24 43 
9 4.59a (20) THF 24 54 
10c 4.59a (20) CDCl3 25 75 
11 4.59a (10) CDCl3 25 71 
12b 4.59a (20) CDCl3 4 68 
a General conditions: 0.1 mmol of 4.73a, 0.1 mmol of NEt3, 0.02 mmol of catalyst, 0.5 mL of 
CDCl3. 





4.5.3 Initial attempts at an enantioselective variant 
We next briefly examined an enantioselective variant of this reaction. H-PIP 4.54 gave the product 
in 54% ee. Unfortunately, other chiral catalysts such as 4.691a and 4.8115 yielded lower or 
comparable levels of enantioenrichement (Figure 4.16).  
 
Figure 4.16. Attempts at an enantioselective variant.  
 While initially surprising there is a good explanation for this low enantioselectivity (Figure 
4.18, vide infra in Section 4.5.6). 
4.5.4 Racemic substrate scope 
 After fruitless efforts to render this reaction enantioselective, it was decided that we would 
analyze the substrate scope as a racemic synthesis using DHIP 4.59a (Table 4.2). All thioester 






Table 4.2: Racemic substrate scope.a 
 
entry R1 R2 R3 R4 Yield (%) 
1 Ph H H Bz 75b 
2 4-MeOC6H4 H H Bz 77 
3 4-CF3C6H4 H H Bz 63 
4 2-MeC6H4 H H Bz 82 
5 2-thienyl H H Bz 56 
6c Me Me H Bz 65 
7c Ph H Me Bz NRd 
8 Ph H H 4-MeOBz 81 
9 Ph H H 4-ClBz 69 
10 Ph H H 4-NO2Bz 53 
11 Ph H H 2-furoyl 71 
12 Ph H H Ac 41 
13c Ph H H CO2Et NR
d 
14 Ph H H CN 0e 
aGeneral conditions: 0.1 mmol of 4.73, 0.1 mmol of NEt3, 0.02 mmol of 4.59a, 0.5 mL of CDCl3, 
rt, 16−24 h. b 60% yield was obtained on a 2.5 mmol scale. c The mixture was heated at 50 °C. d 
No reaction was observed. e A complex mixture formed. 
Aryl substituents with electron-donating and -withdrawing groups, as well as a heteroaryl, 
were well tolerated at position R1 (entries 2-5). While two methyl groups at the β-position also 
worked, heating was required (entry 6). Unfortunately, the introduction of a methyl group at the 
α-position R3 rendered the thioester unreactive to rearrangement (entry 7). A variety of aryls and 
a furoyl group were also tolerated at R4 (entries 8-11). In contrast to aryl ketones, the methyl ketone 
rearranged, but gave additional side reactions that resulted in a lower isolated yield (entry 12). 
When the ketone was replaced with an ester moiety the rearrangement did not occur, not even with 
prolonged heating (entry 13). The cyanomethyl thioester did react, but it did not produce the 
desired product (entry 14).   
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4.5.5 Alternative two-component approach to the same products 
 Early in this project it was discovered that some thioester substrates 4.73 were difficult to 
prepare following the method outlined in Figure 4.14a. In some cases, contamination due to an 
undesired side product resulting from a thio-Michael of the thiocinnamic acid onto the thioester 
was observed. To overcome this obstacle an alternative two-component approach was designed 
that would prevent this problematic side reaction (Figure 4.17).16  
 
Figure 4.17: Alternative two-component approach the dihydrothiophenes 4.79. 
 Instead of starting from the thioester, easy to synthesize trichlorophenyl esters 4.82 were 
used in conjunction with phenacyl mercaptan 4.83.17 Not only did this method produce comparable 
yields (e.g. compare Table 4.1 entry 1 to Figure 4.17), but the substrate scope was increased to 
include cyclohexyl, 1-naphthyl, and 3-pyridyl substituents at position R1.  
4.5.6 Origins of low enantioselectivity 
 One explanation for the low enantioselectivity of this rearrangement can be explained by 
the mechanism given in Figure 4.18. It was discovered that when S-phenacyl thiocinnamate 4.73a 
is reacted with phenacyl mercaptan in the presence of triethylamine, the expected product can be 
obtained in 57% yield. Because phenacyl mercaptan is regenerated in the last step, only a catalytic 
amount is necessary for this racemic background reaction to occur, diverting the reaction from the 
asymmetric pathway. Interestingly, when 2,4,6-trichlorophenyl cinnamate 4.82a is used in lieu of 
thioester 4.73a, only 4% of 4.79a is isolated. In this case, the formation of 2,4,6-trichlorophenol 
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and thioester starting material explains what is happening. Evidently the trichlorophenyl ester is 
much less reactive as a thio-Michael acceptor and undergoes acyl substitution instead. The one 
equivalent of thiolate is quickly consumed and cannot be used in the pathway leading to the 
dihydrothiophene product. The alternative two component approach outlined in Figure 4.19 still 
delivers the dihydrothiophene products since DHIP is capable of reacting with the thioester that 
forms, regenerating the thiolate anion. As expected, low enantioselectivities were also observed 
when catalysts 4.54, 4.69, and 4.81 were employed in this two-component method using the 
trichlorophenyl ester in lieu of thioester.   
 
Figure 4.18: Origins of low enantioselectivity. 
  Though only becoming an issue with this class of thioester substrates, this alternative mode 
of catalysis, a chain reaction initiated by a free thiolate, was discovered by Dr. Nick Ahlemeyer 




Figure 4.19: Alternative mode of catalysis used to make racemic thiochromenes. 
 It was observed that when thioester 4.46a was reacted with 2-mercaptobenzaldehyde 4.86 
in the presence of triethylamine, the racemic thiochromene was isolated in 45% yield. Interestingly 
this racemic background reaction is a negligible pathway when a chiral catalyst is introduced and 
allowed an asymmetric version of this reaction to be developed. However, in the case of the S-
alkyl thioesters, the more reactive S-alkyl thiolate leaving group is probably nucleophilic and 
abundant enough to slowly react with the thioester, leading to a racemic background reaction, in 
addition to the more reactive α,β-unsaturated acyl ammonium cation 4.88 formed in the first step 
of the catalytic pathway (see Figure 4.20).  
 
Figure 4.20. S-aliphatic thiolate capable of reacting with thioester in addition to ammonium 
cation: one possible explanation for the origin of low enantioselectivity. 
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4.6 Additional organocatalyzed rearrangements of S-aryl 
thioesters 
 When our group first explored this area of thioester rearrangements there were two notable 
variations of the S-aryl thioester core that proved troublesome with DHPB (Figure 4.21).  
 
Figure 4.21. Troublesome substrates in the thoichromene synthesis. 
 When the aldehyde moiety is replaced with a methyl ketone, like in 4.89, the less 
electrophilic moiety drastically slowed down the reaction. Additionally, the fluorinated thioester 
4.91 was also less reactive to rearrangement. After publishing our results concerning the 
rearrangements of S-alkyl thioesters1a, we sought to re-explore these tricky substrates with a 
greater understanding of the importance of Lewis basicity of the catalyst.   
4.6.1 Asymmetric synthesis of a 4-substituted thiochromene 
 Knowing that DHIP and its chiral analogue H-PIP proved superior in the synthesis of 
thiochromanes and dihydrothiophenes we attempted to use these catalysts to induce the 
rearrangement of methyl ketone-containing thioester 4.89. It was hypothesized that the enhanced 
Lewis basicity of these catalysts would bode well in the case with the less electrophilic ketone 
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moiety. As predicted, 5-anisyl-PIP 4.69, which delivered low enantioinduction in the 
rearrangement of S-phenacyl thiocinnamate (see Figure 4.16), gave the thiochromene in 79% yield 
and 96% ee after 18 hours (Figure 4.22). 
 
Figure 4.22: Synthesis of a 4-substituted thiochromene.  
4.6.2 Asymmetric synthesis of a 3-fluoro thiochromene 
 With these more Lewis basic ABCs on hand we reinvestigated the rearrangement of  
thioester 4.91 (Table 4.3). As aforementioned DHPB 4.56a (Figure 4.21) gave 4.92 in 28% yield 
after 3 days (entry 1). Its chiral analogue HBTM-2.118 4.96 gave both low yield and negligible 
enantioselectivity (entry 2). This is a very surprising result considering how well this catalyst 
performed with analogous non-fluorinated compounds.9 H-PIP catalyzes the rearrangement well, 
but gives low enantioselectivities (entry 3). Bicyclic isothiourea 4.8115 performed better than H-
PIP, giving higher yield and enantioselectivity (entry 4). With these results in hand, we predicted 
that a possible reason for low enantioinduction in certain cases arose from a reversible Step 2. 
Because enolate intermediate 4.94 is stabilized by the fluorine, Step 3 may be considerably slower 
than for the non-fluorinated analogue. Additionally, fluorine’s slightly larger size than hydrogen 
may also help to impede this intramolecular cyclization. That being said experimental evidence 




Table 4.3: Synthesis of a 3-fluorothiochromene.a 
 
Entry catalyst time % yield % ee 
1 4.56a 3 days 28 N/A 
2 4.96 8 days 25 4 
3 4.54 46 h 50 54 
4 4.81 18 h 75 88 
5 4.97 8 days 54 94 
6b 4.57c 14 h 56 N/A 
aConditions: 0.1 mmol of 4.91, 0.01 mmol of catalyst, 0.5 mL of CDCl3, rt. 










conversions and enantioselectivities than catalysts with fused 5,6-bicyclic cores (e.g. DHIP and 
H-PIP). Keeping that possible geometrical constraint in mind we next tested (R)-BTM19 4.97 (entry 
5). As expected from its inherently lower Lewis basicity the reaction was much slower than with 
catalyst 4.81, but BTM provided the highest levels of enantioselectivity observed up to this point. 
Finally, using achiral isothiourea 4.57c10, we were able to monitor the reaction’s progress by 1H 
NMR and observe the formation and disappearance of the putative fluorinated β-lactone 4.95 
(Figure 4.24). 
 
Figure 4.24: 1H NMR spectra showing formation and disappearance of 4.95.  
 
Interestingly, this same observation cannot be made for the non-fluorinated analogue. It is 
quite possible that the rate of decarboxylation is greatly decreased because of the electron-
withdrawing effects of fluorine destabilizing the benzylic cation that forms (Figure 4.25). This 
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energetic hurdle may explain why a true β-lactone fused thiochromane intermediate is discerned 
in this specific case.  
 
Figure 4.25. Decarboxylation of fluorinated β-lactone intermediate. 
 
4.6.3 Synthesis of fused indanes 
As described in chapters 4.3.1, 4.3.2, and 4.6.1, the precursor thioesters contained the 
terminal electrophile (aldehyde, ketone, or enone) tethered to the thioester moiety through the 
sulfur atom. This guaranteed that the sulfur atom would be incorporated inside of the ring of the 
product heterocycle. However, there is one structural variation of thioesters that our group wanted 
to explore, one in which the thiolate anion would end up outside of the rearranged carbocyclic 
skeleton as a thioether moiety. To investigate this possibility, we constructed thioester substrates 
4.99a and 4.99b, which were expected to give the tricyclic indane-fused dihydropyranones 4.100a  
and 4.100b (Table 4.4).  
Both thioesters underwent rearrangement with DHPB 4.56a at room temperature (Table 
4.4, entries 1-2). Moderate yields of a single diastereomer were obtained. This relative 
stereochemistry was assigned in analogy to the thiochromane syntheses (see Figure 4.9). 
 To test the enantioselective version, chiral catalysts (R)-BTM 4.97 and (R)-HBTM-2.1 
4.96 were used, but required prolonged heating for a week before all of the starting material was 




Table 4.4. Synthesis of fused indanes 4.100a and 4.100b.a 
 
entry catalyst R Temp (°C) Time (h) % yield % ee 
1 4.56a Me 23 48 50 NA 
2 4.56a Ph 23 21 51 NA 
3 4.97 Me 60 168 35 67 (R) 
4 4.97 Ph 60 168 32 16 (S) 
5 4.96 Me 60 168 29 23 (S) 
6 4.96 Ph 60 168 41 69 (R) 
7 4.54 Me 0 72 45 88 (R) 
8 4.54 Ph 0 72 30 35 (R) 
a Conditions: 0.1 mmol of thioester, 0.01 mmol of catalyst, 0.5 mL of CDCl3. 
more Lewis basic catalyst, promoted the rearrangement even at 0 °C (entries 7-8). The ee for the 
methyl enone substrate 4.99a was good, but lower ee was obtained with the phenyl enone 4.99b. 
All these enantioselectivities are poor in comparison to those obtained in our previous works with 
analogous thiochromene and thiochromane syntheses.9,10 Furthermore, X-ray analysis of the two 
products (see Figures 4.27 and 4.28) indicated that, in some cases (for clarity, these cases are 
highlighted in red in Table 4.4), the absolute stereochemistry of the products was opposite from 
what we expected based on the facial selectivity of the sulfa-Michael addition step in our previous 
publications. To further exacerbate this issue, the two substrates responded differently to all three 
chiral catalysts utilized.  
The results with 4.99a are consistent with the opposite absolute configuration of (R)-
HBTM-2.1 vs. (R)-BTM and (R)-H-PIP (entries 3 and 7 give the opposite enantiomer of entry 5); 
though only thioester 4.99b reacts with the expected sulfa-Michael controlled enantioselectivity 
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with catalysts (R)-BTM and (R)-HBTM-2.1 (entries 4 and 6). However, with 4.99b, the opposite 
expected absolute stereochemistry is obtained with (R)-H-PIP (entry 8). To explain this drastic 
inversion of enantioselectivity, we hypothesized that conjugate addition within ion pairs 4.101a 
and 4.101b occurs reversibly (Figure 4.26).  
 
Figure 4.26. Proposed explanation for inversion of enantioselectivity. 
 
Although the sulfa-Michael addition step favors diastereomers 4.102a and b, on account 
that the thiolate adds to the face of the cation unblocked by the phenyl group of the catalyst, the 
subsequent intramolecular Michael addition is hampered by the mismatch between the substrate 
control (the phenylthio group hinders the approach of the enone moiety to the β-face of the enolate) 
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and the catalyst control (the phenyl group of the catalyst blocks the α-face) (cf. 4.103a and b). On 
the other hand, the same factors are matched in the kinetically disfavored diastereomer 4.104a and 
b (cf. 4.105a and b: the α-face remains open). The high level of enantioenrichment of 4.100a in 
entry 7 suggests that asymmetric induction in this case is completely controlled by the second step 
(i.e., the Curtin-Hammett scenario). By contrast, the low ee in entry 8 reflects the residual influence 
of the sulfa-Michael step, which is consistent with the higher electrophilicity of the phenylenone 
moiety in 4.103b relative to the methylenone in 4.103a. Comparison of the ee values obtained with 
three chiral catalysts and both substrates reveals another interesting trend: H-PIP 4.54 leads to the 
highest proportion of the Curtin-Hammett-favored enantiomer, HBTM-2.1 4.96 favors the 
opposite outcome, while BTM 4.97 falls somewhere in between. In summary, while Curtin-
Hammett operates in all cases, it does so to different degrees. With the methyl enone 4.99a, this 
predominates with all catalysts; however, with the phenyl enone 4.99b, the ee is either eroded or 
reversed as a result of the Curtin-Hammett scenario. It should be noted that structurally similar 
substrates have been subjected to tandem double Michael additions of enolate nucleophiles. 
However, in the reported cases, the absolute stereochemistry of the products was set during the 
irreversible intermolecular Michael addition step and was not affected by the mismatch in the 





Figure 4.27. X-ray crystal structure of 4.100b. This crystal structure was obtained from Table 
4.4, entry 6. 
 
 
Figure 4.28. X-ray crystal structure of 4.100a, analyzed as the ring-opened benzyl amide 
(4.100a-BnNH2). This crystal structure was obtained from Table 4.4, entry 7.  
 
4.7 Conclusions and future directions 
 In conclusion, we have developed a new racemic synthesis of highly substituted 
dihydrothiophene derivatives via an organocatalyzed rearrangement of S-phenyl thiocinnamate 
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and its derivatives. In addition to starting from a thioester, an alternative two-component approach 
was devised to overcome limitations in the synthesis of certain thioesters. Even though an 
enantioselective version of this process could not be developed, the importance of synthesizing 
more Lewis basic chiral ABCs in the context of this project cannot be understated. For example, 
thanks to our efforts in catalyst development, a newly designed chiral PIP derivative proved to be 
the best catalyst of choice in catalyzing the rearrangement of methyl ketone 4.89 into a 4-
substituted thiochromene, the first of its kind using our methodology. Though not being currently 
investigated by our group, these chiral PIP derivatives with enhanced Lewis basicity may have 
broad application elsewhere in the field of asymmetric catalysis.  
 Equally important was the discovery that BTM could catalyze the rearrangement of 
fluorine-containing thioester 4.91 into 3-fluorothiochromene 4.92. Not only did this show the first 
synthesis of a 2,3-disubstituted thiochromene using our methodology, but this one example also 
expanded upon the use of fluoroenolates in asymmetric catalysis.  
 Since 2015 our group greatly increased the utility of thioesters in asymmetric catalysis, 
namely through their rearrangements into useful sulfur-containing heterocycles. However, it is still 
possible to find additional uses for thioesters as acyl donors that have remained unexplored in the 
literature. One example is given in Figure 4.29. 
 An aldehyde and activated olefin like an α-substituted nitroethylene are not expected to 
react on their own, but the addition of a phosphine or amine catalyst like DABCO will allow the 
Morita-Baylis-Hillman (MBH) reaction to occur. Surprisingly, employing a thiolate as a 
nucleophile has never been explored. Using a more nucleophilic thiolate may drastically cut down 
on long reaction times, an infamous characteristic of the MBH reaction. Furthermore, the more 
reactive thiolate may allow for the use of β-substituted activated olefins, which are hardly ever 
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used in MBH reactions. Products 4.109 may be obtained with high diastereoselectivity; however, 
an enantioselective process may prove difficult.  
 
Figure 4.29: Possible additional application for thioesters as acyl donors. 
 
4.8 Experimental  
All reagents were obtained commercially and used as received unless specified otherwise. 
Catalysts 4.54, 4.56a, 4.57c, 4.59a-c, 4.69, 4.81, 4.96, and 4.97 were prepared as previously 
described.1a,10,11,12,15,18,19 Reactions that required heating were carried out in an electrically heated 
mineral oil bath. Dichloromethane and deuterated chloroform used as reaction media were freshly 
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distilled from calcium hydride. Triethylamine was freshly distilled from potassium hydroxide. 
Solvents used for chromatography were ACS or HPLC grade. Sorbent Technologies XHL silica 
gel plates (glass-backed, 250 μm) were used for TLC analyses. Flash column chromatography was 
performed over Sorbent Technologies silica gel (40−63 μm). HPLC analyses were performed on 
a Shimadzu LC system using a Chiralcel OD-H or Chiralpak AD-H analytical chiral stationary 
phase columns (4.6 × 250 mm, Chiral Technologies, Inc.) with a UV detector at 254 or 204 nm 
with a flow rate of 0.7 mL/min (4.79a) or 1.0 mL/min (4.90, 4.92, and 4.100a,b). 1H and 13C NMR 
spectra were recorded on Mercury 300 MHz and DD2 500 MHz Agilent spectrometers. The 
chemical shifts are reported as δ values (ppm) relative to TMS using a residual CHCl3 peak (7.26 
ppm for 1H NMR, 77.16 ppm for 13C NMR) or (CH3)2CO (29.84 ppm for 
13C NMR) peaks as the 
reference. Melting points were measured on a Stuart SMP10 melting point apparatus. High-
resolution mass spectral analyses were performed at Washington University MS Center on a 
Bruker MaXis QTOF mass spectrometer using electrospray ionization (ESI). Infrared spectra were 
recorded on a Bruker Alpha Platinum-ATR. Optical rotations were measured on a Rudolph 
Autopol III polarimeter. 
 









General procedure for the synthesis of thioesters 4.73. 
Thiocinnamic acid 4.71 
A solution of cinnamoyl chloride 4.70 (1.00 g, 6.00 mmol) in 10 mL of THF was added to a rapidly 
stirring solution of Na2S (2.00 g, 25.6 mmol, 4.27 equiv) in 5 mL of H2O. After 30 min, the organic 
phase was separated and the aqueous phase extracted with THF (3 × 5 mL). The resulting bright-
orange solution of sodium thiocinnamate in THF was diluted with 50 mL of H2O, acidified with 
20 mL of 1 M HCl, and extracted with EtOAc (3 × 10 mL). The organic extract was dried over 
MgSO4 and rotary evaporated to give crude thiocinnamic acid 4.71, which was used immediately 
without further purification. 
S-phenacyl thiocinnamate 4.73a 
A stirring solution of the crude thiocinnamic acid 4.71 and 2-bromoacetophenone 4.72 (1.20 g, 
6.03 mmol) in 20 mL of freshly distilled CH2Cl2 was treated with NEt3 (1.00 mL, 0.726 g, 7.19 
mmol) dropwise at 0 °C. After completion, the mixture was stirred at 0 °C for an additional 10 min 
and at rt for 50 min, then washed with 1 M HCl (×2) and saturated aqueous NaHCO3 (×2), then 
dried over MgSO4. After rotary evaporation and flash chromatography (hexanes/CH2Cl2 2:1 → 
1:1), 1.05 g of thioester 4.73a was obtained as a white crystalline powder (62% yield). Unless 
indicated otherwise, all thioester substrates listed below were obtained analogously from the 
corresponding acids21 and bromoketones22 and purified by chromatography under conditions 
indicated below. Note that, due to their limited solubility in hexane/ ethyl acetate mixtures, 







S-(2-oxo-2-phenylethyl) (E)-3-phenylprop-2-enethioate (4.73a). 
1H NMR (500 MHz, CDCl3): δ 8.04 (d, J = 8 Hz, 2H), 7.67 (d, J 
= 16 Hz, 1H), 7.63−7.58 (m, 1H), 7.57−7.52 (m, 2H), 7.52−7.47 
(m, 2H), 7.42−7.36 (m, 3H), 6.77 (d, J = 16 Hz, 1H), 4.54 (s, 2H). 
13C{1H} NMR (125 MHz, CDCl3): δ 193.5, 188.2, 141.9, 135.7, 134.0, 133.8, 130.9, 129.1, 
128.9, 128.7, 128.6, 124.2, 36.5. IR (cm−1): 1695, 1656, 1612, 1197, 1038. HRMS (ESI-TOF) 
m/z: [M + Na]+ calcd for C17H14O2S, 305.0607; found, 305.0614. Mp: 117−119 °C.   
S-(2-oxo-2-phenylethyl) (E)-3-(4-methoxyphenyl)prop-2-enethioate (4.73b). 
Isolated as a fine light tan powder (137 mg, 42% yield) 
after chromatography (5 → 15% EtOAc/hexane). 1H NMR 
(500 MHz, CDCl3): δ 8.04 (d, J = 9 Hz, 2H), 7.64 (d, J = 16 
Hz, 1H), 7.61−7.58 (m, 1H), 7.52−7.47 (m, 4H), 6.91 (d, J = 9 Hz, 2H), 6.65 (d, J = 16 Hz, 1H), 
4.52 (s, 2H), 3.85 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 193.7, 188.1, 162.0, 141.7, 
135.8, 133.8, 130.4, 128.9, 128.7, 126.7, 121.9, 114.6, 55.5, 36.4. IR (cm−1): 1697, 1658, 1597, 
1508, 1243, 1037, 995, 809. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C18H16O3S, 335.0712; 
found, 335.0710. Mp: 118−122 °C. 
S-(2-oxo-2-phenylethyl) (E)-3-(4-(trifluoromethyl)phenyl)prop-2-enethioate (4.73c). 
Isolated as a faint yellow powder (379 mg, 58% yield) after 
chromatography (5 → 15% EtOAc/ hexane). 1H NMR (500 
MHz, CDCl3): δ 8.04 (d, J = 7 Hz, 2H), 7.69−7.59 (m, 6H), 7.53−7.48 (m, 2H), 6.83 (d, J = 16 
Hz, 1H), 4.56 (s, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 193.2, 188.1, 139.8, 137.4, 135.7, 
133.9, 132.3 (q, 2JC−F = 33 Hz), 129.0, 128.7, 128.7, 126.5, 126.1 (q, 




= 271 Hz), 36.8. IR (cm−1): 1693, 1661, 1619, 1322, 826, 745, 686. HRMS (ESI-TOF) m/z: [M + 
Na]+ calcd for C18H13F3O2S, 373.0480; found, 373.0483. Mp: 156−159 °C.   
S-(2-oxo-2-phenylethyl) (E)-3-(o-tolyl)prop-2-enethioate (4.73d). 
Isolated as a light tan powder (102 mg, 49% yield) after 
chromatography (2 → 5% EtOAc/ hexanes). 1H NMR (500 MHz, 
CDCl3): δ 8.07−8.03 (m, 2H), 7.97 (d, J = 16 Hz, 1H), 7.64−7.55 
(m, 2H), 7.53−7.48 (m, 2H), 7.32− 7.28 (m, 1H), 7.25−7.19 (m, 2H), 6.70 (d, J = 16 Hz, 1H), 
4.54 (s, 2H), 2.44 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 193.6, 188.4, 139.5, 138.6, 
135.8, 133.8, 132.9, 131.1, 130.7, 128.9, 128.7, 126.6, 126.6, 125.2, 36.6, 19.9. IR (cm−1): 2971, 
2912, 1692, 1656, 1202, 1038, 973. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C18H16O2S, 
297.0944; found, 297.0938. Mp: 78−80 °C. 
S-(2-oxo-2-phenylethyl) (E)-3-(thiophen-2-yl)prop-2-enethioate (4.73e). 
Isolated as a faint yellow powder (110 mg, 48% yield) after 
chromatography (2 → 10% EtOAc/ hexanes). 1H NMR (500 
MHz, CDCl3): δ 8.03 (d, J = 7 Hz, 2H), 7.78 (d, J = 16 Hz, 1H), 7.61 (t, J = 7 H, 1H), 7.50 (t, J = 
7 Hz, 2H), 7.43 (d, J = 5 Hz, 1H), 7.32 (d, J = 4 Hz, 1H), 7.07 (dd, J = 5 Hz, 4 Hz, 1H), 6.57 (d, J 
= 16 Hz, 1H), 4.53 (s, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 193.5, 187.6, 139.2, 135.7, 
134.2, 133.8, 132.4, 129.5, 128.9, 128.6, 128.5, 122.8, 36.5. IR (cm−1): 1692, 1661, 1592, 1196, 
1034, 980. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C15H12O2S2, 289.0352; found, 289.0345. 





S-(2-oxo-2-phenylethyl) 3-methylbut-2-enethioate (4.73f). 
Preparation according to the standard procedure was not successful. 
The compound was synthesized as follows: Phenacyl mercaptan  
(800 μL of 0.62 M stock in CH2Cl2, 0.50 mmol) was added at 0 °C to 3,3-dimethylacryloyl 
chloride (55 μL, 0.5 mmol) in 2.5 mL of freshly distilled CH2Cl2. Triethylamine (83 μL, 0.60 
mmol) was added dropwise. The reaction mixture was slowly warmed to rt, stirred for an 
additional 2 h, and quenched by adding 1 M aq HCl. The organic layer was separated, washed 
with 1 M aq NaHCO3, dried with Na2SO4, and concentrated by rotary evaporation. The residue 
was purified by column chromatography (3 → 7% EtOAc/hexanes) to afford the thioester as a 
clear, light yellow oil (110 mg, 94% yield). 1H NMR (500 MHz, CDCl3): δ 8.03−8.00 (m, 2H), 
7.61−7.57 (m, 1H), 7.50−7.46 (m, 2H), 6.06−6.04 (m, 1H), 4.41 (s, 2H), 2.17 (d, J = 1 Hz, 3H), 
1.90 (d, J = 1 Hz, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 193.8, 187.1, 155.5, 135.7, 133.6, 
128.8, 128.6, 122.5, 36.2, 27.3, 21.4. IR (cm−1): 2911, 1673, 1625, 1447, 1276, 1199, 1010. 
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C13H14O2S, 257.0607; found, 257.0601. 
S-(2-oxo-2-phenylethyl) (E)-2-methyl-3-phenylprop-2-enethioate (4.73g). 
Isolated as a clear, colorless oil (185 mg, 72% yield) after 
chromatography (2 → 6% EtOAc/hexane). 1H NMR (500 MHz, 
CDCl3): δ 8.07−8.03 (m, 2H), 7.73 (d, J = 1 Hz, 1H), 7.64−7.59 (m, 1H), 7.53−7.48 (m, 2H), 
7.43−7.39 (m, 4H), 7.37−7.33 (m, 1H), 4.50 (s, 2H), 2.19 (d, J = 1 Hz, 3H). 13C{1H} NMR (125 
MHz, CDCl3): δ 193.8, 192.8, 138.4, 135.9, 135.6, 135.3, 133.8, 130.0, 129.0, 128.9, 128.7, 
128.6, 36.9, 14.4. IR (cm−1): 3058, 2915, 1685, 1650, 1447, 1179, 1019, 988, 908, 747, 687. 
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C18H16O2S, 319.0763; found, 319.0758. 
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S-(2-(4-methoxyphenyl)-2-oxoethyl) (E)-3-phenylprop-2-enethioate (4.73h). 
Isolated as a fine white powder (123 mg, 57% yield) after 
chromatography (5 → 15% EtOAc/ hexanes). 1H NMR 
(500 MHz, CDCl3): δ 8.02 (d, J = 9 Hz, 2H), 7.67 (d, J = 16 
Hz, 1H), 7.57−7.51 (m, 2H), 7.43−7.36 (m, 3H), 6.96 (d, J = 9 Hz, 2H), 6.76 (d, J = 16 Hz, 1H), 
4.49 (s, 2H), 3.87 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 192.0, 188.4, 164.1, 141.7, 
134.0, 131.0, 130.9, 129.1, 128.7, 128.6, 124.3, 114.1, 55.6, 36.2. IR (cm−1): 1687, 1598, 1257, 
1033, 982, 757. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C18H16O3S, 335.0712; found, 
335.0715. Mp: 116−118 °C.  
S-(2-(4-chlorophenyl)-2-oxoethyl) (E)-3-phenylprop-2-enethioate (4.73i). 
Isolated as a fine white powder (967 mg, 57% yield) after 
chromatography (5 → 15% EtOAc/ hexane). 1H NMR (500 
MHz, CDCl3): δ 7.98 (d, J = 9 Hz, 2H), 7.67 (d, J = 16 Hz, 
1H), 7.57−7.51 (m, 2H), 7.47 (d, J = 9 Hz, 2H), 7.43− 7.36 (m, 3H), 6.76 (d, J = 16 Hz, 1H), 
4.48 (s, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 192.5, 188.1, 142.1, 140.4, 134.0, 133.9, 
131.0, 130.1, 129.2, 129.1, 128.6, 124.0, 36.3. IR (cm−1): 1693, 1655, 1614, 1039, 754. HRMS 
(ESI-TOF) m/z: [M + Na]+ calcd for C17H13ClO2S, 339.0217; found, 339.0218. Mp: 127−129 
°C.  
S-(2-(4-nitrophenyl)-2-oxoethyl) (E)-3-phenylprop-2-enethioate (4.73j). 
Isolated as a faint yellow powder (320 mg, 25% yield) after 
chromatography (5 → 20% EtOAc/ hexane). 1H NMR (500 
MHz, CDCl3): δ 8.35 (d, J = 9 Hz, 2H), 8.20 (d, J = 9 Hz, 
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2H), 7.68 (d, J = 16 Hz, 1H), 7.57−7.54 (m, 2H), 7.44− 7.38 (m, 3H), 6.76 (d, J = 16 Hz, 1H), 
4.51 (s, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 192.6, 187.8, 150.8, 142.6, 140.3, 133.8, 
131.2, 129.8, 129.2, 128.7, 124.1, 123.8, 36.4. IR (cm−1): 1698, 1675, 1514, 973, 762. HRMS 
(ESI-TOF) m/z: [M + Na]+ calcd for C17H13NO4S, 350.0457; found, 350.0450. Mp: 157−160 °C.  
S-(2-(furan-2-yl)-2-oxoethyl) (E)-3-phenylprop-2-enethioate (4.73k). 
Isolated as a yellow crystalline solid (171 mg, 66% yield) after 
chromatography (2 → 10% EtOAc/ hexanes). 1H NMR (500 
MHz, CDCl3): δ 7.68−7.63 (m, 2H), 7.55− 7.51 (m, 2H), 7.41−7.34 (m, 4H), 6.75 (d, J = 16 Hz, 
1H), 6.59− 6.55 (m, 1H), 4.36 (s, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 188.0, 182.3, 151.6, 
147.3, 142.0, 133.9, 131.0, 129.1, 128.6, 124.1, 118.7, 112.7, 35.5. IR (cm−1): 2925, 1669, 1615, 
1465, 1392, 1236, 1036. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C15H12O3S, 295.0399; 
found, 295.0397. Mp: 102−104 °C.  
S-(2-oxopropyl) (E)-3-phenylprop-2-enethioate (4.73l). 
Isolated as a light yellow oil (210 mg, 76% yield), which crystallized 
upon standing, after chromatography (2 → 6% EtOAc/hexane). 1H 
NMR (500 MHz, CDCl3): δ 7.66 (d, J = 16 Hz, 1H), 7.58−7.52 (m, 2H), 7.44−7.37 (m, 3H), 6.76 
(d, J = 16 Hz, 1H), 3.88 (s, 2H), 2.32 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 201.9, 188.1, 
141.9, 133.8, 130.9, 129.0, 128.5, 124.0, 39.4, 28.8. IR (cm−1): 2920, 1712, 1611, 1046, 772. 






ethyl 2-(cinnamoylthio)acetate (4.73m). 
Isolated as a clear oil (124 mg, 70% yield) after chromatography (2 
→ 6% EtOAc/hexane). 1H NMR (500 MHz, CDCl3): δ 7.66 (d, J = 
16 Hz, 1H), 7.57−7.53 (m, 2H), 7.43−7.38 (m, 3H), 6.75 (d, J = 16 Hz, 1H), 4.22 (q, J = 7 Hz, 
2H), 3.83 (s, 2H), 1.30 (t, J = 7 Hz, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 187.9, 168.9, 
141.9, 134.0, 131.0, 129.1, 128.6, 124.1, 62.0, 31.5, 14.3. IR (cm−1): 2982, 1733, 1656, 1613, 
1449, 1293, 1262, 1133, 1022, 752. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C13H14O3S, 
251.0737; found, 251.0736.  
S-(cyanomethyl) (E)-3-phenylprop-2-enethioate (4.73n). 
Isolated as a white powder (483 mg, 79% yield) after chromatography 
(2 → 10% EtOAc/hexane). 1H NMR (500 MHz, CDCl3): δ 7.70 (d, J = 
16 Hz, 1H), 7.58−7.54 (m, 2H), 7.47−7.39 (m, 3H), 6.72 (d, J = 16 Hz, 1H), 3.81 (s, 2H). 
13C{1H} NMR (125 MHz, CDCl3): δ 185.7, 143.7, 133.5, 131.5, 129.2, 128.8, 122.9, 116.0, 
14.3. IR (cm−1): 3059, 2970, 2927, 1672, 1607, 1038, 997, 752, 688. HRMS (ESI-TOF) m/z: [M 
+ Na]+ calcd for C11H9NOS, 226.0297; found, 226.0289. Mp: 82−83 °C.  








General procedure for the rearrangements (0.1 mmol scale) 
Synthesis of 4.79a 
Thioester 4.73a (0.1 mmol) was dissolved in freshly distilled CDCl3 (450 μL) and transferred to 
an NMR tube. To this solution was added 20 mol % of DHIP 4.59a (50 μL of 0.4 M solution in 
CDCl3) followed by triethylamine (14 μL, 0.10 mmol). The contents were mixed, and the 
reaction progress was monitored by 1H NMR. After complete consumption of the thioester 
(16−24 h), the reaction was quenched with 1 M aqueous HCl. The aqueous layer was extracted 
twice with CH2Cl2. The combined organic layers were dried with Na2SO4 and concentrated by 
rotary evaporation. The crude product was adsorbed on silica gel and purified by flash 
chromatography (1 → 3% EtOAc/hexane). The product 4.79a was isolated as an orange oil (21 
mg, 75%), which solidified upon standing. Other thioester substrates were rearranged on a 0.1 
mmol scale as described above for 4.73a to give the products listed below. 
Large scale (2.5 mmol) rearrangement 
The reaction was conducted analogously to the small scale procedure using the following 
quantities: 706 mg of substrate 4.73a (2.50 mmol), 1.08 mL of 0.463 M DHIP 4.59a (0.5 mmol) 
in CDCl3, 349 μL of triethylamine (2.50 mmol), 11.5 mL of CDCl3. The product was obtained in 
60% yield (426 mg). 
Enantioselective rearrangement 
The reaction was conducted analogously to the small-scale procedure described above using 
chiral catalysts 4.54, 4.69, and 4.81. Reaction times were extended appropriately. Product 4.79a 
was obtained in 36% yield (10 mg) using catalyst 4.54. HPLC (0.5% isopropanol/hexanes): 
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minor enantiomer, 37.3 min; major enantiomer, 42.2 min; 54% ee; [α]𝐷
23= −7.5° (c 0.133, 
CH2Cl2). 
(3-hydroxy-5-phenyl-4,5-dihydrothiophen-2-yl)(phenyl)methanone (4.79a). 
1H NMR (500 MHz, CDCl3): δ 13.96 (s, 1H), 7.89−7.85 (m, 2H), 
7.48−7.40 (m, 5H), 7.38−7.33 (m, 2H), 7.32−7.28 (m, 1H), 4.78 (t, J = 8 
Hz, 1H), 3.23 (dd, J = 17 Hz, 8 Hz, 1H), 3.14 (dd, J = 17 Hz, 8 Hz, 1H). 
13C{1H} NMR (125 MHz, CDCl3): δ 206.1, 163.4, 140.0, 134.1, 131.3, 129.1, 128.5, 128.3, 
128.1, 127.2, 106.4, 47.5, 46.6. IR (cm−1): 1560, 1489, 1446, 1236, 1095, 690. HRMS (ESI-
TOF) m/z: [M + Na]+ calcd for C17H14O2S, 305.0607; found, 305.0597. Mp: 81−83 °C.  
(3-hydroxy-5-(4-methoxyphenyl)-4,5-dihydrothiophen-2-yl)(phenyl)methanone (4.79b). 
Isolated as a yellow oil (24 mg, 77% yield) after chromatography 
(2.5 → 5% EtOAc/ hexane). 1H NMR (500 MHz, CDCl3): δ 13.95 
(s, 1H), 7.88−7.84 (m, 2H), 7.47−7.42 (m, 3H), 7.34 (d, J = 9 Hz, 
2H), 6.88 (d, J = 9 Hz, 2H), 4.75 (t, J = 8 Hz, 1H), 3.80 (s, 3H), 3.19 (dd, J = 17 Hz, 8 Hz, 1H), 
3.11 (dd, J = 17 Hz, 8 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 206.3, 163.3, 159.6, 134.1, 
131.8, 131.3, 128.5, 128.4, 128.1, 114.4, 106.6, 55.5, 47.7, 46.3. IR (cm−1): 1609, 1561, 1512, 
1339, 1250, 1178, 1102. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C18H16O3S, 335.0712; 







Isolated as a yellow oil (22 mg, 63% yield) after chromatography (1 
→ 6% EtOAc/ hexane). 1H NMR (500 MHz, CDCl3): δ 13.97 (s, 
1H), 7.88−7.84 (m, 2H), 7.61 (d, J = 9 Hz, 2H), 7.53 (d, J = 9 Hz, 
2H), 7.49−7.44 (m, 3H), 4.79 (t, J = 8 Hz, 1H), 3.28 (dd, J = 18 Hz, 8 Hz, 1H), 3.10 (dd, J = 18 
Hz, 8 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 205.3, 164.1, 144.4, 134.0, 131.6, 130.5 (q, 
2JC−F = 33 Hz), 128.6, 128.1, 127.7, 127.3, 126.1 (q, 
3JC−F = 4 Hz), 124.0 (q, 
1JC−F = 270 Hz), 
47.2, 45.8. IR (cm−1): 2925, 1619, 1589, 1561, 1324, 1112, 1069. HRMS (ESI-TOF) m/z: [M + 
Na]+ calcd for C18H13F3O2S, 373.0480; found, 373.0471. 
(3-hydroxy-5-(o-tolyl)-4,5-dihydrothiophen-2-yl)(phenyl)methanone (4.79d). 
Isolated as a yellow oil (23 mg, 82%), which solidified upon standing, 
after chromatography (2 → 6% EtOAc/hexane). 1H NMR (500 MHz, 
CDCl3): δ 14.01 (s, 1H), 7.89−7.83 (m, 2H), 7.50 (d, J = 8 Hz, 1H), 
7.47−7.41 (m, 3H), 7.25−7.15 (m, 3H), 4.98 (t, J = 8 Hz, 1H), 3.22 (dd, J = 17 Hz, 8 Hz, 1H), 
3.15 (dd, J = 17 Hz, 8 Hz, 1H), 2.40 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 206.4, 163.8, 
138.0, 136.1, 134.1, 131.3, 130.9, 128.5, 128.1, 128.0, 126.9, 125.8, 106.0, 46.4, 42.6, 19.7. IR 
(cm−1): 1556, 1488, 1443, 1341, 1242, 1095, 832, 779, 687. HRMS (ESI-TOF) m/z: [M + Na]+ 







Isolated as a yellow oil (15 mg, 56% yield) after chromatography (2 → 
10% EtOAc/ hexane). 1H NMR (500 MHz, CDCl3): δ 13.96 (s, 1H), 
7.87−7.83 (m, 2H), 7.48−7.44 (m, 3H), 7.26−7.23 (m, 1H), 7.06−7.03 
(m, 1H), 6.96−6.94 (m, 1H), 5.02 (t, J = 8 Hz, 1H), 3.28 (dd, J = 17 Hz, 8 Hz, 1H), 3.15 (dd, J = 
17 Hz, 8 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 205.2, 164.0, 144.0, 134.0, 131.4, 128.5, 
128.1, 127.1, 125.6, 125.4, 106.0, 48.6, 42.0. IR (cm−1): 3066, 1630, 1586, 1557, 1338, 1237, 
1097, 690. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C15H12O2S2, 311.0171; found, 311.0159. 
(3-hydroxy-5,5-dimethyl-4,5-dihydrothiophen-2-yl)(phenyl)methanone (4.79f). 
The rearrangement was carried out for 24 h at 50 °C. Isolated as a yellow 
crystalline solid (15 mg, 65% yield) after chromatography (1 → 3% 
EtOAc/hexane). 1H NMR (500 MHz, CDCl3): δ 13.92 (s, 1H), 7.86−7.82 
(m, 2H), 7.48−7.44 (m, 3H), 2.76 (s, 2H), 1.53 (s, 6H). 13C{1H} NMR (125 MHz, CDCl3): δ 
206.9, 163.5, 134.2, 131.2, 128.4, 128.1, 107.5, 55.1, 48.8, 30.1. IR (cm−1): 2957, 2925, 1633, 
1589, 1562, 1338, 1249. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C13H14O2S, 235.0787; 
found, 235.0782. Mp: 64−65 °C.  
(3-hydroxy-5-phenyl-4,5-dihydrothiophen-2-yl)(4-methoxyphenyl)methanone (4.79h). 
Isolated as a yellow oil (25 mg, 81% yield) after chromatography 
(2.5 → 5% EtOAc/ hexane). 1H NMR (500 MHz, CDCl3): δ 14.19 (s, 
1H), 7.87 (d, J = 9 Hz, 2H), 7.44−7.40 (m, 2H), 7.38−7.33 (m, 2H), 
7.32−7.28 (m, 1H), 6.96 (d, J = 9 Hz, 2H), 4.77 (t, J = 8 Hz, 1H), 
3.85 (s, 3H), 3.21 (dd, J = 17 Hz, 8 Hz, 1H), 3.12 (dd, J = 17 Hz, 8 Hz, 1H). 13C{1H} NMR (125 
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MHz, CDCl3): δ 205.2, 164.1, 162.1, 140.2, 130.1, 129.1, 128.2, 127.3, 126.3, 114.0, 104.8, 
55.6, 47.4, 46.6. IR (cm−1): 2930, 2839, 1599, 1506, 1253, 1175, 1102, 1026, 837, 697. HRMS 
(ESI-TOF) m/z: [M + Na]+ calcd for C18H16O3S, 335.0712; found, 335.0708.  
(4-chlorophenyl)(3-hydroxy-5-phenyl-4,5-dihydrothiophen-2-yl)methanone (4.79i). 
Isolated as an orange oil (22 mg, 69%), which solidified upon standing, 
after chromatography (2 → 5% EtOAc/hexane). 1H NMR (500 MHz, 
CDCl3): δ 13.92 (s, 1H), 7.83 (d, J = 9 Hz, 2H), 7.44−7.39 (m, 4H), 
7.39−7.34 (m, 2H), 7.34−7.29 (m, 1H), 4.78 (t, J = 8 Hz, 1H), 3.23 (dd, 
J = 17 Hz, 8 Hz, 1H), 3.13 (dd, J = 17 Hz, 8 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 
206.3, 161.8, 139.8, 137.3, 132.5, 129.4, 129.1, 128.8, 128.4, 127.2, 106.7, 47.4, 46.6. IR (cm−1): 
1578, 1485, 1230, 1088, 830. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C17H13ClO2S, 
317.0398; found, 317.0376. Mp: 72−75 °C.  
(3-hydroxy-5-phenyl-4,5-dihydrothiophen-2-yl)(4-nitrophenyl)methanone (4.79j). 
Isolated as a red oil (17 mg, 53% yield) after chromatography (1 → 
4% EtOAc/hexane). Note that the solution may need to be heated to 
fully dissolve thioester 4.76j prior to the addition of the catalyst. 1H 
NMR (500 MHz, CDCl3): δ 13.68 (s, 1H), 8.29 (d, J = 9 Hz, 2H), 
8.04 (d, J = 9 Hz, 2H), 7.43−7.30 (m, 5H), 4.83 (t, J = 8 Hz, 1H), 3.28 (dd, J = 18 Hz, 8 Hz, 1H), 
3.16 (dd, J = 18 Hz, 8 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 207.2, 159.1, 148.7, 140.1, 
139.4, 129.2, 129.0, 128.6, 127.2, 123.7, 109.2, 47.4, 46.6. IR (cm−1): 1640, 1566, 1519, 1344, 





Isolated as an orange oil (20 mg, 71%), which solidified upon standing, 
after chromatography (2 → 10% EtOAc/hexane). 1H NMR (500 MHz, 
CDCl3): δ 13.48 (s, 1H), 7.65−7.62 (m, 1H), 7.42 (d, J = 8 Hz, 2H), 
7.38−7.33 (m, 2H), 7.33−7.28 (m, 1H), 7.09 (d, J = 4 Hz, 1H), 6.59−6.56 (m, 1H), 4.80 (t, J = 8 
Hz, 1H), 3.22 (dd, J = 17 Hz, 8 Hz, 1H), 3.09 (dd, J = 17 Hz, 8 Hz, 1H). 13C{1H} NMR (125 
MHz, CDCl3): δ 205.9, 153.0, 147.8, 145.9, 140.3, 129.1, 128.2, 127.2, 116.3, 112.7, 104.8, 
47.6, 46.3. IR (cm−1): 1604, 1455, 1255, 1242, 1164, 1113, 1009, 745, 694. HRMS (ESI-TOF) 
m/z: [M + Na]+ calcd for C15H12O3S, 295.0399; found, 295.0389. Mp: 79−82 °C.  
1-(3-hydroxy-5-phenyl-4,5-dihydrothiophen-2-yl)ethan-1-one (4.79l).  
Isolated as a yellow oil (9 mg, 41%, ca. 90% pure by 1H NMR) after 
chromatography (0.5 → 1.5% EtOAc/hexane). 1H NMR (500 MHz, 
CDCl3): δ 13.00 (s, 1H), 7.44−7.33 (m, 4H), 7.32−7.28 (m, 1H), 4.73 (t, J = 
8 Hz, 1H), 3.12 (dd, J = 17 Hz, 8 Hz, 1H), 3.01 (dd, J = 17 Hz, 8 Hz, 1H), 2.01 (s, 3H). 13C{1H} 
NMR (125 MHz, CDCl3): δ 203.1, 167.8, 140.4, 129.0, 128.2, 127.2, 107.2, 47.7, 46.2, 21.8. IR 
(cm−1): 2922, 1646, 1598, 1332, 1219, 698. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for 
C12H12O2S, 243.0450; found, 243.0442.  






2,4,6-trichlorophenyl cinnamate 4.82a (R1=Ph) 
Following a published procedure16, to a solution of cinnamic acid (1.00 g, 6.75 mmol) in 10 mL 
of CH2Cl2 stirring at 0 °C was added a solution of DCC (1.67 g, 8.10 mmol, 1.2 equiv) and 
DMAP (17 mg, 0.14 mmol, 2 mol %) in 5 mL of CH2Cl2 under an inert atmosphere. After 20 
min, a solution of 2,4,6-trichlorophenol (1.33 g, 6.75 mmol, 1.0 equiv) in 5 mL of CH2Cl2 was 
added dropwise. In 1 h, the mixture was allowed to warm to rt and the stirring continued until 
complete consumption of the phenol by TLC (10% EtOAc/hexane). The reaction mixture was 
filtered, and the precipitated N,N′-dicyclohexylurea was washed on the filter with CH2Cl2. The 
filtrate was concentrated by rotary evaporation, and the crude product was purified by column 
chromatography (2 → 10% EtOAc/hexane) to afford the product as a white crystalline solid 
(2.10 g, 95% yield, mp 79−80 °C). Its spectroscopic data matched those reported in the 
literature.23 Other trichlorophenyl esters listed below were obtained analogously from the 
corresponding carboxylic acids21 and purified by chromatography using the same eluent as 
above. 
2,4,6-trichlorophenyl (E)-3-cyclohexylacrylate (4.82o). 
White crystalline solid (619 mg, 89% yield). 1H NMR (500 MHz, 
CDCl3): δ 7.38 (s, 2H), 7.23 (dd, J = 16 Hz, 7 Hz, 1H), 6.02 (dd, J 
= 16 Hz, 2 Hz, 1H), 2.30−2.20 (m, 1H), 1.89−1.76 (m, 4H), 
1.75−1.67 (m, 1H), 1.40−1.16 (m, 5H). 13C{1H} NMR (125 MHz, CDCl3): δ 162.9, 158.8, 143.2, 
131.8, 129.8, 128.6, 116.4, 40.9, 31.5, 26.0, 25.8. IR (cm−1): 2933, 2851, 1746, 1645, 1564, 
1445, 1096, 854. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C15H15Cl3O2, 355.0030; found, 




2,4,6-trichlorophenyl (E)-3-(naphthalen-1-yl)acrylate (4.82p). 
Colorless crystalline solid (265 mg, 88% yield). 1H NMR (500 
MHz, CDCl3): δ 8.12 (d, J = 16 Hz, 1H), 8.04−8.00 (m, 1H), 
7.92−7.84 (m, 3H), 7.77−7.73 (m, 1H), 7.58−7.51 (m, 2H), 7.42 
(s, 2H), 6.80 (d, J = 16 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 163.2, 148.6. 143.3, 134.8, 
133.4, 132.1, 131.5, 131.1, 130.0, 129.1, 128.9, 128.8, 128.0, 127.9, 127.1, 123.6, 115.5. IR 
(cm−1): 3059, 2927, 2853, 1736, 1626, 1562, 1444, 1110, 814. HRMS (ESI-TOF) m/z: [M + 
Na]+ calcd for C19H11Cl3O2, 398.9723; found, 398.9705. Mp: 144−146 °C.  
 
2,4,6-trichlorophenyl (E)-3-(pyridin-3-yl)acrylate (4.82q). 
Light tan crystalline solid (596 mg, 80% yield). 1H NMR (500 
MHz, CDCl3): δ 8.81 (s, 1H), 8.66−8.62 (m, 1H), 7.92 (d, J = 16 
Hz, 1H), 7.92−7.87 (m, 1H), 7.40−7.32 (m, 3H), 6.74 (d, J = 16 
Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 162.4, 151.8, 150.2, 144.7, 142.9, 134.6, 132.2, 
129.7, 129.6, 128.7, 123.9, 117.5. IR (cm−1): 3079, 2928, 1736, 1447, 1412, 1204, 801. HRMS 
(ESI-TOF) m/z: [M + H]+ calcd for C14H8Cl3NO2, 327.9701; found, 327.9686. Mp: 133−135 °C.  
 




A solution of trichlorophenyl cinnamate 4.82a (33 mg, 0.1 mmol) and phenacylmercaptan 4.83 
(15 mg, 0.1 mmol) in 450 μL of CDCl3 was placed into an NMR tube and treated with a stock 
solution of DHIP (50 μL of 0.4 M in CDCl3) followed by triethylamine (14 μL, 0.1 mmol). The 
contents were mixed, and the reaction progress was monitored by 1H NMR. After complete 
consumption of the ester (16−20 h), the reaction was quenched by pouring into 1 M HCl. The 
aqueous layer was extracted twice with CH2Cl2. The combined organic extracts were dried with 
Na2SO4 and concentrated by rotary evaporation. The crude product was adsorbed on silica gel 
and purified by flash chromatography (1 → 3% EtOAc/hexane). The product 4.82a was isolated 
as an orange oil (27 mg, 82% yield), which solidified upon standing. Other dihydrothiophene 
products listed below were obtained analogously. 
(5-cyclohexyl-3-hydroxy-4,5-dihydrothiophen-2-yl)(phenyl)methanone (4.79o). 
Isolated as a yellow oil (24 mg, 73% yield), which solidified upon 
standing, after chromatography (1 → 3% ether/hexane). 1H NMR (500 
MHz, CDCl3): δ 13.93 (s, 1H), 7.92−7.87 (m, 2H), 7.49−7.44 (m, 3H), 
3.47−3.40 (m, 1H), 2.94 (dd, J = 17 Hz, 8 Hz, 1H), 2.71 (dd, J = 17 Hz, 8 Hz, 1H), 1.86−1.72 
(m, 4H), 1.71−1.64 (m, 1H), 1.62−1.50 (m, 3H), 1.32−1.00 (m, 3H). 13C{1H} NMR (125 MHz, 
CDCl3): δ 207.3, 162.9, 134.3, 131.1, 128.5, 128.1, 106.5, 49.5, 44.3, 43.6, 31.1, 30.9, 26.3, 26.1, 
26.0. IR (cm−1): 2922, 2852, 1629, 1583, 1555, 1335, 1241, 685. HRMS (ESI-TOF) m/z: [M + 
Na]+ calcd for C17H20O2S, 311.1076; found, 311.1065. Mp: 68−71 °C.  
(3-hydroxy-5-(naphthalen-1-yl)-4,5-dihydrothiophen-2-yl)(phenyl)methanone (4.79p). 
 Isolated as a yellow solid (19 mg, 50% yield) after chromatography 
(2 → 6% EtOAc/ hexane). 1H NMR (500 MHz, CDCl3): δ 14.01 (s, 
1H), 7.91−7.80 (m, 6H), 7.57−7.44 (m, 6H), 4.95 (t, J = 8 Hz, 1H), 
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3.31 (dd, J = 18 Hz, 8 Hz, 1H), 3.25 (dd, J = 18 Hz, 8 Hz, 1H). 13C{1 H} NMR (125 MHz, 
CDCl3): δ 206.1, 163.6, 137.3, 134.1, 133.4, 133.2, 131.4, 129.1, 128.5, 128.1, 128.0, 127.9, 
126.7, 126.5, 126.1, 125.0, 106.4, 47.4, 46.7. IR (cm−1): 3058, 2923, 1631, 1554, 1335, 1235, 
1098, 825. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C21H16O2S, 355.0763; found, 355.0761. 
Mp: 94−96 °C.  
(3-hydroxy-5-(pyridin-3-yl)-4,5-dihydrothiophen-2-yl)(phenyl)methanone (4.79q). 
Isolated as a light brown oil (18 mg, 55% yield) after chromatography 
using a short silica gel column (approximately 3 g of silica gel/50 mg of 
crude material loaded) (10% EtOAc/hexane → pure EtOAc). 1H NMR 
(500 MHz, CDCl3): δ 13.97 (s, 1H), 8.64 (s, 1H), 8.57−8.53 (m, 1H), 7.88−7.83 (m, 2H), 
7.80−7.75 (m, 1H), 7.49−7.43 (m, 3H), 7.32−7.27 (m, 1H), 4.76 (t, J = 8 Hz, 1H), 3.28 (dd, J = 
18 Hz, 8 Hz, 1H), 3.09 (dd, J = 18 Hz, 8 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 205.1, 
164.2, 149.7, 148.9, 136.1, 134.6, 133.9, 131.6, 128.6, 128.1, 123.9, 105.6, 47.2, 43.8. IR (cm−1): 
2921, 1677, 1629, 1586, 1237, 1099, 688. HRMS (ESI-TOF) m/z: [M + H]+ calcd for 
C16H13NO2S, 284.0740; found, 284.0737.  
 






Synthesis of thioester 4.89. 
Cinnamoyl chloride (366 mg, 2.2 mmol, 1.16 equiv), 4- dimethylaminopyridine (23 mg, 0.189 
mmol, 0.1 equiv), and triethylamine (300 μL, 2.2 mmol, 1.16 equiv) were dissolved in 4 mL of 
freshly distilled CH2Cl2 under an inert atmosphere. A solution of o-mercaptoacetophenone 4.112 
(288 mg, 1.89 mmol, 1.0 equiv) in 3 mL of CH2Cl2 (final concentration of ∼0.3 M in thiol) was 
added dropwise at 0 °C over 30 min. The solution was allowed to slowly warm to rt and stirred 
overnight. The mixture was concentrated by rotovap and subjected to column chromatography (5 
→ 20% EtOAc/ hexanes). 4.89 was isolated as a very fine white powder (346 mg, 73%). 1H 
NMR (500 MHz, CDCl3): δ 7.71−7.68 (m, 1H), 7.68 (d, J = 16 Hz, 1H), 7.64−7.61 (m, 1H), 
7.58−7.53 (m, 2H), 7.53−7.48 (m, 2H), 7.43−7.38 (m, 3H), 6.79 (d, J = 16 Hz, 1H), 2.61 (s, 3H). 
13C{1H} NMR (125 MHz, CDCl3): δ 200.9, 187.3, 143.2, 142.0, 136.7, 134.0, 131.3, 131.0, 
129.5, 129.1, 128.6, 128.6, 125.9, 124.2, 29.4. IR (cm−1): 2922, 1693, 1673, 1573, 1249, 1033, 
973, 761, 693. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C17H14O2SNa, 305.0612; found, 
305.0595. mp: 117−121 °C. 
Enantioselective rearrangement of thioester 4.89 
 
An NMR tube was charged with thiocinnamate ester 4.89 (28 mg, 0.10 mmol, 1 equiv), catalyst 
4.69 (100 μL of 0.10 M in CDCl3, 0.010 mmol, 0.1 equiv), and an additional 400 μL of CDCl3, 
shaken, and left at rt. The reaction progress was monitored by 1H NMR. After 18 h (>95% 
conversion), the mixture was rotary evaporated and subjected to column chromatography (0.5% 
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EtOAc/hexanes). The product was isolated as a clear colorless oil (19 mg, 79% yield). 1H NMR 
(500 MHz, CDCl3): δ 7.39−7.36 (m, 1H), 7.35−7.33 (m, 2H), 7.31−7.27 (m, 2H), 7.26−7.21 (m, 
2H), 7.17−7.10 (m, 2H), 5.95 (d, J = 6 Hz, 1H), 4.80 (d, J = 6 Hz, 1H), 2.20 (s, 3H). 13C{1H} 
NMR (125 MHz, CDCl3): δ 141.9, 133.9, 133.6, 131.8, 128.8, 128.0, 127.8, 127.7, 127.3, 125.6, 
125.1, 123.8, 42.7, 21.1. IR (cm−1): 3057, 3026, 2919, 1451, 1431, 1033, 752, 695. HRMS (ESI-
TOF) m/z: [M + Na]+ calcd for C16H14SNa, 261.0714; found, 261.0685. HPLC: (0.25% 
isopropanol/hexane, AD-H): minor enantiomer: 6.9 min; major enantiomer: 7.8 min, 96% ee. 
[α] 𝐷
22 = −63.1° (c = 0.867, CH2Cl2).  
4.8.6 Synthesis of a 3-fluorothiochromene 
 
Synthesis of thioester 4.91 
4.91 was synthesized following a published procedure.9 To a solution of α-fluorocinnamic acid24 
(1.284 g, 7.73 mmol, 1.0 equiv) dissolved in 39 mL of freshly distilled THF (0.2 M) was added 
DCC (0.796 g, 3.87 mmol, 0.5 equiv). This mixture was cooled to 0 °C and stirred for 20 min. 
Then, triphenylphosphine (1.22 g, 4.64 mmol, 0.6 equiv) and 2,2′-dithiobisbenzaldehyde 4.11425  
(1.06 g, 3.87 mmol, 0.5 equiv) were added in one portion and allowed to slowly warm to rt. After 
the mixture was stirred at rt for 24 h, it was filtered and concentrated under reduced pressure. 
The product 4.91 was isolated as a tan powder (434 mg, 1.51 mmol, 20% yield) after 
chromatography (2 → 8% EtOAc/hexanes). 1H NMR (500 MHz, CDCl3): δ 10.27 (s, 1H), 8.10 
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(dd, J = 8 Hz, 2 Hz, 1H), 7.71−7.62 (m, 4H), 7.59−7.56 (m, 1H), 7.45−7.41 (m, 3H), 6.88 (d, J = 
37 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 190.5, 183.8 (d, J = 39 Hz), 151.5 (d, J = 269 
Hz), 137.6, 137.0, 134.5, 131.2 (d, J = 8 Hz), 130.9, 130.6 (d, J = 3 Hz), 130.6 (d, J = 4 Hz), 
129.5, 129.3 (d, J = 5 Hz), 129.2, 115.2 (d, J = 4 Hz). IR (cm−1): 2924, 2871, 1692, 1675, 1637, 
1156, 942, 746. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C16H11FO2SNa, 309.0361; found, 
309.0347. mp: 95−99 °C. 
Enantioselective rearrangement of thioester 4.91 
 
4.92 was prepared as described above (see synthesis of 4.90) using thioester 4.91 (29 mg, 0.10 
mmol, 1 equiv) and (R)-BTM 4.97 (100 μL of 0.10 M in CDCl3, 0.010 mmol, 0.1 equiv). After 1 
week (>90% conversion), the mixture was rotary evaporated and subjected to column 
chromatography (1% EtOAc/hexanes). The product was isolated as a colorless oil (13 mg, 54% 
yield). 1H NMR (500 MHz, CDCl3): δ 7.33−7.24 (m, 5H), 7.20−7.17 (m, 1H), 7.14−7.09 (m, 
3H), 6.42 (d, J = 15 Hz, 1H), 4.77 (d, J = 13 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 157.7 
(d, J = 271 Hz), 139.8 (d, J = 3 Hz), 130.6 (d, J = 8 Hz), 129.0, 128.4, 127.9 (d, J = 9 Hz), 
127.88, 126.9, 126.8, 126.5, 126.1, 107.5 (d, J = 23 Hz), 43.1 (d, J = 29 Hz). IR (cm−1): 3061, 
2923, 2852, 1678, 1471, 1105, 749. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C15H11FSNa, 
265.0463; found, 265.0431. HPLC: (0.25% isopropanol/hexane, OD-H): major enantiomer: 12.0 
min; minor enantiomer: 14.9 min, 94% ee. [α]  𝐷




4.8.7 Synthesis of new catalysts 
 
Synthesis of Aminoalcohol 4.62 
A mixture of 2,6-dibromopyridine (2.00 g, 8.45 mmol) and ethanolamine (2.55 mL, 38.36 mmol, 
4.0 equiv) was heated at 130 °C for 18 h, at which time TLC (5% MeOH/CH2Cl2) indicated 
complete consumption of the starting material. This crude reaction mixture was dissolved in a 
minimum amount of water and extracted three times with EtOAc. The combined organic layers 
were washed with brine, dried over Na2SO4, and concentrated in vacuo. Flash chromatography (1 
→ 5% MeOH/CH2Cl2) afforded the product as a clear, colorless oil (1.60 g, 87% yield). 
1H 
NMR (500 MHz, CDCl3): δ 7.22 (dd, J = 9 Hz, 8 Hz, 1H), 6.72 (d, J = 8 Hz, 1H), 6.34 (d, J = 9 
Hz, 1H), 5.08 (br s, 1H), 3.81 (t, J = 5 Hz, 2H), 3.48−3.44 (m, 2H), 3.34 (br s, 1H). 13C{1H} 
NMR (125 MHz, CDCl3): δ 159.1, 140.0, 139.6, 116.1, 106.0, 62.5, 44.9. IR (cm
−1): 3311 
(broad), 2926, 2867, 1591, 1555, 1497, 1431, 1388, 1325, 1160, 1102, 1048, 973, 768. HRMS 
(ESI-TOF) m/z: [M + H]+ calcd for C7H9BrN2O, 216.9971; found, 216.9985. 
Synthesis of Aminoalcohol 4.64a 
 
To a solution of 4.62 (454 mg, 2.09 mmol), phenylboronic acid (510 mg, 4.18 mmol, 2.0 equiv), 
and triphenylphosphine (93 mg, 0.355 mmol, 0.17 equiv) in 10 mL of 1,2- dimethoxyethane 
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were added 10 mL of water and K2CO3 (1.94 g, 14 mmol, 6.7 equiv). The mixture was degassed 
three times using the freeze−pump−thaw technique. Pd(OAc)2 (19 mg, 0.084 mmol, 4 mol %) 
was added under argon, and the solution was gently refluxed for 20 h, at which time TLC (1% 
MeOH/CH2Cl2) indicated near complete consumption of the starting material. The reaction 
mixture was diluted with 5 mL of EtOAc and 5 mL of water. The aqueous layer was extracted 
twice with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated by 
rotary evaporation. The crude mixture was subjected to column chromatography (1 → 5% 
MeOH/CH2Cl2) to afford the product as a clear, colorless oil (296 mg, contaminated with ca. 
10% triphenylphosphine oxide, 66% corrected yield). 1H NMR (300 MHz, CDCl3): δ 7.91 (d, J = 
8 Hz, 2H), 7.53−7.33 (m, 4H), 7.04 (d, J = 8 Hz, 1H), 6.43 (d, J = 8 Hz, 1H), 4.95 (br s, 1H), 
3.86 (br t, J = 5 Hz, 2H), 3.67−3.59 (m, 2H). 13C{1H} NMR (125 MHz, CDCl3): δ 158.9, 155.7, 
139.5, 138.4, 128.9, 128.8, 126.9, 110.5, 107.4, 64.5, 45.7. IR (cm−1): 3344 (br), 2922, 2857, 
1598, 1574, 1509, 1492, 1442, 1337, 1265, 1161, 1047, 760. HRMS (ESI-TOF) m/z: [M + H]+ 
calcd for C13H14N2O, 215.1179; found, 215.1188. 
Aminoalcohol 4.64b was prepared analogously to 4.64a using the following quantities: 537 mg 
(2.47 mmol) of 4.62, 752 mg (4.95 mmol) of 4-methoxyphenylboronic acid, 12 mL of glyme, 12 
mL of water, 110 mg (0.42 mmol) of triphenylphosphine, 2.28 g (16.5 mmol) of K2CO3, and 22 
mg (0.099 mmol) of Pd(OAc)2. 4.64b was isolated as a clear light brown oil (497 mg, 82%) after 
chromatography (pure CH2Cl2→2 % MeOH/CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.86 (d, J 
= 9 Hz, 2H), 7.44 (t, J = 8 Hz, 1H), 6.97 (d, J = 9 Hz, 2H), 6.99-6.95 (m, 1H), 6.36 (d, J = 8 Hz, 
1H), 4.87 (br s, 1H), 3.86-3.83 (m, 2H), 3.84 (s, 3H), 3.61 (q, J = 5 Hz, 2H). 13C NMR (125 
MHz, CDCl3): δ 160.34, 158.82, 155.37, 138.33, 132.24, 128.14, 114.16, 109.65, 106.61, 64.54, 
55.46, 45.64; MS: HR-ESI calculated for [C14H16N2O2+Na]
+: 267.1104, found 267.1083. 
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Synthesis of 4.65a (Hydrochloride salt) 
 
To a solution of 4.64a (92 mg, containing ca. 10% Ph3PO, see above) in freshly distilled 
chloroform (1.2 mL) was added SOCl2 (93 μL, 1.28 mmol, ca. 3 equiv) dropwise at 0 °C. The 
mixture was refluxed for 2 h, cooled to rt, and quenched by adding 100 μL of methanol. The 
solvent was removed by rotary evaporation. The resulting oil was suspended in 2 mL of water 
and heated to 60 °C. The aqueous phase was passed through a cotton plug to remove the gummy 
residue. The filtrate was basified with 2 M aqueous NaOH and extracted repeatedly with benzene 
until the aqueous phase was only pale yellow. The combined benzene extracts were dried briefly 
over Na2SO4, decanted into a round-bottom flask, and refluxed overnight. The mixture was 
cooled to 0 °C, and the precipitated product (4.65a) was filtered off and washed several times 
with benzene to remove the Ph3PO impurity carried forward from the previous step. Compound 
4.65a was isolated as a light orange solid (60 mg, 71% yield). 1H NMR (500 MHz, D2O; HOD 
used as a reference peak at δ 4.79 ppm): δ 7.96 (t, J = 9 Hz, 1H), 7.70−7.57 (m, 5H), 7.04 (d, J = 
9 Hz, 1H), 6.89 (d, J = 9 Hz, 1H), 4.55 (t, J = 10 Hz, 2H), 3.70 (t, J = 10 Hz, 2H). 13C{1H} NMR 
(125 MHz, D2O, (CH3)2CO added and used as a reference peak at δ 29.84 ppm): δ 157.1, 149.0, 
144.8, 132.2, 131.1, 129.4, 128.7, 114.8, 108.3, 50.8, 42.9. IR (cm−1): 3409, 2954, 1647, 1571, 
1550, 1298, 1145, 778, 706. HRMS (ESI-TOF) m/z: [M]+ calcd for C13H13N2, 197.1073; found, 




Synthesis of 4.61b (free base) 
 
The hydrochloride salt of 4.65a (18 mg, 0.078 mmol) was dissolved in 1 mL of water and treated 
with 2 mL of 33 wt % aqueous NaOH. The resulting yellow oil was extracted with CH2Cl2 
several times until the aqueous phase was only faint yellow. The organic extract was dried over 
NaOH pellets and rotary evaporated to afford the product as a dark yellow oil (15 mg, 
quantitative yield). 1H NMR (500 MHz, CDCl3): δ 7.44−7.40 (m, 3H), 7.40−7.36 (m, 2H), 6.83 
(dd, J = 10 Hz, 7 Hz, 1H), 6.32 (d, J = 10 Hz, 1H), 5.52 (d, J = 7 Hz, 1H), 3.90−3.80 (m, 4H). 
13C{1H} NMR (125 MHz, CDCl3): δ 159.4, 147.5, 136.4, 135.4, 129.2, 128.6, 127.8, 113.8, 
103.4, 52.3, 49.4. 
The hydrochloride salt 4.65b and free base 4.59c were prepared analogously to 4.65a and 4.59b 
as above using the following quantities: 157 mg (0.643 mmol) of 4.64b, 140 μL (1.93 mmol) of 
SOCl2, and 1.8 mL of CHCl3. Characterization of free base
 4.59c:  1H NMR (500 MHz, CDCl3) δ 
7.30 (d, J = 9 Hz, 2H), 6.93 (d, J = 9 Hz, 2H), 6.81 (dd, J = 10 Hz, 7 Hz, 1H), 6.29 (d, J = 10 Hz, 
1H), 5.49 (d, J = 7 Hz, 1H), 3.86-3.83 (m, 7H). 13C NMR (125 MHz, CDCl3): δ 160.34, 159.66, 
147.48, 136.54, 129.26, 127.96, 114.06, 113.39, 103.30, 55.52, 52.31, 49.56. 




2,6-Dibromopyridine (3.45 g, 14.5 mmol), (R)-2-phenylglycinol (2.00 g, 14.5 mmol), and N,N-
diisopropylethylamine (3.8 mL, 22 mmol) were added to a high pressure flask and heated at 150 
°C for 36 h. After cooling to room temperature, the crude mixture was dissolved in CH2Cl2 and 
loaded directly onto the column. Flash chromatography (CH2Cl2 → 4% MeOH/CH2Cl2) afforded 
the product as a white powder (3.67 g, 86% yield). 1H NMR (500 MHz, CDCl3): δ 7.38−7.34 (m, 
4H), 7.33−7.28 (m, 1H), 7.16 (t, J = 8 Hz, 1H), 6.73 (d, J = 8 Hz, 1H), 6.15 (d, J = 8 Hz, 1H), 
5.48 (br s, 1H), 4.77−4.72 (m, 1H), 4.00−3.94 (m, 1H), 3.90−3.83 (m, 1H), 2.63 (br s, 1H). 
13C{1H} NMR (125 MHz, CDCl3): δ 158.6, 139.9, 139.8, 139.5, 129.1, 128.1, 126.8, 116.6, 
105.5, 67.4, 58.8. IR (cm−1): 3287 (br), 1594, 1441, 1166, 1108, 1068, 977, 755, 700. HRMS 
(ESI-TOF) m/z: [M + H]+ calcd for C13H13BrN2O, 293.0284; found, 293.0284. Mp: 137−138 °C.  
[α] 𝐷
21 = −32.8° (c 0.400, CH3CN). 
Chiral aminoalcohol 4.68 
 
The compound was prepared analogously to 4.64a using the following quantities: 504 mg of 4.67 
(1.72 mmol), 523 mg of 4-methoxyphenylboronic acid (3.44 mmol), 77 mg of 
triphenylphosphine (0.29 mmol), 1.59 g of K2CO3 (11.5 mmol), 15 mg of Pd(OAc)2 (0.69 
mmol), 10 mL of water, and 10 mL of 1,2-dimethoxyethane. The product was isolated as a light 
gray powder (343 mg, 62% yield) after chromatography (CH2Cl2 → 4% MeOH/ CH2Cl2). 
1H 
NMR (500 MHz, CDCl3): δ 7.87−7.83 (m, 2H), 7.43− 7.35 (m, 5H), 7.33−7.29 (m, 1H), 
7.00−6.95 (m, 3H), 6.26 (d, J = 8 Hz, 1H), 5.12 (br d, J = 5 Hz, 1H), 4.96 (dd, J = 11 Hz, 6 Hz, 
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1H), 4.46 (br s, 1H), 3.98−3.93 (m, 2H), 3.85 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 
160.4, 158.4, 155.4, 140.5, 138.5, 132.3, 129.0, 128.3, 127.8, 126.9, 114.2, 110.1, 106.1, 68.5, 
59.8, 55.5. IR (cm−1): 3254 (br), 1595, 1572, 1460, 1449, 1245, 1171, 1029, 786, 699. HRMS 
(ESI-TOF) m/z: [M + H]+ calcd for C20H20N2O2, 321.1598; found, 321.1606. Mp: 134−136 °C. 
[α]𝐷
21 = −72.6° (c 0.333, CH3CN). 
Synthesis of catalyst 4.69 
 
The compound was prepared analogously to 4.65a following a slightly modified procedure. To a 
solution of 4.68 (206 mg, 0.64 mmol) in freshly distilled chloroform (1.8 mL) was added SOCl2 
(140 μL, 1.93 mmol, 3 equiv) dropwise at 0 °C. The mixture was refluxed for 4 h, cooled to rt, 
and quenched by adding 100 μL of methanol. The solvent was removed by rotary evaporation. 
The resulting oil was suspended in 2 mL of water and heated to 60 °C. The aqueous phase was 
passed through a cotton plug to remove the gummy residue. The filtrate was basified with 2 M 
aqueous NaOH and extracted repeatedly with benzene until the aqueous phase was only pale 
yellow. The combined benzene extracts were dried briefly over Na2SO4, decanted into a round-
bottom flask, and refluxed overnight. After cooling to room temperature, the benzene was 
removed by rotary evaporation. The yellow flaky solid was dissolved in a minimal 10% ethyl 
acetate/hexane mixture and cooled to 0 °C until a yellow solid precipitated out of the solution. 
The yellow solid, determined to be free base 4.69, was filtered off and left to dry (140 mg, 64% 
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yield). 1H NMR (500 MHz, CDCl3): δ 7.36−7.27 (m, 6H), 7.26−7.25 (m, 1H), 7.25−7.21 (m, 
1H), 6.93−6.89 (m, 3H), 6.43 (d, J = 10 Hz, 1H), 5.59 (d, J = 7 Hz, 1H), 5.19 (dd, J = 11 Hz, 10 
Hz, 1H), 4.26 (t, J = 11 Hz, 1H), 3.83 (s, 3H), 3.73 (dd, J = 11 Hz, 10 Hz, 1H). 13C{1H} NMR 
(125 MHz, CDCl3): δ 160.4, 159.3, 147.2, 145.0, 137.0, 129.3, 128.7, 127.6, 127.2, 126.7, 114.1, 
113.2, 103.9, 66.9, 57.3, 55.5. IR (cm−1): 2933, 1640, 1608, 1553, 1505, 1248, 1176, 1029, 907, 
724, 698. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C20H18N2O, 303.1492; found, 303.1498. 
Mp: 122−124 °C. [𝛼]𝐷
21 = +203.6° (c 0.333, CH2Cl2). 
4.8.8 Synthesis of fused indanes 4.100a,b 
Synthesis of thioesters 4.99a,b 
 
A stirring solution of 4.11516 (490 mg, 2.25 mmol, 1.0 equiv) in 15 mL of freshly distilled 
CH2Cl2 stirred was treated with a solution of DMAP (6 mg, 0.045 mmol, 0.02 equiv) and DCC 
(557 mg, 2.7 mmol, 1.2 equiv) in 7 mL of CH2Cl2 added dropwise at 0 °C. This was stirred for 
20 min. Then, thiophenol (185 μL, 1.8 mmol, 0.8 equiv) dissolved in 6 mL of CH2Cl2 was added 
dropwise over 30 min. The reaction was left to slowly warm to rt and stirred overnight. The 
mixture was then filtered, concentrated under reduced pressure, and subjected to column 
chromatography (10 → 20% EtOAc/hexanes). 4.99a was isolated as a light tan solid (487 mg, 
88% yield). 1H NMR (500 MHz, CDCl3): δ 8.03 (d, J = 16 Hz, 1H), 7.86 (d, J = 16 Hz, 1H), 
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7.64−7.58 (m, 2H), 7.52−7.48 (m, 2H), 7.47−7.42 (m, 5H), 6.71 (d, J = 16 Hz, 1H), 6.62 (d, J = 
16 Hz, 1H), 2.40 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 197.9, 187.8, 139.8, 138.0, 135.1, 
134.6, 134.1, 131.0, 130.7, 130.4, 129.7, 129.4, 128.0, 127.9, 127.6, 127.4, 27.8. IR (cm−1): 
1662, 1258, 1127, 956, 749. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C19H16O2SNa, 
331.0769; found, 331.0760. mp: 88−89 °C. 
Thioester 4.99b was prepared analogously to the methyl derivative 4.99a (see above) using the 
following quantities: o-(3-oxo-3-phenylpropenyl)-cinnamic acid16 (626 mg, 2.25 mmol, 1.0 
equiv), DCC (557 mg, 2.7 mmol, 1.2 equiv), DMAP (6 mg, 0.045 mmol, 0.02 equiv), thiophenol 
(185 μL, 1.8 mmol, 0.8 equiv), and 28 mL of CH2Cl2. 4.99b was isolated as a yellow solid (517 
mg, 78%) after chromatography (5 → 15% EtOAc/hexanes). 1H NMR (500 MHz, CDCl3): δ 8.13 
(d, J = 16 Hz, 1H), 8.10 (d, J = 16 Hz, 1H), 8.05−8.02 (m, 2H), 7.72−7.68 (m, 1H), 7.65−7.62 (m, 
1H), 7.61−7.57 (m, 1H), 7.53−7.48 (m, 4H), 7.48−7.43 (m, 5H), 7.41 (d, J = 16 Hz, 1H), 6.72 (d, 
J = 16 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 190.1, 187.7, 141.4, 138.6, 138.0, 135.6, 
134.7, 134.4, 133.1, 130.6, 130.3, 129.6, 129.4, 128.8, 128.7, 128.4, 128.0, 127.7, 127.5, 126.5. 
IR (cm−1): 1669, 1656, 1593, 1292, 1216. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for 
C24H18O2SNa, 393.0925; found, 393.0902. mp: 61−65 °C. 




4.100a was prepared by mixing thioester 4.99a (31 mg, 0.10 mmol, 1 equiv) and (R)-H-
PIP 4.54 (100 μL of 0.10 M in CDCl3, 0.010 mmol, 0.1 equiv). After 3 days at 0 °C (complete 
consumption of the starting material by 1H NMR), the mixture was rotary evaporated, and the 
crude product was preadsorbed onto silica gel. The pure product (14 mg, 45% yield) was obtained 
as a clear, colorless oil after column chromatography (1 → 2% EtOAc/hexanes). 1H NMR (500 
MHz, CDCl3): δ 7.48–7.45 (m, 2H), 7.37–7.35 (m, 1H), 7.34–7.24 (m, 5H), 7.18–7.16 (m, 1H), 
5.42 (d, J = 2 Hz, 1H), 5.32 (dd, J = 6 Hz, 1 Hz, 1H), 4.11–4.06 (m, 1H), 3.33 (dd, J = 9 Hz, 2 Hz, 
1H), 1.91–1.89 (m, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 169.0, 148.7, 143.7, 139.9, 135.0, 
131.1, 129.3, 129.0, 128.0, 127.4, 125.7, 123.8, 99.4, 53.6, 48.8, 39.5, 19.1. IR (cm–1): 3069, 2921, 
1748, 1706, 1169, 1150, 1090. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C19H17O2S, 309.0949; 
found, 309.0945. HPLC: (2% isopropanol/hexane, AD-H): minor enantiomer: 12.1 min; major 
enantiomer: 19.0 min, 88% ee (Table 4.4, entry 7). [α]D
26 = +63.1° (c = 0.800, CHCl3). 
4.100b was prepared analogously as described above using thioester 4.99b (37 mg, 0.10 mmol, 1 
equiv) and (R)-H-PIP 4.54 (100 μL of 0.10 M in CDCl3, 0.010 mmol, 0.1 equiv). After 3 days at 
0 °C, the mixture was rotary evaporated and purified by chromatography (1 → 2% 
EtOAc/hexanes). The pure product (11 mg, 30% yield) was obtained as a clear, colorless oil that 
crystallized on standing. 1H NMR (500 MHz, CDCl3): δ 7.63–7.60 (m, 2H), 7.50–7.47 (m, 2H), 
7.40–7.22 (m, 10H), 6.09 (d, J = 6 Hz, 1H), 5.48 (d, J = 2 Hz, 1H), 4.33–4.29 (m, 1H), 3.45 (dd, J = 
9 Hz, 2 Hz, 1H). 13C{1H} NMR (125 MHz, CDCl3): δ 168.5, 149.4, 143.3, 140.0, 134.9, 132.3, 
131.3, 129.4, 129.3, 129.2, 128.7, 128.1, 127.5, 125.8, 124.9, 123.9, 99.3, 53.7, 49.0, 39.9. IR (cm–
1): 3059, 2922, 1752, 1332, 1164, 753, 735. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for 
C24H18O2SNa, 393.0925; found, 393.0910. HPLC: (1% isopropanol/hexane, OD-H): major 
enantiomer: 30.0 min; minor enantiomer: 34.9 min, 35% ee (Table 4.4, entry 8). Specific optical 
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rotation was measured using a sample with 69% ee (see entry 6 in Table 4.4): [α]D
26 = +12.1° (c = 
0.667, CHCl3). 
Aminolysis of 4.100a  
 
In order to determine its absolute configuration, tricycle 4.100a (56 mg, 0.182 mmol, 1.0 equiv) 
was subjected to aminolysis with benzylamine (30 μL, 0.27 mmol, 1.5 equiv) in 900 μL of 
CH2Cl2 (20 h at rt). The reaction mixture was washed successively with 1 M aqueous HCl, 
water, and brine. The organic phase was dried over Na2SO4 and concentrated under reduced 
pressure to yield almost pure product, which was recrystallized from a 1:1 CH2Cl2/hexanes 
mixture. The product was isolated as a colorless, crystalline solid (66 mg, 0.16 mmol, 87% 
yield). 1H NMR (500 MHz, CDCl3): δ 7.45–7.21 (m, 13H), 7.11–7.07 (m, 1H), 5.90 (br s, 1H), 
5.10 (d, J = 7 Hz, 1H), 4.35 (dd, J = 15 Hz, 6 Hz, 1H), 4.24 (dd, J = 15 Hz, 5 Hz, 1H), 4.01–3.95 
(m, 1H), 3.23 (dd, J = 8 Hz, 7 Hz, 1H), 3.01 (dd, J = 19 Hz, 10 Hz, 1H), 2.63 (dd, J = 19 Hz, 5 
Hz, 1H), 2.01 (s, 3H). 13C{1H} NMR (125 MHz, CDCl3): δ 207.9, 171.7, 144.3, 141.8, 138.1, 
134.6, 132.0, 129.1, 128.8, 128.4, 128.1, 127.8, 127.7, 127.4, 125.2, 123.7, 56.5, 54.0, 45.7, 43.9, 
41.3, 30.3. IR (cm–1): 3306, 3023, 2924, 1703, 1641, 1525, 1360, 1234, 1211, 748, 738, 693. 





4.9 X-ray crystal structure of 4.100a-BnNH2 
Table 4.5.  Crystal data and structure refinement for 4.100a-BnNH2. 
Identification code  v22219t5/lt/venture/Straub-Birman 
Empirical formula  C26 H25 N O2 S 
Formula weight  415.53 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.0234(2) Å a= 82.3574(16)°. 
 b = 9.9548(4) Å b= 83.6826(18)°. 
 c = 10.9540(5) Å g = 83.417(2)°. 
Volume 536.83(4) Å3 
Z 1 
Density (calculated) 1.285 Mg/m3 
Absorption coefficient 1.510 mm-1 
F(000) 220 
Crystal size 0.298 x 0.124 x 0.091 mm3 
Theta range for data collection 4.505 to 72.223°. 
Index ranges -6≤h≤6, -12≤k≤12, -13≤l≤13 
Reflections collected 19886 
Independent reflections 6011 [R(int) = 0.043] 
Completeness to theta = 67.679° 99.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7536 and 0.6038 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6011 / 3 / 273 
Goodness-of-fit on F2 1.078 
Final R indices [I>2sigma(I)] R1 = 0.0320, wR2 = 0.0862 
R indices (all data) R1 = 0.0322, wR2 = 0.0864 
Absolute structure parameter -0.016(10) 




Table 4.6.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for 4.100a-BnNH2.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
______________________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________________ 
S(1) 4014(1) 2587(1) 4483(1) 26(1) 
O(1) 5214(5) 6308(2) 5621(2) 20(1) 
O(2) 1208(4) 6582(2) 8477(2) 35(1) 
N(1) 751(5) 6404(2) 5522(2) 17(1) 
C(1) 5320(5) 3345(3) 5705(2) 18(1) 
C(2) 3122(5) 4269(2) 6395(2) 17(1) 
C(3) 3739(5) 4044(3) 7790(2) 18(1) 
C(4) 5470(6) 2692(3) 7871(3) 20(1) 
C(5) 6335(6) 1910(3) 8937(3) 28(1) 
C(6) 8087(7) 746(3) 8814(3) 33(1) 
C(7) 8977(7) 357(3) 7650(3) 34(1) 
C(8) 8127(6) 1130(3) 6593(3) 27(1) 
C(9) 6364(5) 2306(3) 6716(2) 20(1) 
C(10) 3108(5) 5744(2) 5804(2) 16(1) 
C(11) 509(5) 7869(3) 5111(2) 20(1) 
C(12) 1433(5) 8254(3) 3762(3) 19(1) 
C(13) 3287(6) 9209(3) 3430(3) 26(1) 
C(14) 4041(7) 9624(3) 2187(3) 33(1) 
C(15) 2978(7) 9087(3) 1273(3) 31(1) 
C(16) 1165(8) 8117(3) 1600(3) 32(1) 
C(17) 375(6) 7713(3) 2837(3) 26(1) 
C(18) 5960(6) 3297(3) 3143(3) 23(1) 
C(19) 5292(7) 4635(3) 2631(3) 29(1) 
C(20) 6833(8) 5190(4) 1606(3) 38(1) 
C(21) 9034(8) 4417(4) 1075(3) 41(1) 
C(22) 9673(8) 3086(4) 1579(3) 42(1) 
C(23) 8145(7) 2516(3) 2621(3) 31(1) 
C(24) 5263(5) 5118(3) 8221(2) 20(1) 
C(25) 3642(6) 6484(3) 8329(3) 22(1) 
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Table 4.7.   Bond lengths [Å] and angles [°] for 4.100a-BnNH2. 
_____________________________________________________  
S(1)-C(18)  1.782(3) 
S(1)-C(1)  1.835(3) 
O(1)-C(10)  1.239(4) 
O(2)-C(25)  1.210(4) 
N(1)-C(10)  1.333(4) 
N(1)-C(11)  1.464(3) 
N(1)-H(1)  0.8800 
C(1)-C(9)  1.506(4) 
C(1)-C(2)  1.550(4) 
C(1)-H(1A)  1.0000 
C(2)-C(10)  1.524(3) 
C(2)-C(3)  1.574(4) 
C(2)-H(2)  1.0000 
C(3)-C(4)  1.514(4) 
C(3)-C(24)  1.535(4) 
C(3)-H(3)  1.0000 
C(4)-C(9)  1.384(4) 
C(4)-C(5)  1.397(4) 
C(5)-C(6)  1.385(4) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.394(5) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.383(5) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.397(4) 
C(8)-H(8)  0.9500 
C(11)-C(12)  1.511(4) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(17)  1.389(4) 
C(12)-C(13)  1.393(4) 
C(13)-C(14)  1.394(4) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.377(5) 
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C(14)-H(14)  0.9500 
C(15)-C(16)  1.388(5) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.389(4) 
C(16)-H(16)  0.9500 
C(17)-H(17)  0.9500 
C(18)-C(23)  1.386(4) 
C(18)-C(19)  1.394(4) 
C(19)-C(20)  1.381(5) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.392(6) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.382(6) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.396(5) 
C(22)-H(22)  0.9500 
C(23)-H(23)  0.9500 
C(24)-C(25)  1.514(4) 
C(24)-H(24A)  0.9900 
C(24)-H(24B)  0.9900 
C(25)-C(26)  1.492(4) 
C(26)-H(26A)  0.9800 
C(26)-H(26B)  0.9800 
































































































































Table 4.8.   Anisotropic displacement parameters (Å2x 103) for 4.100a-BnNH2.  The 
anisotropicdisplacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S(1) 31(1)  29(1) 22(1)  -6(1) -1(1)  -14(1) 
O(1) 13(1)  21(1) 26(1)  1(1) -3(1)  -3(1) 
O(2) 18(1)  36(1) 50(1)  -13(1) -2(1)  6(1) 
N(1) 13(1)  18(1) 20(1)  1(1) -2(1)  -2(1) 
C(1) 18(1)  18(1) 18(1)  -2(1) -3(1)  -3(1) 
C(2) 14(1)  18(1) 17(1)  0(1) -2(1)  -3(1) 
C(3) 15(1)  22(1) 17(1)  1(1) -1(1)  -1(1) 
C(4) 17(1)  19(1) 24(1)  2(1) -2(1)  -3(1) 
C(5) 29(2)  27(1) 25(1)  6(1) -6(1)  -5(1) 
C(6) 32(2)  27(2) 37(2)  12(1) -12(2)  -1(1) 
C(7) 32(2)  21(1) 46(2)  0(1) -9(2)  6(1) 
C(8) 26(2)  19(1) 34(2)  -4(1) -1(1)  0(1) 
C(9) 18(1)  18(1) 23(1)  1(1) -2(1)  -4(1) 
C(10) 15(1)  17(1) 15(1)  -1(1) -3(1)  0(1) 
C(11) 19(1)  15(1) 24(1)  -2(1) -2(1)  3(1) 
C(12) 16(1)  16(1) 23(1)  -1(1) -2(1)  2(1) 
C(13) 26(2)  23(1) 30(2)  -1(1) -5(1)  -5(1) 
C(14) 34(2)  28(2) 36(2)  6(1) -1(1)  -12(1) 
C(15) 35(2)  30(1) 26(2)  3(1) 2(1)  -1(1) 
C(16) 40(2)  33(2) 25(1)  -3(1) -8(1)  -6(1) 
C(17) 28(1)  24(1) 27(1)  0(1) -4(1)  -8(1) 
C(18) 22(1)  31(2) 18(1)  -6(1) -3(1)  -8(1) 
C(19) 33(2)  29(2) 25(1)  -4(1) -4(1)  -5(1) 
C(20) 49(2)  42(2) 25(2)  2(1) -11(2)  -20(2) 
C(21) 40(2)  68(2) 20(2)  -6(2) -2(2)  -26(2) 
C(22) 26(2)  69(3) 32(2)  -20(2) 2(2)  -3(2) 
C(23) 27(2)  39(2) 29(2)  -10(1) -5(1)  0(1) 
C(24) 16(1)  24(1) 18(1)  -3(1) -4(1)  2(1) 
C(25) 20(1)  29(1) 19(1)  -7(1) -5(1)  4(1) 
C(26) 26(2)  26(1) 40(2)  -13(1) -7(1)  5(1) 
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Table 4.9.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 4.100a-BnNH2. 
______________________________________________________________________________ 
 x  y  z  U(eq) 
______________________________________________________________________________ 
H(1) -676 5953 5584 21 
H(1A) 6806 3900 5327 22 
H(2) 1326 3952 6339 20 
H(3) 2022 3947 8335 22 
H(5) 5732 2172 9732 33 
H(6) 8689 206 9532 40 
H(7) 10176 -446 7582 41 
H(8) 8731 867 5798 32 
H(11A) 1574 8315 5620 24 
H(11B) -1399 8235 5265 24 
H(13) 4041 9579 4054 31 
H(14) 5296 10281 1968 40 
H(15) 3482 9378 426 38 
H(16) 461 7727 974 38 
H(17) -897 7064 3051 31 
H(19) 3781 5164 2986 35 
H(20) 6388 6106 1262 45 
H(21) 10091 4801 370 49 
H(22) 11166 2555 1213 50 
H(23) 8598 1602 2968 37 
H(24A) 5892 4757 9038 24 
H(24B) 6877 5260 7632 24 
H(26A) 6111 7872 7442 46 
H(26B) 6531 7491 8879 46 
















































































Table 4.11.  Hydrogen bonds for 4.100a-BnNH2 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1)...O(1)#1 0.88 2.05 2.783(3) 140.0 
 C(26)-H(26B)...O(2)#2 0.98 2.43 3.115(4) 126.2 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x-1,y,z    #2 x+1,y,z       
 





4.10 X-ray crystal structure of 4.100b 
Table 4.12.  Crystal data and structure refinement for 4.100b. 
Identification code  v21019/lt/venture/Straub-Birman 
Empirical formula  C24 H18 O2 S 
Formula weight  370.44 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 8.7451(4) Å a= 90°. 
 b = 5.0040(2) Å b= 95.527(2)°. 
 c = 21.5160(9) Å g = 90°. 
Volume 937.17(7) Å3 
Z 2 
Density (calculated) 1.313 Mg/m3 
Absorption coefficient 1.653 mm-1 
F(000) 388 
Crystal size 0.400 x 0.033 x 0.027 mm3 
Theta range for data collection 2.063 to 74.578°. 
Index ranges -10≤h≤10, -5≤k≤6, -26≤l≤26 
Reflections collected 18969 
Independent reflections 3783 [R(int) = 0.0548] 
Completeness to theta = 67.679° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.6627 and 0.5127 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3783 / 1 / 244 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0315, wR2 = 0.0818 
R indices (all data) R1 = 0.0352, wR2 = 0.0834 
Absolute structure parameter 0.019(11) 




Table 4.13.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for 4.100b.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________
 x y z U(eq) 
______________________________________________________________________________ 
S(1) 4489(1) 5844(1) 1189(1) 27(1) 
O(1) 6947(2) 2768(3) 3396(1) 25(1) 
O(2) 7189(2) 613(4) 2528(1) 24(1) 
C(1) 6664(2) 2531(5) 2767(1) 20(1) 
C(2) 5785(2) 4736(4) 2407(1) 19(1) 
C(3) 4604(2) 6103(5) 2788(1) 21(1) 
C(4) 5161(3) 6333(5) 3466(1) 23(1) 
C(5) 6269(3) 4789(5) 3732(1) 21(1) 
C(6) 4837(3) 3503(5) 1833(1) 21(1) 
C(7) 3308(2) 2958(5) 2084(1) 21(1) 
C(8) 2127(3) 1282(5) 1841(1) 27(1) 
C(9) 828(3) 1043(6) 2165(1) 30(1) 
C(10) 717(3) 2466(6) 2716(1) 31(1) 
C(11) 1886(3) 4169(5) 2950(1) 26(1) 
C(12) 3188(2) 4402(5) 2631(1) 21(1) 
C(13) 6917(3) 4783(5) 4393(1) 22(1) 
C(14) 6407(3) 6618(6) 4814(1) 34(1) 
C(15) 6992(3) 6605(6) 5436(1) 35(1) 
C(16) 8104(3) 4782(6) 5647(1) 32(1) 
C(17) 8627(4) 2953(6) 5238(1) 40(1) 
C(18) 8030(3) 2939(6) 4611(1) 33(1) 
C(19) 6331(3) 6563(5) 957(1) 25(1) 
C(20) 7675(3) 5191(5) 1162(1) 27(1) 
C(21) 9061(3) 5965(6) 950(1) 31(1) 
C(22) 9120(3) 8045(6) 533(1) 32(1) 
C(23) 7782(3) 9380(6) 323(1) 35(1) 






Table 4.14.   Bond lengths [Å] and angles [°] for 4.100b. 
_____________________________________________________  
S(1)-C(19)  1.769(3) 
S(1)-C(6)  1.818(2) 
O(1)-C(1)  1.359(3) 
O(1)-C(5)  1.407(3) 
O(2)-C(1)  1.200(3) 
C(1)-C(2)  1.515(3) 
C(2)-C(3)  1.540(3) 
C(2)-C(6)  1.546(3) 
C(2)-H(2)  1.0000 
C(3)-C(4)  1.496(3) 
C(3)-C(12)  1.514(3) 
C(3)-H(3)  1.0000 
C(4)-C(5)  1.326(3) 
C(4)-H(4)  0.9500 
C(5)-C(13)  1.478(3) 
C(6)-C(7)  1.514(3) 
C(6)-H(6)  1.0000 
C(7)-C(8)  1.393(3) 
C(7)-C(12)  1.395(3) 
C(8)-C(9)  1.394(3) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.395(4) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.388(4) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.389(3) 
C(11)-H(11)  0.9500 
C(13)-C(18)  1.390(4) 
C(13)-C(14)  1.394(4) 
C(14)-C(15)  1.385(4) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.378(4) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.378(4) 
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C(16)-H(16)  0.9500 
C(17)-C(18)  1.398(4) 
C(17)-H(17)  0.9500 
C(18)-H(18)  0.9500 
C(19)-C(24)  1.395(3) 
C(19)-C(20)  1.396(3) 
C(20)-C(21)  1.390(3) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.379(4) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.385(4) 
C(22)-H(22)  0.9500 
C(23)-C(24)  1.385(4) 
C(23)-H(23)  0.9500 



































































































Table 4.15.   Anisotropic displacement parameters (Å2x 103) for 4.100b.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S(1) 26(1)  34(1) 22(1)  5(1) 3(1)  6(1) 
O(1) 26(1)  24(1) 24(1)  -2(1) -1(1)  6(1) 
O(2) 18(1)  22(1) 32(1)  -4(1) 2(1)  1(1) 
C(1) 13(1)  22(1) 25(1)  -1(1) 4(1)  -5(1) 
C(2) 18(1)  18(1) 22(1)  0(1) 4(1)  -2(1) 
C(3) 20(1)  19(1) 24(1)  0(1) 4(1)  2(1) 
C(4) 21(1)  24(1) 25(1)  -2(1) 5(1)  1(1) 
C(5) 19(1)  18(1) 25(1)  -1(1) 5(1)  -4(1) 
C(6) 21(1)  21(1) 22(1)  1(1) 1(1)  1(1) 
C(7) 16(1)  22(1) 25(1)  4(1) 1(1)  2(1) 
C(8) 23(1)  26(1) 30(1)  -1(1) -4(1)  2(1) 
C(9) 18(1)  32(1) 39(1)  4(1) -5(1)  -2(1) 
C(10) 17(1)  42(2) 33(1)  7(1) 2(1)  0(1) 
C(11) 19(1)  33(1) 25(1)  4(1) 3(1)  2(1) 
C(12) 18(1)  22(1) 23(1)  3(1) -1(1)  2(1) 
C(13) 20(1)  23(1) 25(1)  2(1) 4(1)  -6(1) 
C(14) 31(1)  40(2) 32(1)  -8(1) -2(1)  4(1) 
C(15) 32(1)  44(2) 29(1)  -9(1) 2(1)  -5(1) 
C(16) 34(1)  37(1) 23(1)  1(1) -2(1)  -12(1) 
C(17) 47(2)  38(2) 32(1)  2(1) -7(1)  7(1) 
C(18) 37(1)  33(1) 27(1)  1(1) 0(1)  5(1) 
C(19) 32(1)  26(1) 18(1)  -3(1) 5(1)  1(1) 
C(20) 34(1)  24(1) 25(1)  2(1) 9(1)  5(1) 
C(21) 33(1)  31(1) 32(1)  0(1) 10(1)  5(1) 
C(22) 38(1)  34(1) 26(1)  -2(1) 11(1)  -5(1) 
C(23) 44(2)  36(2) 25(1)  8(1) 4(1)  -6(1) 





Table 4.16.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 4.100b. 
______________________________________________________________________________ 
 x  y  z  U(eq) 
______________________________________________________________________________ 
H(2) 6517 6094 2267 23 
H(3) 4397 7939 2617 25 
H(4) 4706 7628 3713 28 
H(6) 5318 1817 1696 25 
H(8) 2205 326 1464 32 
H(9) 12 -99 2009 36 
H(10) -170 2267 2934 37 
H(11) 1798 5158 3322 31 
H(14) 5648 7896 4673 41 
H(15) 6624 7858 5718 42 
H(16) 8508 4787 6073 38 
H(17) 9396 1699 5382 48 
H(18) 8387 1659 4333 39 
H(20) 7644 3738 1445 33 
H(21) 9979 5050 1095 38 
H(22) 10072 8558 390 39 
H(23) 7817 10799 31 42 

























































































Table 4.18.  Hydrogen bonds for 4.100b [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2)...O(2)#1 1.00 2.39 3.188(3) 136.2 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x,y+1,z      
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A.1 Isodesmic study: An attempt to elucidate the 
spontaneous ring closure of 3.44m-Me 
 
An isodesmic study of the hypothetical equation above was performed to study and compare the 
thermodynamic preferences of isoxazolidinones and their ring opened methyl esters. Geometry 
optimization of the isoxazolidinones and methyl esters (R = H, Me, Et, i-Pr, and t-Bu) was 
performed in Spartan ’16 (Wavefunction, Inc.) at the B3LYP/6-31G* level of theory using a gas 
phase model. The results are shown in the Table A.1 below. Results show that as the steric bulk 
of R increases, ∆H rel becomes more negative. This suggests that the ring closed form is more 
thermodynamically favored to the ring opened form as R increases in size.  
Table A.1. Results of isodesmic study. 










































A.2 Kinetic data for 5-aryl DHIP derivatives 
 
A published procedure was followed.10 Each catalyst was tested in duplicate in the 
rearrangement of thioester 4.53a. Procedure: 0.0675 mmol of thioester (25 mg) was dissolved in 
575 μL of CDCl3. Then, 100 μL of 0.068 M catalyst in CDCl3 (0.0068 mmol, 10 mol %) was 
added to create a final volume of 675 μL (0.1 M in thioester). The contents were very quickly 
mixed and the reaction was analyzed by 1H NMR. The conversions were calculated by 
comparing the integrations of starting material and product peaks. The results are summarized in 










Table A.2. Conversion data obtained for catalyst 4.59b. 
Time (minutes) % conversion (Run 1) % conversion (Run 2) 
Average 
conversion Error 
2.5 14.38 14.18 14.28 0.1 
4 18.45 19.31 18.88 0.43 
5 22.17 21.6 21.89 0.29 
6 26.39 25.38 25.89 0.51 
7 28.9 28.33 28.62 0.29 
8 32.05 31.06 31.56 0.5 
9 33.78 33.67 33.73 0.06 
10 36.76 36.63 36.7 0.07 
12 41.84 40.82 41.33 0.51 
13 44.44 43.67 44.06 0.39 
14 46.08 44.84 45.46 0.62 
15 48.78 48.31 48.55 0.24 
17 51.55 51.55 51.55 0 
19 54.95 55.25 55.1 0.15 
20 57.8 57.14 57.47 0.33 
22 60.61 59.52 60.07 0.55 
24 63.69 63.29 63.49 0.2 
26 65.79 66.67 66.23 0.44 
28 68.03 68.49 68.26 0.23 
30 70.42 69.93 70.18 0.25 
33 74.63 74.07 74.35 0.28 
36 75.76 75.76 75.76 0 
39 78.74 77.52 78.13 0.61 
42 80 79.37 79.69 0.32 
45 83.33 81.97 82.65 0.68 
50 84.75 84.03 84.39 0.36 
55 87.72 86.21 86.97 0.76 









Table A.3. Conversion data obtained for catalyst 4.59c. 
Time (minutes) % conversion (Run 1) % conversion (Run 2) Average 
conversion 
Error 
3 17.51 17.99 17.75 0.24 
5 24.1 23.64 23.87 0.23 
6 27.32 26.53 26.93 0.4 
7 30.58 29.85 30.22 0.37 
8 33.11 33 33.06 0.06 
9 36.36 36.1 36.23 0.13 
10 39.37 38.02 38.7 0.68 
12 44.05 43.48 43.77 0.29 
13 46.95 46.08 46.52 0.44 
14 49.26 48.54 48.9 0.36 
15 51.28 50.76 51.02 0.26 
17 55.87 54.05 54.96 0.91 
19 59.17 58.14 58.66 0.52 
20 60.98 60.24 60.61 0.37 
22 63.69 63.69 63.69 0 
24 66.67 67.11 66.89 0.22 
26 68.97 68.97 68.97 0 
28 70.92 71.94 71.43 0.51 
30 74.07 74.07 74.07 0 
33 75.76 76.92 76.34 0.58 
36 78.74 78.74 78.74 0 
39 81.3 80.65 80.98 0.33 
42 82.64 82.64 82.64 0 
45 84.03 84.75 84.39 0.36 
50 85.47 86.96 86.22 0.74 
55 88.5 88.5 88.5 0 
60 90.09 90.09 90.09 0 
 
The t1/2 values were calculated by choosing the two data points that 50 % conversion lay in 
between (these are highlighted in yellow in Tables A.1 and A.2 above). These two data points 
were plotted for each catalyst and the linear regression line was used to calculate the t1/2 value 
(see Figures A.1 and A.2 below). While this method of calculation assumes a linear correlation 





Figure A.1. Linear regression for Catalyst 4.59b. 
Thus, when y = 50% conversion, x = 16 minutes. 
 
Figure A.2. Linear regression for catalyst 4.59c. 
Thus, when y = 50% conversion, x = 14.5 minutes. 
 
























Linear regression for Catalyst 4.59b




























































































Reaction with catalyst DHPB 2.48a 
 
Peak# Ret. Time Area Height Area% 
1 18.179 19537258 92719 48.091 
2 33.001 21088265 70320 51.909 
Total   40625523 163039 100 
 
Reaction with catalyst 2.30 (Table 2.2, entry 1)  
 
Peak# Ret. Time Area Height Area% 
1 18.322 2612016 13432 0.421 
2 31.397 6.17E+08 1814444 99.579 
























































Reaction with catalyst 2.31c (Table 2.2, entry 2) 
 
Peak# Ret. Time Area Height Area% 
1 17.236 19736273 92725 99.984 
2 33.754 3238 37 0.016 
Total   19739510 92762 100 
 
Reaction with catalyst 2.31a (Table 2.2, entry 3) 
 
Peak# Ret. Time Area Height Area% 
1 17.213 26542867 128138 99.492 
2 39.016 135629 647 0.508 
























































Reaction with 2.31b (Table 2.2, entry 4)  
 
Peak# Ret. Time Area Height Area% 
1 17.256 674012 3549 0.126 
2 31.667 5.34E+08 1548451 99.874 
Total   5.34E+08 1552000 100 
 
Reaction with 2.31b (Table 2.2, entry 8) 
 
Peak# Ret. Time Area Height Area% 
1 19.975 46286 320 0.291 
2 32.304 15851440 49999 99.709 


























































Reaction with catalyst 2.31b (Table 2.2, entry 9)   
 
Peak# Ret. Time Area Height Area% 
1 18.454 761260 4980 0.447 
2 32.795 1.69E+08 534832 99.553 
Total   1.7E+08 539811 100 
 
Reaction with catalyst 2.31b (Table 2.2, entry 10) 
 
Peak# Ret. Time Area Height Area% 
1 18.982 1062185 7898 0.785 
2 33.742 1.34E+08 449095 99.215 

































































2.51a-OMe (Table 2.2, entry 5) 
 
Peak# Ret. Time Area Height Area% 
1 30.88 26157539 140162 49.663 
2 47.256 26512154 105498 50.337 
Total   52669692 245660 100 
 
 
Peak# Ret. Time Area Height Area% 
1 30.954 74565606 385418 98.08 
2 42.072 1460035 6972 1.92 


























































2.51a-NHBn (Table 2.2, entry 6) 
 
 
Peak# Ret. Time Area Height Area% 
1 19.214 31812120 243133 50.298 
2 24.491 31434603 209289 49.702 
Total   63246723 452422 100 
 
 
Peak# Ret. Time Area Height Area% 
1 17.465 729624 7430 1.039 
2 24.452 69524581 415400 98.961 
























































2.51a-NEt2                                       (Table 2.2, entry 7) 
 
Peak# Ret. Time Area Height Area% 
1 15.659 13829271 107060 50.267 
2 25.843 13682126 95236 49.733 
Total   27511397 202297 100 
 
 
Peak# Ret. Time Area Height Area% 
1 16.969 31575 1000 0.092 
2 25.654 34191197 238384 99.908 




























































2.51b-OBn   (Table 2.3, entry 2) 
 
 
Peak# Ret. Time Area Height Area% 
1 31.082 3016518 9133 52.819 
2 59.699 2694544 5144 47.181 
Total   5711062 14277 100 
 
 
Peak# Ret. Time Area Height Area% 
1 29.964 170756 434 0.138 
2 55.491 123742048 197289 99.862 


























































2.51c-OBn (Table 2.3, entry 3) 
 
 
Peak# Ret. Time Area Height Area% 
1 29.164 5659186 35122 50.824 
2 42.768 5475722 26161 49.176 
Total   11134908 61283 100 
 
 
Peak# Ret. Time Area Height Area% 
1 27.531 2081685 16799 2.396 
2 41.317 84809008 348442 97.604 


























































2.51d-OBn   (Table 2.3, entry 5) 
 
 
Peak# Ret. Time Area Height Area% 
1 39.41 39273261 155484 50.357 
2 57.834 38716174 101280 49.643 
Total   77989435 256765 100 
 
 
Peak# Ret. Time Area Height Area% 
1 39.508 78564203 290755 99.931 
2 59.75 54302 765 0.069 























































2.51e-OBn  (Table 2.3, entry 6) 
 
 
Peak# Ret. Time Area Height Area% 
1 27.294 22301803 128520 50.603 
2 38.286 21770214 85582 49.397 
Total   44072017 214102 100 
 
 
Peak# Ret. Time Area Height Area% 
1 27.291 61274147 349427 99.741 
2 38.832 158929 1259 0.259 























































2.51f-OBn (Table 2.3, entry 7) 
 
 
Peak# Ret. Time Area Height Area% 
1 33.74 34854387 251141 50.771 
2 45.577 33796160 146151 49.229 




Peak# Ret. Time Area Height Area% 
1 33.088 163089305 1112407 98.782 
2 52.195 2010888 11085 1.218 
























































2.51g-OBn  (Table 2.3, entry 8) 
 
Peak# Ret. Time Area Height Area% 
1 36.236 3434379 17936 51.738 
2 48.578 3203646 12628 48.262 
Total  6638025 30564 100 
 
 
Peak# Ret. Time Area Height Area% 
1 36.173 504467 2364 99.976 
2 46.342 123 8 0.024 

























































Peak# Ret. Time Area Height Area% 
1 37.512 65972760 294434 49.883 
2 55.852 66281978 207923 50.117 
Total  132254738 502357 100 
 
 
Peak# Ret. Time Area Height Area% 
1 36.912 218936 1778 0.583 
2 55.157 37359961 118785 99.417 






















































2.51i-OBn  (Table 2.3, entry 10) 
 
 
Peak# Ret. Time Area Height Area% 
1 18.86 17982890 67960 51.353 
2 34.08 17035283 49787 48.647 
Total   35018173 117747 100 
 
 
Peak# Ret. Time Area Height Area% 
1 18.509 956430 5868 0.483 
2 33.016 197062356 642349 99.517 

























































2.51j-OBn  (Table 2.3, entry 11) 
 
 
Peak# Ret. Time Area Height Area% 
1 36.28 3288433 18181 50.718 
2 44.808 3195369 16393 49.282 
Total   6483802 34574 100 
 
 
Peak# Ret. Time Area Height Area% 
1 32.182 6053014 25834 13.259 
2 45.506 39599267 152520 86.741 






























































Peak# Ret. Time Area Height Area% 
1 7.266 4030886 88091 50.072 
2 10.490 4019266 66433 49.928 








Table 3.8, entry 1  
 
Peak# Ret. Time Area Height Area% 
1 7.074 1126919 23164 9.197 
2 10.071 11126691 173475 90.803 







Table 3.8, entry 1 
 
Peak# Ret. Time Area Height Area% 
1 7.061 28262006 619342 99.301 
2 10.116 198972 5202 0.699 








































































Table 3.8, entry 2  
 
Peak# Ret. Time Area Height Area% 
1 6.918 7583789 179096 10.229 
2 9.574 66554917 1063797 89.771 







Table 3.8, entry 2  
  
Peak# Ret. Time Area Height Area% 
1 6.854 72261704 1489893 99.692 
2 9.713 223327 9250 0.308 









Peak# Ret. Time Area Height Area% 
1 6.616 28092256 611495 49.798 
2 10.307 28319960 313909 50.202 










































































Table 3.8, entry 3  
Peak# Ret. Time Area Height Area% 
1 6.390 9809895 223936 21.191 
2 9.742 36483068 452120 78.809 







Table 3.8, entry 3  
Peak# Ret. Time Area Height Area% 
1 6.386 16789882 383169 99.482 
2 9.881 87395 1517 0.518 






hexanes, AD-H)  
Peak# Ret. Time Area Height Area% 
1 14.844 6776789 87795 49.931 
2 21.761 6795594 61915 50.069 
Total  13572383 149710 100.000 
Dataf ile Name:MS_04_109b_isoxtoME_7%IPA_AS_H01.lcd
Sample Name:MS_04_109b_isoxtoME_7%IPA_AS_H


































































Table 3.8, entry 4  
Peak# Ret. Time Area Height Area% 
1 14.507 2076361 26881 84.453 
2 21.364 382243 3622 15.547 







Table 3.8, entry 4 
 
Peak# Ret. Time Area Height Area% 
1 14.353 5749 105 0.686 
2 21.527 832194 7836 99.314 









Peak# Ret. Time Area Height Area% 
1 11.299 2135297 33952 49.928 
2 21.380 2141469 18287 50.072 
Dataf ile Name:MS_04_109aredo_enantioisox_5%IPA_AD_H01.lcd
Sample Name:MS_04_109aredo_enantioisox_5%IPA_AD_H











































































Table 3.8, entry 5 
 
Peak# Ret. Time Area Height Area% 
1 10.844 17655179 302586 72.157 
2 21.793 6812431 58481 27.843 







Peak# Ret. Time Area Height Area% 
1 23.304 5643838 49543 50.278 
2 30.010 5581386 39282 49.722 






Table 3.8, entry 5 
 
Peak# Ret. Time Area Height Area% 
1 21.723 10513496 94361 98.794 
2 27.714 128372 2860 1.206 
Total  10641868 97221 100.000 
Dataf ile Name:MS_04_114_enantioisox_20%IPA_AD_H01.lcd
Sample Name:MS_04_114_enantioisox_20%IPA_AD_H
















































































Peak# Ret. Time Area Height Area% 
1 6.907 7412522 202693 49.935 
2 22.947 7431735 57979 50.065 







(Table 3.8, entry 6) 
 
Peak# Ret. Time Area Height Area% 
1 7.123 3986484 107456 11.759 
2 23.375 29913966 223453 88.241 









Peak# Ret. Time Area Height Area% 
1 13.725 9294723 141482 49.267 
2 17.840 9571175 113377 50.733 
Dataf ile Name:MS_03_272_Rxnb_isoxracemate_5%IPA_AD_H01.lcd
Sample Name:MS_03_272_Rxnb_isoxracemate_5%IPA_AD_H













































































(Table 3.8, entry 
6) 
 
Peak# Ret. Time Area Height Area% 
1 13.361 1485371 23337 2.124 
2 16.999 68460040 776207 97.876 









Peak# Ret. Time Area Height Area% 
1 13.633 117057159 1466373 49.012 
2 22.222 121774914 1010228 50.988 







(Table 3.8, entry 7) 
 
Peak# Ret. Time Area Height Area% 
Datafile Name:MS_04_99a_DPMEtoME_7%IPA_AD_H01.lcd
Sample Name:MS_04_99a_DPMEtoME_7%IPA_AD_H



































































1 13.602 111060525 1418886 90.425 
2 22.070 11759777 106293 9.575 








Peak# Ret. Time Area Height Area% 
1 10.003 4540531 75644 50.537 
2 14.239 4443997 56118 49.463 







(Table 3.8, entry 
7) 
 
Peak# Ret. Time Area Height Area% 
1 9.965 10534028 187432 99.418 
2 13.552 61652 1339 0.582 







Peak# Ret. Time Area Height Area% 
1 8.163 34530360 1208388 49.922 
2 10.092 34637684 1234049 50.078 
Total  69168044 2442437 100.000 
Dataf ile Name:MS_04_23Rxnb_ME_7%IPA_AS_H01.lcd
Sample Name:MS_04_23Rxnb_ME_7%IPA_AS_H













































































Table 3.8, entry 8 
 
Peak# Ret. Time Area Height Area% 
1 7.844 86301651 2708593 69.923 
2 9.804 37121844 1295092 30.077 







Table 3.8, entry 8  
Peak# Ret. Time Area Height Area% 
1 8.095 459649 14853 0.860 
2 9.980 52971484 1776171 99.140 





hexanes, AS-H)  
Peak# Ret. Time Area Height Area% 
1 8.145 11877505 215404 50.154 
2 13.311 11804708 135219 49.846 
Total  23682212 350623 100.000 
Dataf ile Name:MS_04_104a_isoxtoME_7%IPA_OD_H01.lcd
Sample Name:MS_04_104a_isoxtoME_7%IPA_OD_H











































































Table 3.8, entry 9  
Peak# Ret. Time Area Height Area% 
1 8.181 4152865 79023 13.723 
2 13.196 26108412 362290 86.277 






Table 3.8, entry 9 
 
Peak# Ret. Time Area Height Area% 
1 8.109 43320337 800380 99.352 
2 13.361 282711 3900 0.648 







Peak# Ret. Time Area Height Area% 
1 8.551 7999208 162026 50.236 
2 12.179 7924077 117452 49.764 
Total  15923285 279478 100.000 
Dataf ile Name:MS_04_102b_isoxtoMEdiluted_7%IPA_AS_H01.lcd
Sample Name:MS_04_102b_isoxtoMEdiluted_7%IPA_AS_H








































































Table 3.8, entry 
10 
 
Peak# Ret. Time Area Height Area% 
1 8.369 1192721 25191 4.163 
2 11.604 27458719 465843 95.837 







Table 3.8, entry 
10 
 
Peak# Ret. Time Area Height Area% 
1 8.403 22056495 460001 99.081 
2 11.937 204664 4652 0.919 







Peak# Ret. Time Area Height Area% 
1 11.351 145863536 2442983 50.090 
2 18.607 145341638 1586888 49.910 
Dataf ile Name:MS_04_96b_isoxtoME_7%IPA_AS_H01.lcd
Sample Name:MS_04_96b_isoxtoME_7%IPA_AS_H















































































(Table 3.8, entry 
11) 
 
Peak# Ret. Time Area Height Area% 
1 11.273 50294585 818986 95.625 
2 18.594 2300825 26147 4.375 







Peak# Ret. Time Area Height Area% 
1 8.312 6607022 220888 50.124 
2 18.289 6574231 118174 49.876 







Table 3.8, entry 
11) 
 
Peak# Ret. Time Area Height Area% 
1 8.013 2183036 74389 3.839 
2 17.221 54687323 1039945 96.161 
Total  56870359 1114334 100.000 
Dataf ile Name:MS_04_98a_enantioisox_5%IPA_AD_H01.lcd
Sample Name:MS_04_98a_enantioisox_5%IPA_AD_H





































































Peak# Ret. Time Area Height Area% 
1 7.492 2824660 52722 50.595 
2 9.987 2758177 44354 49.405 






Table 3.8, entry 
12 
 
Peak# Ret. Time Area Height Area% 
1 7.586 9978817 181271 81.170 
2 10.107 2314917 37980 18.830 







Table 3.8, entry 
12 
 
Peak# Ret. Time Area Height Area% 
1 7.526 1111662 22546 2.749 
2 9.924 39324465 567427 97.251 
Total  40436127 589973 100.000 
Dataf ile Name:MS_04_06_Rxnc_racemicME_5%IPA_AD_H01.lcd
Sample Name:MS_04_06_Rxnc_racemicME_5%IPA_AD_H






































































Peak# Ret. Time Area Height Area% 
1 9.398 1689443 29988 49.098 
2 13.350 1751514 24011 50.902 






Table 3.8, entry 
13 
 
Peak# Ret. Time Area Height Area% 
1 9.179 54841927 900549 65.825 
2 12.850 28472318 389207 34.175 







Table 3.8, entry 
13 
 
Peak# Ret. Time Area Height Area% 
1 9.480 134668 1617 0.894 
2 12.921 14922779 209517 99.106 
Total  15057447 211135 100.000 
Dataf ile Name:MS_03_303b_racemicME_5%IPA_AD_H01.lcd
Sample Name:MS_03_303b_racemicME_5%IPA_AD_H















































































Peak# Ret. Time Area Height Area% 
1 7.089 7211617 395920 50.380 
2 16.003 7102892 237169 49.620 






(Table 3.8, entry 
14) 
 
Peak# Ret. Time Area Height Area% 
1 7.063 4256376 238606 23.555 
2 15.920 13813934 455145 76.445 







Table 3.8, entry 
14 
 
Peak# Ret. Time Area Height Area% 
1 9.324 353050 7657 1.163 
2 12.863 29990917 392883 98.837 
Total  30343967 400540 100.000 
Dataf ile Name:MS_03_273_Rxna_isoxracemate_5%IPA_OD_H01.lcd
Sample Name:MS_03_273_Rxna_isoxracemate_5%IPA_OD_H












































































(Table 3.8, entry 
15) 
 
Peak# Ret. Time Area Height Area% 
1 6.958 21323408 1126104 21.272 
2 14.852 78920462 1532470 78.728 







Table 3.8, entry 
15 
 
Peak# Ret. Time Area Height Area% 
1 9.323 194116 3088 1.910 
2 12.980 9968128 132980 98.090 







Peak# Ret. Time Area Height Area% 
1 30.491 21636625 117013 50.000 
2 41.911 21636456 102501 50.000 
Total  43273081 219514 100.000 
Dataf ile Name:MS_04_103b_pureisox_5%IPA_OD_H01.lcd
Sample Name:MS_04_103b_pureisox_5%IPA_OD_H
















































































Peak# Ret. Time Area Height Area% 
1 17.590 33352608 384253 50.264 
2 25.473 33002599 266574 49.736 






(Table 3.8, entry 
19) 
 
Peak# Ret. Time Area Height Area% 
1 30.108 637458 5600 3.356 
2 38.830 18355333 95663 96.644 







Table 3.8, entry 19 
 
Peak# Ret. Time Area Height Area% 
1 16.790 71593867 815621 89.031 
2 24.115 8820954 76775 10.969 
Total  80414821 892395 100.000 
Dataf ile Name:MS_03_206bredo_transME_10%IPA_AD_H01.lcd
Sample Name:MS_03_206bredo_transME_10%IPA_AD_H















































































(Table 3.8, entry 
20) 
 
Peak# Ret. Time Area Height Area% 
1 29.614 9936592 64818 5.967 
2 39.046 156585274 602808 94.033 







Table S3.8 entry 20 
 
Peak# Ret. Time Area Height Area% 
1 16.259 72406654 794576 93.263 
2 23.294 5230489 44254 6.737 






(Table 3.8, entry 
21) 
 
Peak# Ret. Time Area Height Area% 
1 29.534 10143270 65289 6.633 
2 38.943 142785787 569648 93.367 
Dataf ile Name:MS_04_111a_enantioisox_15%IPA_AS_H01.lcd
Sample Name:MS_04_111a_enantioisox_15%IPA_AS_H











































































(Table 3.8, entry 
21) 
 
Peak# Ret. Time Area Height Area% 
1 16.220 36334916 412247 94.676 
2 23.295 2043159 18127 5.324 











































With catalyst DHIP 4.59a  
 
Peak# Ret. Time Area Height Area% 
1 38.273 2004875 15564 48.334 
2 43.69 2143115 14653 51.666 
Total  4147989 30218 100 
 
With catalyst 4.54 (Figure 4.16) 
 
Peak# Ret. Time Area Height Area% 
1 37.25 478894 3866 23.15 
2 42.231 1589788 10369 76.85 


























Dataf ile Name:MS_03_131_w ithHPIP_point5%IPA_point7mLmin_oldODH01.lcd
Sample Name:MS_03_131_w ithHPIP_point5%IPA_point7mLmin_oldODH



























With catalyst 4.69 (Figure 4.16) 
 
Peak# Ret. Time Area Height Area% 
1 38.281 1806748 13149 34.104 
2 43.367 3490995 22180 65.896 
Total  5297743 35328 100 
 
With catalyst 4.81 (Figure 4.16) 
 
Peak# Ret. Time Area Height Area% 
1 37.734 845452 6684 25.044 
2 42.962 2530477 16068 74.956 






























































Peak# Ret. Time Area Height Area% 
1 7.459 2376750 166683 49.026 
2 8.554 2471160 240385 50.974 
Total  4847909 407068 100.000 
 
(S)-4.90  





Peak# Ret. Time Area Height Area% 
1 6.883 156832 10999 2.031 
2 7.833 7564420 347025 97.969 
Total  7721253 358024 100.000 
 
(±)-4.92  
Table 4.3, entry 1 
with DHPB 4.56a  
 
 
Peak# Ret. Time Area Height Area% 
1 9.594 8144423 342721 49.994 
2 11.576 8146351 411249 50.006 









































































Peak# Ret. Time Area Height Area% 
1 12.047 23816300 1098606 97.196 
2 14.871 687180 36923 2.804 
Total  24503480 1135528 100.000 
 
(±)-4.100a  
Table 4.4, entry 1 
with DHPB 4.56a 
 
Peak# Ret. Time Area Height Area% 
1 12.155 66956565 1345344 50.050 
2 19.107 66821953 858497 49.950 
Total  133778518 2203842 100.000 
 
(R)-4.100a  




Peak# Ret. Time Area Height Area% 
1 11.889 1674949 29525 16.643 
2 18.614 8388747 96793 83.357 




















































































Peak# Ret. Time Area Height Area% 
1 12.233 16248476 296709 61.334 
2 19.228 10243160 130263 38.666 
Total  26491636 426972 100.000 
 
(R)-4.100a  




Peak# Ret. Time Area Height Area% 
1 12.094 453445 9615 6.037 
2 18.987 7057550 88554 93.963 
Total  7510996 98169 100.000 
 
(±)-4.100b  
Table 4.4, entry 2 
with DHPB 4.56a 
 
Peak# Ret. Time Area Height Area% 
1 37.617 25894316 356101 50.344 
2 40.438 25540532 285918 49.656 































Dataf ile Name:MS_03_241_methylw HPIPatzerodeg_2%IPA_AD_H01.lcd
Sample Name:MS_03_241_methylw HPIPatzerodeg_2%IPA_AD_H



















































Peak# Ret. Time Area Height Area% 
1 28.900 1699800 29018 42.125 
2 34.598 2335331 30998 57.875 
Total  4035131 60015 100.000 
 
(S)-4.100b  




Peak# Ret. Time Area Height Area% 
1 31.434 9827826 155622 84.504 
2 36.270 1802150 24180 15.496 
Total  11629977 179803 100.000 
 
(S)-4.100b  




Peak# Ret. Time Area Height Area% 
1 30.013 145748772 2178280 67.361 
2 34.905 70619990 840205 32.639 




































































































































































































































   
 
3.43h 
3.43h 
269 
 
 
 
 
3.43i 
3.43i 
270 
 
 
 
 
3.43m 
3.43m 
271 
 
 
 
3.44a-Me 
3.44a-Me 
272 
 
 
 
 
 
273 
 
 
 
3.44a-Allyl 
3.44a-Allyl 
274 
 
 
 
3.44a-Bzh 
3.44a-Bzh 
275 
 
 
 
3.44b-Me 
3.44b-Me 
276 
 
 
 
3.44b-Bzh 
3.44b-Bzh 
277 
 
 
 
3.44c-Me 
3.44c-Me 
278 
 
 
 
3.44c-Bzh 
3.44c-Bzh 
279 
 
 
 
3.44d-Me 
3.44d-Me 
280 
 
 
 
3.44d-Bzh 
3.44d-Bzh 
281 
 
 
 
3.44f-Me 
3.44f-Me 
282 
 
 
 
3.44f-Bzh 
3.44f-Bzh 
283 
 
 
 
3.44e-Me 
3.44e-Me 
284 
 
 
 
3.44e-Bzh 
3.44e-Bzh 
285 
 
 
 
3.44g-Me 
3.44g-Me 
286 
 
 
 
3.44g-Bzh 
3.44g-Bzh 
287 
 
 
 
3.44h-Me 
3.44h-Me 
288 
 
 
 
3.44h-Bzh 
3.44h-Bzh 
289 
 
 
 
3.44i-Me 
3.44i-Me 
290 
 
 
 
3.44i-Bzh 
3.44i-Bzh 
291 
 
 
 
3.44j-Me 
3.44j-Me 
292 
 
 
 
3.44j-Bzh 
3.44j-Bzh 
293 
 
 
 
3.44k-Me 
3.44k-Me 
294 
 
 
 
3.44k-Bzh 
3.44k-Bzh 
295 
 
 
 
3.44l-Me 
3.44l-Me 
296 
 
 
 
3.44l-Bn 
3.44l-Bn 
297 
 
 
 
3.44l-Allyl 
3.44l-Allyl 
298 
 
 
 
3.44l-Bzh 
3.44l-Bzh 
299 
 
 
 
3.44m-Me 
3.44m-Me 
300 
 
 
 
3.44n-Me 
3.44n-Me 
301 
 
 
 
3.44n-Bn 
3.44n-Bn 
302 
 
 
 
3.44n-Allyl 
3.44n-Allyl 
303 
 
 
 
 
 
 
 
 
 
 
 
 
3.53a 
304 
 
 
4.62 
4.62 
305 
 
 
 
4.64a 
4.64a 
306 
 
 
 
4.65a 
 
4.65a 
 
307 
 
 
 
4.59b 
4.59b 
308 
 
 
 
4.64b 
4.64b 
309 
 
 
 
4.59c 
4.59c 
310 
 
 
 
4.67 
4.67 
311 
 
 
 
4.68 
4.68 
312 
 
 
 
4.69 
4.69 
313 
 
 
 
4.73a 
8a 4.73a 
314 
 
 
 
8b 
8b 
4.73b 
4.73  
315 
 
 
 
8c 
8c 
4.73c 
4.73c 
316 
 
 
 
8d 
8d 
4.73d 
4.73d 
317 
 
 
 
8e 
8e 
4.73e 
4.73e 
318 
 
 
 
8f 
8f 
4.73f 
4.73f 
319 
 
 
 
8g 
8g 
4.73g 
4.73g 
320 
 
 
 
8h 
8h 
4.73h 
4.73h 
321 
 
 
 
8i 
8i 
4.73i 
4.73i 
322 
 
 
 
8j 
8j 
4.73j 
4.73j 
323 
 
 
 
8k 
8k 
4.73k 
4.73k 
324 
 
 
 
8l 
8l 
4.73l 
4.73l 
325 
 
 
 
8m 
8m 
4.73m 
4.73m 
326 
 
 
 
8n
 
 8m 
8n 4.73n 
4.73n 
327 
 
 
 
4.82a 
23a 4.82a 
328 
 
 
 
23o 
23o 
4.82o 
4.82o 
329 
 
 
 
23p 
23p 
4.82p 
4.82p 
330 
 
 
 
23q 
23q 
4.82q 
4.82q 
331 
 
 
 
4.79a 
 
4.79a 
332 
 
 
 
4.79b 
21b 4.79b 
333 
 
 
 
21c 
21c 
4.79c 
4.79c 
334 
 
 
 
21d 
21d 
4.79d 
4.79d 
335 
 
 
21e 
21e 
4.79e 
4.79
336 
 
 
 
21f 
21f 
4.79f 
4.79f 
337 
 
 
 
21h 
21h 
4.79  
4.79h 
338 
 
 
 
21i 
21i 
4.79
4.79i 
339 
 
 
 
21j 
21j 
4.79  
4.79
340 
 
 
 
21k 
21k 
4.79k 
4.79  
341 
 
 
 
21l 
21l 
4.79l 
4.79l 
342 
 
 
 
21o 
21o 
4.79o 
4.79o 
343 
 
  
 
21p 
21p 
4.79p 
4.79p 
344 
 
 
 
21q 
21q 
4.79q 
4.79q 
345 
 
 
 
4.89 
4.89 
346 
 
 
 
4.91 
4.91 
347 
 
 
 
4.99a 
4.99a 
348 
 
 
 
4.99b 
4.99b 
349 
 
 
 
4.90 
4.90 
350 
 
 
 
4.92 
4.92 
351 
 
 
 
4.100a 
4.100a 
352 
 
 
 
4.100a-BnNH2 
4.100a-BnNH2 
353 
 
 
 
4.100b 
4.100b 
